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Introduction 
Despite remarkable improvements in its prevention and therapy, cardiovascular disease 
(CVD) remains the leading cause of morbidity and mortality in most Western countries. 
CVD is a term used to describe diseases of the heart and blood vessels, such as angina, 
myocardial infarction, diseases of the heart valves or muscle, heart failure, and stroke. 
Increased age, male sex, family history of CVD, smoking, unhealthy dietary habits, physical 
inactivity, obesity and overweight, hypertension, type 2 diabetes (DM2), and abnormal 
blood lipid levels [high serum levels of low-density lipoprotein (LDL) cholesterol, low 
levels of high-density lipoprotein (HDL) cholesterol, and/or high levels of triacylglycerols 
(TAG)] are some of the major risk factors for CVD. 
The pathogenesis of CVD 
Atherosclerosis is a slow, complex, chronic disease and the primary cause of CVD (1). The 
initiating step involves damage to the vascular endothelium, which can be triggered by 
smoking, hypertension, DM2, low-grade systemic inflammation, and hypercholesterolemia. 
The injured endothelium becomes more permeable, which results in accumulation of 
atherogenic LDL particles in the intimae. At this location, the lipoprotein particles can 
undergo oxidation. Oxidized LDL cholesterol stimulates endothelial expression of adhesion 
molecules, which attract monocytes to the arterial wall. In addition, oxidation of LDL 
cholesterol results in the expression of pro-inflammatory cytokines. These cytokines 
stimulate the endothelial adhesion of monocytes and their migration into the arterial wall. 
The monocytes, once recruited into the arterial intimae, transform into macrophages. These 
macrophages can take up oxidized LDL cholesterol through their scavenger receptors and 
become lipid-filled foam cells. Further damage occurs when surrounding smooth muscle 
cells (SMC) and endothelial cells start to secrete cytokines and growth factors. These 
molecules stimulate the proliferation and endothelial transmigration of SMC. At that time, 
SMC start synthesizing an extracellular matrix, in particular collagen. Cycles of accumula-
tion of monocytes, migration, and proliferation of SMC and formation of fibrous tissue lead 
to further enlargement and restructuring in the atherosclerotic intimae. This eventually 
leads to the formation of a fibrous cap that covers the lipid-filled foam cells and consists of 
collagen-rich fibrous tissue, SMC, macrophages and T-lymphocytes. This is called the 
mature atherosclerotic plaque. The plaque protrudes into the arterial lumen, grows slowly 
over years, and can finally obstruct the artery. Moreover, the plaque can rupture, thereby 
exposing collagen and lipids to the blood stream. This leads to adherence and aggregation 
of platelets and initiates formation of a thrombus, which can block the artery and result in 
myocardial infarction and stroke. 
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TAG metabolism 
Abnormal blood lipid levels (high serum levels of LDL cholesterol, low levels of HDL 
cholesterol, and/or high levels of TAG) are an important risk factor for CVD. Over 95% of 
dietary lipids are TAG; the remaining are phospholipids, free fatty acids, and cholesterol 
(present as esterified cholesterol). Dietary TAG are digested in the stomach and duodenum 
into monoacylglycerols and free fatty acids by gastric and pancreatic lipases. Monoacyl-
glycerols, free fatty acids, and free cholesterol (unesterified) are then solubilized into 
micelles, which transport these lipids to the enterocytes. Once absorbed into the entero-
cytes, they are reassembled into TAG and packaged with cholesterol into chylomicrons (2). 
Chylomicrons [containing apolipoprotein (apo)B-48, apoC-II, and apoE] transport dietary 
TAG and cholesterol from within the enterocytes through the lymphatics into the circula-
tion. In the circulation, TAG transported by chylomicrons undergo lipolysis through the 
action of lipoprotein lipase (LPL) at the surface of the capillary endothelium, liberating free 
fatty acids and glycerol. Glycerol and free fatty acids can be absorbed in the peripheral 
tissues, especially adipose tissue and muscle, for energy and storage. The TAG-depleted 
chylomicron remnants are then internalized by the hepatocytes expressing apoE receptors. 
TAG are also synthesized by the liver where they are packaged as very-low-density 
lipoproteins (VLDL; containing apoB-100, apoC-II, and apoE), and released into the 
circulation (2). Again like chylomicrons, VLDL particles circulate and encounter LPL 
expressed on endothelial cells, causing hydrolysis of the VLDL particle. A degraded or 
TAG-reduced VLDL particle is referred to as intermediate-density lipoprotein (IDL), 
reflecting the fact that decreasing TAG content increases particle density while decreasing 
particle size. Further, LPL works on IDL releasing more free fatty acids changing the 
particles to LDL. LDL particles are the primary carriers of cholesterol for delivery to all 
tissues. 
The liver and intestine secrete HDL particles, which contain mainly phospholipids and 
apoA-1, with very little TAG or cholesterol (2). HDL particles scavenge unesterified (free) 
cholesterol in the circulation. Lecithin-cholesterol acyltransferase (LCAT), an enzyme 
associated with HDL, esterifies free cholesterol in the particle. Cholesteryl ester-transfer 
protein (CETP) transfers the LCAT-generated cholesteryl esters from HDL to apoB-100 
containing lipoproteins (VLDL, IDL, and LDL) in exchange for TAG. 
Cholesterol metabolism 
Cholesterol is derived from both exogenous dietary sources and endogenous cholesterol 
synthesis. Under normal conditions, cholesterol homeostasis is maintained by balancing 
dietary cholesterol absorption and endogenous synthesis with excretion of bile acids and 
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intestinal cholesterol (3). In the intestinal lumen, cholesterol is incorporated into mixed 
micelles and transported to the intestinal cells. From the intestinal cells, cholesterol can 
either be transported back into the lumen or into the circulation by means of chylomicrons. 
Similar to TAG, cholesterol is transported by the different lipoproteins (chylomicrons, 
VLDL, IDL, LDL, and HDL) in the circulation. The complete cholesterol absorption 
pathway has, however, not yet been fully defined. The Niemann-Pick C1 Like-1 (NPC1L1) 
transporter is suggested to play a role in the intestinal uptake of cholesterol and phytos-
terols (4). In addition, four members of the ATP-binding cassette (ABC) transporter family 
play an important role in modulating circulating and tissue cholesterol levels (5). ABCA1 
and ABCG1 export excess cellular cholesterol into the HDL pathway and reduce choles-
terol accumulation in macrophages. ABCG5 and ABCG8 are known to transport phytos-
terols back into the intestinal lumen, and some authors suggest that these transporters are 
involved in cholesterol efflux as well (6). 
The liver is the major site of both synthesis and catabolism of cholesterol. Cholesterol is 
synthesized from acetyl-coenzyme A (acetyl-CoA) (3). The rate-limiting reaction for 
cholesterol synthesis is catalyzed by the microsomal enzyme 3-hydroxy-3-methyl-glutaryl 
(HMG)-CoA reductase. The activity of this enzyme depends on cellular cholesterol 
concentrations. Increasing dietary cholesterol intake, providing the cells with more 
exogenous cholesterol, suppresses hepatic HMG-CoA reductase synthesis and lowers LDL 
receptor expression. By controlling cholesterol synthesis and uptake, the cell can control its 
intracellular cholesterol levels. 
The synthesis (and excretion) of bile acids is the major pathway by which the liver 
eliminates cholesterol (3). The adult human liver converts approximately 500 mg choles-
terol to bile acids on a daily basis. The primary bile acids, cholic acid and chenodeoxy-
cholic acid, are synthesized from cholesterol in the liver by the hepatocytes. The initial and 
rate-limiting step in this process is the hydroxylation of cholesterol at the α-position, which 
is catalyzed by cholesterol 7α-hydroxylase. Before secretion into bile, the primary bile 
acids are conjugated to either glycine or taurine. In the terminal ileum, 90 to 95% of these 
bile acids are reabsorbed and returned to the liver. This process is known as the entero-
hepatic circulation (7). The remainder is lost to the colon, where the primary bile acids are 
transformed by bacterial metabolism into the secondary bile acids, deoxycholic acid and 
lithocholic acid. Some of the secondary bile acids are also reabsorbed and the rest is 
excreted with the faeces. 
The levels of bile acids in the hepatocytes influence the activity of cholesterol 7α-
hydroxylase (8). Decreased cellular levels of bile acids, as may be the case with increased 
viscous soluble fiber intake, promote bile acid synthesis from cholesterol through de-
creased feedback inhibition on cholesterol 7α-hydroxylase. Consequently, hepatic 
cholesterol levels decrease and HMG-CoA reductase activity and LDL-receptor activity 
increase. As a result, serum LDL cholesterol concentrations decrease (net effect). 
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Functional foods and CVD risk 
Dietary therapy has been shown to be effective in reducing CVD risk and mortality 
associated with high serum LDL cholesterol levels. Functional foods made to lower the 
atherogenic LDL particles, and therefore the risk for CVD, are gaining a prominent position 
in dietary guidelines (9). Such foods contain one or more functional components and 
therefore provide positive health effects beyond their traditional nutritional value. Examples 
of such food components with Food and Drug Administration (FDA)-approved health 
claims are the viscous soluble fiber β-glucan from oats (10) and barley (11) (see Chapter 2 
and Figure 1) and plant sterols and stanols (12, 13) (see §5). 
 
Figure 1: Structure of oat β-glucan.  
Oat β-glucan is a polysaccharide composed of glucose molecules which are joined by β-(1→4)- and β-(1→3)-
glycosidic bonds. 
 
 
The combination of oat β-glucan and plant stanols in one food product may result in even 
larger reductions in serum LDL cholesterol concentrations, also because the underlying 
mechanisms of these two ingredients are suggested to be different. The study as described 
in Chapter 3 was therefore designed to investigate this. 
Plant sterols and stanols as functional foods 
Plant sterols are found in a wide variety of plant lipids, such as oils from vegetables, nuts, 
grains, seeds, wood pulp, and leaves. Plant stanols, which are saturated plant sterols, occur 
in even smaller quantities in many of the same sources. Plant sterols and stanols, collec-
tively referred to as phytosterols, are essential components of plant cell membranes and 
structurally resemble cholesterol. The human body cannot synthesize these components 
and therefore all phytosterols present, originate from the diet. In Western countries, people 
consume on average 160 to 360 mg/d of phytosterols as part of their normal healthy diet 
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(14). Typical diets commonly provide sitosterol, campesterol, and stigmasterol, along with 
smaller amounts of plant stanols, like sitostanol (Figure 2).  
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Figure 2: Structures of phytosterols.  
Plant sterols and stanols are essential components of plant cell membranes and structurally resemble cholesterol.  
 
Under normal circumstances, the Western diet contains almost equal amounts of choles-
terol and phytosterols. However, the net absorption of plant sterols and stanols is much 
lower than that of cholesterol [<5% versus 55 to 60% (15)]. Despite their initial absorption 
from the intestinal tract using the same pathway as cholesterol, phytosterols are almost 
completely returned to the intestinal lumen through specific transporters (16). Conse-
quently, serum levels of phytosterols are very low and in the range from 2.5 to 30 μmol/L 
(17). 
The cholesterol-lowering potential of phytosterols has been known for over 50 years. 
Although people consume plant sterols and stanols every day, the amounts are often not 
large enough to have significant cholesterol-lowering effects (14). By modifying phytos-
terols structurally to form sterol and stanol esters, larger amounts can be easily incorpo-
rated into high-fat foods (spreads, dressings) without loosing their effectiveness in lowering 
serum LDL cholesterol concentrations. Phytosterol esters are also added to a wide variety 
of low-fat products, such as low-fat yoghurt, low-fat milk, bread, and cereals. A recent 
GENERAL INTRODUCTION 
13  
meta-analysis concluded that daily consumption of 2.0 to 2.4 g phytosterols in ester form 
lowers on average serum LDL cholesterol concentrations by 8.9% (14). The FDA has 
authorized the claim that foods containing at least 0.65 g per serving of phytosterol esters 
(daily total intake ≥1.3 g), as part of a diet low in saturated fat and cholesterol, can reduce 
the risk of CVD (12). 
This hypocholesterolemic effect of plant sterols and stanols can be (partly) explained by 
their ability to compete with cholesterol for incorporation into micelles, particles that 
transport lipids and cholesterol into the intestinal mucosa (18). This competition reduces 
dietary and biliary cholesterol absorption in the gastrointestinal tract. However, recent 
findings suggest that phytosterols also can enter the intestinal cells and promote cholesterol 
efflux back into the intestinal lumen through a yet unknown mechanism (18). The decrease 
in cholesterol absorption results in a compensatory increase in endogenous cholesterol 
synthesis (19). Additionally, receptor-mediated cholesterol uptake becomes upregulated 
(19). The overall effect is a reduction in serum LDL cholesterol concentrations (Figure 3). 
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Figure 3: Postulated hypocholesterolemic mechanism of phytosterols.  
Phytosterols may compete with cholesterol for incorporation into micelles, which reduces cholesterol absorption into 
the enterocytes (1). Phytosterols may also enter the enterocytes and promote cholesterol efflux back into the intestinal 
lumen (2). This results in a compensatory increase in endogenous cholesterol synthesis (3). Additionally, receptor-
mediated cholesterol uptake becomes upregulated (4). The overall effect is a reduction in serum LDL cholesterol 
levels (5). 
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Phytosterols and their esters are Generally Recognized as Safe (GRAS) food substances, as a 
history of intake has not demonstrated any harmful health effects (20). Nevertheless, a first 
potential concern is that they may also reduce absorption of fat-soluble vitamins (18). 
However, after several years of use in Europe and the U.S, no impaired vitamin status or 
related adverse effects have been reported. Recently, however, it has been hypothesized 
that increased serum plant sterol levels probably may increase CVD risk. This hypothesis is 
based on the observation that patients with a rare recessive genetic lipid storage disease, 
known as phytosterolemia, have an uncontrolled sterol absorption, severely elevated serum 
plant sterol concentrations, low endogenous cholesterol synthesis, xanthomas, and 
premature atherosclerosis (15). However, results from epidemiological studies in the 
general population are conflicting and there is no evidence at present that marginally 
increased serum plant sterol levels can increase CVD risk (15). One possibility by which 
plant sterols may be potentially atherogenic is through oxidative modification (see next 
paragraph). 
Oxy(phyto)sterols and CVD risk 
Oxidized forms of cholesterol (also known as oxysterols; Figure 4) are suggested to be 
atherogenic and accordingly may also play an active role in the pathogenesis of CVD (21). 
Oxysterols arise in tissues as a result of enzymatic (during cholesterol catabolism) or non-
enzymatic (in vivo oxidation; e.g. 27-hydroxycholesterol) oxidation reactions and are also 
obtained from dietary sources (dairy products, egg, meat, fish, bakery products) (21). In 
vitro, oxysterols perturb several aspects of cellular cholesterol homeostasis (including 
cholesterol biosynthesis, esterification, and efflux), impair vascular reactivity, are cytotoxic, 
and induce apoptosis (21). However, there is no direct evidence yet in humans that 
oxysterols are causally linked to atherogenesis. Nevertheless, animal studies have shown 
that oxysterols in the diet can accelerate fatty streak lesion formation (22, 23). 
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Figure 4: Structures of oxysterols. 
 
 
Plant sterols structurally resemble cholesterol and the presence of one or more unsaturated 
bonds makes phytosterols susceptible to oxidation as well. Small amounts of oxidized 
phytosterols (oxyphytosterols) have been found in the diet (coffee, fried potatoes, wheat 
flour, and vegetable oils) (24), and in serum from phytosterolemic patients (25) and healthy 
subjects (26). Animal studies have shown that oxyphytosterols are absorbed from the diet 
and accumulate in serum, liver, and aorta (27). Further, in vitro studies have shown that 
oxyphytosterols exhibit toxic effects in cultured macrophages similar to those of oxysterols 
(28). However, it is unknown whether oxyphytosterols are atherogenic, as has been 
suggested for oxysterols. In Chapter 6, the results are discussed from a randomized, 
controlled animal study, in which we investigated the effects of oxysterols and oxyphytos-
terols side-by-side on lipid metabolism and atherosclerotic lesion development using 
heterozygous LDL receptor-deficient (LDLR+/-) mice. 
Inflammation and CVD risk 
Inflammation is the process by which the body responds to injury or infections. Inflamma-
tion in the vessel wall plays an essential part in both the development of atherosclerosis 
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and the rupture of atherosclerotic plaques (1). All stages, like initiation, growth, and 
complication of the atherosclerotic plaque, can be considered to be an inflammatory 
response to injury. Recent findings suggest that statins, commonly prescribed LDL choles-
terol-lowering drugs, reduce this inflammation, indicating an additional beneficial effect. 
Examination of the possibility to interfere with the inflammatory part in atherosclerosis by 
diet or functional foods in particular, currently receives a lot of attention. 
Besides their hypocholesterolemic effects, in vitro and animal studies have suggested that 
oat β-glucan and phytosterols may also affect inflammatory parameters (29-37). Data from 
human studies concerning these effects are however limited and inconsistent. To explore 
whether the effects of oat β-glucan and plant stanols on CVD risk may be mediated in part 
by affecting the inflammatory process, we first examined in Chapter 4 their effects on 
serum high-sensitivity CRP (hs-CRP) concentrations in slightly hypercholesterolemic 
subjects. Hs-CRP is considered a marker for low-grade systemic inflammation and is 
positively associated with an increased risk for future cardiovascular events (38). Since 
leukocyte reactivity is easily triggered by modified LDL cholesterol, potential changes may 
be more evident in hypercholesterolemic subjects. We therefore determined the effects of 
oat β-glucan and plant stanols on leukocyte function in these subjects (Chapter 4). This 
was studied ex vivo by measurement of inflammatory cytokine (IL-6, IL-8, TNF-α) produc-
tion after lipopolysaccharide (LPS) stimulation by isolated peripheral blood mononuclear 
cells (PBMC) and whole blood. Il-6, IL-8, and TNF-α are pro-inflammatory markers 
involved in the development of atherosclerotic lesions. Finally, we investigated the effects 
of oat β-glucan and plant stanols on the expression of 84 atherosclerosis-related genes in 
PBMC to enhance the understanding of underlying mechanisms of these dietary com-
pounds (Chapter 4). 
Hypertriglyceridemia and CVD risk 
The link between high serum LDL cholesterol levels and CVD has been clearly established. 
However, evidence is accumulating that high levels of TAG, also known as hypertriglyc-
eridemia, and low levels of HDL cholesterol are also related to CVD (39). TAG are major 
lipids in chylomicrons (transport of TAG of dietary origin) and VLDL particles (transport of 
TAG synthesized by the liver). These particles are closely related to the metabolism of other 
lipoproteins, including HDL. High TAG and low HDL concentrations often occur together, 
frequently with normal serum concentrations of LDL cholesterol. This lipid abnormality is a 
fundamental characteristic of patients with the metabolic syndrome, a condition strongly 
associated with the risk to develop DM2 and CVD. 
Interestingly, a recent meta-analysis has indicated that consumption of plant stanols may 
decrease serum TAG concentrations, especially in subjects with high serum TAG concen-
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trations (40). This meta-analysis was based on the individual data from 5 trials carried out 
at our Department and included almost 400 subjects. The reason that these effects have not 
been observed in previous studies may be due to a lack of statistical power, as effects have 
been marginal in subjects with normal serum TAG concentrations. We therefore designed a 
study to evaluate the effects of plant stanols on the lipoprotein profile in a population 
especially selected for elevated serum TAG concentrations (Chapter 5).  
OUTLINE OF THE THESIS 
This thesis focuses on the role of different dietary components (oat β-glucan, plant stanols, 
and oxy(phyto)sterols) in managing CVD risk. Chapter 2 describes the relationship between 
viscous soluble fibers and CVD. Chapter 3 was designed to investigate the effects of a 
simultaneous intake of 2 functional foods, oat β-glucan and plant stanols, on lipid metabo-
lism in mildly hypercholesterolemic volunteers. In Chapter 4, we investigated the effects of 
these functional ingredients on serum hs-CRP levels in the same study population. We also 
determined their effects on leukocyte function, by measuring the production of pro-
inflammatory cytokines (IL-6, IL-8, and TNF-α) by isolated PBMC and whole blood after 
LPS stimulation (Chapter 4). In addition, we studied the effects of oat β-glucan and plant 
stanols on the expression of 84 atherosclerosis-related genes in PBMC (Chapter 4). Chapter 
5 describes the effects of plant stanols on serum TAG concentrations in subjects with 
hypertriglyceridemia. In Chapter 6, we investigated the effects of oxysterols and oxyphytos-
terols on lipid metabolism and atherosclerotic lesion development in LDLR+/- mice. 
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ABSTRACT 
Review One well-established way to reduce the risk of developing cardiovascular disease 
(CVD) is to lower serum LDL cholesterol levels by reducing saturated fat intake. However, 
the importance of other dietary approaches, such as increasing the intake of viscous 
soluble fibers is increasingly recognized. Well-controlled intervention studies have now 
shown that four major viscous soluble fiber types - β-glucan, psyllium, pectin and guar 
gum - effectively lower serum LDL cholesterol concentrations, without affecting HDL 
cholesterol or triacylglycerol concentrations. It is estimated that for each additional gram of 
viscous soluble fiber in the diet serum total and LDL cholesterol concentrations decrease 
by -0.028 mmol/L and -0.029 mmol/L, respectively. Despite large differences in molecular 
structure, no major differences existed between the different types of viscous soluble fiber, 
suggesting a common underlying mechanism. In this respect, it is most likely that viscous 
soluble fibers lower the (re)absorption of in particular bile acids. As a result hepatic 
conversion of cholesterol into bile acids increases, which ultimately leads to increased LDL 
uptake by the liver. Additionally, epidemiological studies suggest that a diet high in viscous 
soluble fiber is inversely associated with the risk of CVD. These findings underlie current 
dietary recommendations to increase viscous soluble fiber intake. 
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INTRODUCTION 
Despite remarkable improvements in its prevention and therapy, cardiovascular disease 
(CVD) remains the leading cause of morbidity and mortality in the United States and most 
Western countries. One well-established way to reduce the risk of developing CVD is to 
lower serum LDL cholesterol levels by making dietary changes. In addition to reducing 
saturated fat and cholesterol intake, and increasing cis-unsaturated fat intake, the impor-
tance of other dietary approaches, such as increasing the intake of viscous soluble fibers 
has become increasingly recognized. 
Dietary fiber is a collective term for a variety of plant substances that are resistant to 
digestion by human gastrointestinal enzymes. Dietary fiber can be classified as either 
soluble or insoluble in water (41). Cellulose, lignin, some pectins, and some hemicelluloses 
are insoluble fibers. Vegetables and cereal grains are especially rich in insoluble fiber, with 
the highest amounts in wheat and corn. Insoluble fiber is responsible for increased stool 
bulk and helps to regulate bowel movements. The natural gel-forming fibers, such as β-
glucans, gums, mucilages (e.g. psyllium), pectins, and some hemicelluloses are soluble. 
Foods rich in soluble fiber are dried beans, oats, barley, and some fruits and vegetables. 
The mean total daily fiber intake amongst adults in most industrialized countries is well 
below 25 g, the minimal amount recommended by various health organizations. Of total 
dietary fiber intake, approximately 20% is soluble and 80% is insoluble (42). 
Further research has revealed that solubility does not reliably predict the physiological 
effects of fiber. It is the viscosity of dietary fiber that seems to be important for its physio-
logical properties. Some fibers form very viscous solutions or gels in water (43). This 
property is linked to the ability of these fibers to slow the emptying of the stomach, delay 
the absorption of some nutrients in the small intestine, and lower serum cholesterol levels. 
Viscous fibers include β-glucans, pectins, some gums (e.g. guar gum) and mucilages (e.g. 
psyllium). Cellulose, lignin, and some hemicelluloses are nonviscous fibers. However, the 
terms “water-soluble” and “water-insoluble” are still used by many nutrition and health 
care professionals, as well as the FDA for nutrition labeling. 
 
The main purpose of this review is to discuss the effects of different viscous soluble fiber 
types - β-glucan, psyllium, pectin, and guar gum - on cholesterol metabolism and cardio-
vascular risk. We limited the review to those viscous soluble fibers for which more than 
five intervention studies were published. First, we focused on the hypocholesterolemic 
effects of these four major viscous soluble fiber types. Next, possible mechanisms underly-
ing the cholesterol-lowering effects were described. Finally, we summarized the epidemi-
ological studies that contrasted the intake of total dietary fiber with that of cereal fiber, an 
important source of viscous soluble fiber. 
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HYPOCHOLESTEROLEMIC EFFECT OF VISCOUS SOLUBLE FIBERS 
β-Glucan 
β-Glucan is a viscous soluble fiber found in cereals, in particular oats and barley, as well as 
in yeast, bacteria, algae, and mushrooms. In fact, one of the richest sources of β-glucan is 
the cell wall of baker's yeast Saccharomyces Cerevisae. Regardless of its source, β-glucan is 
a polysaccharide composed of glucose molecules. In bacteria and algae, however, the 
glucose molecules are joined by β-(1→3)-glycosidic bonds forming a linear chain, while in 
yeast and mushrooms the glucose molecules are joined by β-(1→3)- and β-(1→6)-
glycosidic bonds, and in oats and barley by β-(1→4)- and β-(1→3)-glycosidic bonds. Thus, 
β-glucan from these latter sources is composed of branched chains. Functional foods 
enriched with β-glucan from mainly oats are widely available on the market to decrease 
serum LDL cholesterol concentrations. 
In 1963, De Groot et al. were the first to report that in healthy men 3-week consumption of 
300 g of bread, containing 140 g of rolled oats, decreased serum total cholesterol concen-
trations by 11% (44). Since that time, many studies have been carried out on the choles-
terol-lowering effects of oats, which were later found to be due to its β-glucan content (45). 
Results of several uncontrolled metabolic ward trials have been summarized by Anderson 
et al. and reductions in serum total cholesterol from 13 to 26% were reported (46). These 
reductions were mainly found in the LDL cholesterol fraction. Although many of these 
metabolic ward studies showed impressive lipid reductions (47-49), trials with free-living 
subjects reported considerably more variability in lipid responses. Some studies found 
reductions greater than 10% (50-52), but a few studies demonstrated virtually no benefit 
(53-55). Inconsistencies in the reported effects of oat products may be due to several 
factors, such as mode of administration, or differences in solubility or molecular weight. 
Kerckhoffs et al., for example, investigated the effects of β-glucan in bread and cookies 
(study 1) and in orange juice (study 2). In study 1, forty-eight mildly hypercholesterolemic 
subjects received bread and cookies rich in wheat fiber or rich in β-glucan (5.9 g/d) for 3 
weeks. Serum LDL cholesterol concentrations decreased slightly by 3% after β-glucan 
consumption. This change however did not reach statistical significance. In study 2, the 
same sources and daily amounts (as in study 1) of control fiber and β-glucan were 
provided. Twenty-five subjects now consumed orange juice containing either wheat fiber 
or β-glucan for 2 weeks. It was found that serum LDL cholesterol concentrations decreased 
significantly by 6.7% (56). The authors concluded that the food matrix and/or food 
processing can have detrimental effects on the hypocholesterolemic properties of oat β-
glucan. Solubility and molecular weight of β-glucan may also influence its hypocholes-
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terolemic effects. Indeed, it has been postulated that the viscosity of β-glucan in the 
intestinal tract, which is positively related to its solubility in water and molecular weight, is 
an important determinant of its LDL-cholesterol lowering effects. Highly soluble β-glucan, 
with moderate to high molecular weight, may reduce serum LDL cholesterol levels better 
than β-glucan with a low solubility and low molecular weight. This difference in effect has 
been explained by the assumption that a higher intestinal viscosity lowers the reabsorption 
of bile acids, leading to an increased excretion of bile acids. Increased bile acid excretion 
promotes bile acid synthesis from cholesterol, which increases LDL cholesterol uptake by 
the liver. 
Although a few individual studies showed virtually no effects, several meta-analyses 
concluded that viscous soluble fiber from oat products effectively lowered serum total and 
LDL cholesterol concentrations (57-59). In the most recent meta-analysis, Brown et al. 
estimated that the intake of 1 g of viscous soluble fiber from oats lowered total and LDL 
cholesterol concentrations with -0.037 mmol/L and -0.032 mmol/L, respectively (59) 
(Figure 1). 
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Figure 1: Effects of each gram of four major viscous soluble fiber types on changes in total and LDL cholesterol 
concentrations (mmol/L) [Adapted from (59)] 
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Studies were carried out with healthy volunteers, hypercholesterolemic subjects, hyperten-
sive subjects, diabetics, and subjects with an ileostoma (60-66). Oat was incorporated in 
breads, (hot) cereals, muffins, flakes, biscuits, shakes, and in drinks. After reviewing 37 
studies, the Food and Drug Administration (FDA) approved in January 1997 a health claim 
that “Viscous soluble fiber from oatmeal, as part of a low saturated fat, low cholesterol diet, 
may reduce the risk of heart disease”. The FDA determined that 3 g/d of β-glucan must be 
consumed to achieve a clinically relevant serum cholesterol-lowering effect. The whole 
oat-containing food should provide at least 0.75 g of viscous soluble fiber per serving (10). 
Elevated postprandial lipidemia is also a marker for CVD risk. As fasting serum lipid 
concentrations are only slightly changed after consumption of oat bran, it has been 
suggested that postprandial lipid and lipoprotein responses after a meal may be more 
relevant to explain the effects of increased oat consumption on cardiovascular health (67). 
Yet, the results on the effects on postprandial lipoproteins are inconclusive. Many of the 
published postprandial studies investigated the effect of oat bran added to a test meal and 
found significant beneficial effects on lipid responses (45, 68, 69). However, some trials did 
not observe any significant postprandial effects of oat bran consumption (47, 55), while a 
few studies even reported significantly higher postprandial TAG concentrations (67, 70).  
Another important source of β-glucan is barley. While oats contain around 4% β-glucan, 5 
to 10% β-glucan is present in barley. Despite its naturally high β-glucan content, fewer 
trials have investigated barley fiber since barley is not significantly consumed across 
regions. Nevertheless, the FDA recently concluded, based on the totality of available 
scientific evidence, that whole grain barley and dry milled barley products, such as flakes, 
grits, flour, and pearled barley, are appropriate sources of β-glucan viscous soluble fiber to 
claim that they reduce the risk of CVD (11). The effects of this viscous soluble fiber on 
serum cholesterol concentrations have been examined in healthy normocholesterolemic 
and hypercholesterolemic subjects (71-76). β-Glucan intake varied from 3 to 12 g. The test 
foods were made from barley bran, barley flakes, barley flour, and barley concentrate. 
Reductions in LDL cholesterol varied from 0 to 17%. Like for oats, not all studies reported 
improvements in the serum lipid profile (72). It was suggested that the lack of effect, at least 
in part, could be a consequence of structural changes in β-glucan due to processing of the 
barley into a highly enriched β-glucan product. Freezing, storage, or baking of the product 
may have influenced the efficacy of the fiber. 
Finally, β-glucan is abundant in yeast as used in breweries and bakeries. After processing, 
the yeast contains up to 85% of β-glucan. In contrast to β-glucan from oats, yeast-derived 
β-glucan has a low viscosity and low solubility in water. Still, it may improve the serum 
lipoprotein profile, as demonstrated by Nicolosi et al. (77). After a 3-week period on their 
usual diets, 15 obese, hypercholesterolemic men consumed 15 g of fiber added to an 
orange juice for 8 weeks. The authors found that, compared with baseline, fiber consump-
tion significantly reduced serum total cholesterol levels by 6%. Serum LDL concentrations 
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declined significantly by 8% and HDL concentrations increased significantly with 9% after 
8 weeks. Serum TAG concentrations were unaffected. It should be noted, however, that 
this study lacked a proper control group. Obviously, more research is needed to confirm 
the cholesterol-lowering effects of this source of β-glucan and its potential beneficial effects 
on HDL cholesterol concentrations.  
Psyllium 
Psyllium is a gel-forming mucilage from the Plantago ovata plant, a native herb from parts 
of Asia, Mediterranean regions of Europe, and North Africa. Mucilage is a gelatinous 
substance, related to natural gums. The term psyllium is used interchangeably for the seed 
husk, the seed, and the entire plant. Psyllium is cultivated, because the seed husk is a rich 
source of viscous soluble fiber, known as psyllium hydrophilic mucilloid, psyllium 
hydrocolloid, and psyllium seed gum. The bioactive fraction in psyllium is a fiber com-
posed of a highly branched arabinoxylan. The backbone consists of xylose units, while 
arabinose and xylose form the side chains. In contrast to the arabinoxylans in cereal grains 
that are extensively fermented, psyllium possesses an as yet unidentified structural feature 
that hinders its fermentation by typical colonic microflora (78). Nowadays, psyllium is 
incorporated into foods, such as ready-to-eat cereals, for its LDL cholesterol-lowering 
properties. 
In 1965, Garvin et al. published the first study to suggest that psyllium lowered serum total 
cholesterol concentrations. In a non-placebo controlled trial, subjects received 9.6 g/d of 
psyllium in addition to their habitual diet (psyllium group) or a high-egg diet (control 
group). After eight weeks, serum total cholesterol concentrations were decreased by 9% in 
the psyllium group. On the high-egg diet, however, a reduction of 7% was observed as 
well (79). Since then, psyllium has been investigated in numerous clinical trials. In these 
studies, it was found that psyllium lowered serum total and LDL cholesterol levels in 
hypercholesterolemic subjects, subjects with non-insulin dependent diabetes mellitus, and 
in subjects receiving lipid-lowering drug therapy (59, 80). Furthermore, effects of psyllium 
did not depend on the amount of fat or cholesterol in the diet (59). In these studies, mainly 
psyllium-enriched cereals and powder-preparations were used (59, 80, 81). The efficacy of 
psyllium was confirmed by the meta-analysis from Brown et al. (59), that concluded that 
each gram of viscous soluble fiber from psyllium lowered total and LDL cholesterol levels 
by -0.028 mmol/L and -0.029 mmol/L, respectively (Figure 1). No effects on serum levels of 
HDL cholesterol or triacylglycerols (TAG) were observed (59). Based on the total body of 
evidence, the FDA has approved in 1998 a health claim for psyllium that “A food product 
containing viscous soluble fiber from psyllium seed husk, consumed as part of a diet low in 
saturated fat and cholesterol, may reduce the risk of heart disease”. For this, 7 g of viscous 
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soluble psyllium fiber must be consumed daily. Foods carrying the health claim must 
provide at least 1.7 g of viscous soluble fiber from psyllium per reference amount habitu-
ally consumed (82).  
Pectin 
Pectin is a gum found in many plants, but mainly in citrus fruits (oranges, lemons, grape-
fruits) and apples. During ripening, pectin changes from an insoluble substance to a much 
more soluble component. Pectin is a linear polysaccharide containing about 300 to 1,000 
monosaccharide units, mainly D-galacturonic acid plus some polysaccharides. The D-
galacturonic acid molecules are linked together by α-(1→4)-glycosidic bonds. The 
galacturonic acid residues in pectin can be esterified with methyl groups. There are 
different types of pectin. Pectin in which more than 50% of the galacturonic acid residues 
are esterified is called “high-methoxyl” pectin. Pectin in which less than 50% of the 
galacturonic acid residues are esterified is called “low-methoxyl” pectin (83). Pectin is 
widely used in the food industry as a gelling agent to create a gelled texture to foods, but it 
also has hypocholesterolemic properties. Because of its strong gelling properties, it is 
difficult to incorporate high amounts of pectin into foods. 
In 1961, Keys et al. already published the first human study that suggested that pectin 
supplementation lowered serum total cholesterol concentrations. Twenty-four healthy 
subjects consumed a series of 3-week experimental diets and 3-week standard diets for a 
total of 12 weeks. Consumption of biscuits with pectin (15 g/d) reduced total cholesterol by 
5% (84). Since then, many studies have confirmed the hypocholesterolemic effects of 
pectin. Pectin lowered serum cholesterol levels in hypercholesterolemic subjects, normo-
cholesterolemic subjects, and in subjects with essential hypertension (59). Different sources 
of pectin, such as guava fruit, prunes, grapefruit gelatin capsules, and citrus pectin desserts 
were all effective. However, not all trials showed that pectin supplementation was 
associated with decreased serum cholesterol levels (85). Mahalko et al. investigated 
persons with type II diabetes in 2 studies. In the first study, daily consumption of 26 g of 
dehydrated powdered apple incorporated into seven slices of bread lowered serum total 
and LDL cholesterol concentrations by 4.7% and 8.3%, respectively. In the second study, 
52 g of the same fiber source (26 g incorporated into seven slices of bread plus 26 g into 
other food products), significantly increased serum total and LDL cholesterol by 6.4% and 
10.8%, respectively, compared with the control period (white bread). However, only 6 
subjects completed the second study (86). When all the available studies were however 
summarized, Brown et al. reported in their meta-analysis that viscous soluble fiber from 
pectin effectively lowered total and LDL cholesterol concentrations. The range of effects on 
total cholesterol varied from -16 to -5%. On average, each gram of viscous soluble fiber 
VISCOUS SOLUBLE FIBERS & CVD 
27  
from pectin decreased total and LDL cholesterol concentrations by -0.070 mmol/L and -
0.055 mmol/L, respectively (Figure 1). Pectin did not significantly alter serum levels of HDL 
cholesterol or TAG (59).  
Guar gum 
Guar, or Indian cluster bean Cyamopsis tetragonolobus, is a drought-tolerant annual 
leguminous plant originating from India and Pakistan. Guar gum is the primary marketable 
product of the plant. Guar gum is a galactomannan storage polysaccharide made up of 
polymers comprising about 10,000 molecules. The fiber consists of a (1→4)-linked-β-D-
mannopyranose backbone with (1→6)-linked-α-D-galactose side-chains. The overall ratio 
of mannose to galactose is around 2:1. Guar gum is used as a thickener and stabilizer in 
food and pharmaceutical products. It hydrates easily in cold water giving a highly viscous 
solution. Guar gum is also used to treat constipation and to decrease serum LDL choles-
terol concentrations. 
Forty years ago, Fahrenbach et al. found that guar administration effectively lowered serum 
total cholesterol levels in normocholesterolemic subjects (87). Since then, this serum lipid-
lowering effect of guar gum has been investigated in a large number of human trials. The 
results of these studies were consistent in that total and LDL cholesterol were effectively 
decreased by guar gum supplementation, whereas HDL cholesterol and TAG remained 
unchanged. From their meta-analysis, Brown et al. estimated that one gram of viscous 
soluble fiber from guar gum lowered serum total and LDL cholesterol by -0.026 mmol/L 
and -0.033 mmol/L, respectively (59) (Figure 1). Guar gum lowered total cholesterol 
concentrations in healthy volunteers, hyperlipidemic subjects, and in subjects with 
diabetes mellitus (59). Also in subjects receiving oral hypoglycaemic drugs, antihyperten-
sive medication, or lipid-lowering drugs, the cholesterol-lowering effects were still present 
(59). Numerous forms of guar gum were used, including powder, (coated) granules, and 
depolymerized forms. Guar gum was incorporated into various foodstuffs, such as bread, 
crackers, pasta and snack bars (59, 88). Human studies further showed that the physiologic 
effects of guar gum were not decreased after treatment with galactomannase, an enzyme 
that degrades the mannose and galactose units (89). An important benefit of using depoly-
merized guar gum is that much larger quantities of the galactomannan can be incorporated 
into food products without serious loss of sensory qualities (88). 
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Conclusion  
Since 1960, many studies have documented the hypocholesterolemic effects of four major 
viscous soluble fiber types - β-glucan, psyllium, pectin, and guar gum - in humans. High 
intakes of these viscous soluble fibers have been associated with significant decreases in 
serum total and LDL cholesterol concentrations. HDL cholesterol and TAG levels were not 
affected by viscous soluble fiber intake. Based on a recent meta-analysis, a mean reduction 
of -0.029 mmol/L in serum LDL cholesterol concentrations can be expected for each 
additional gram intake of viscous soluble fiber. No major differences were reported 
between the different sources of viscous soluble fiber, suggesting a common mechanism 
underlying the hypocholesterolemic effects.  
HYPOCHOLESTEROLEMIC MECHANISM OF VISCOUS SOLUBLE FIBERS 
The exact mechanism by which viscous soluble fibers lower serum LDL cholesterol levels 
is not known. Evidence suggests that viscous soluble fibers may interfere with lipid and/or 
bile acid metabolism. Other suggested mechanisms include: the inhibition of hepatic 
cholesterol synthesis by fermentation products, and delayed absorption of carbohydrates 
leading to increased insulin sensitivity. 
Interference with lipid and/or bile acid metabolism  
Evidence suggests that some viscous soluble fibers may bind bile acids during formation of 
micelles in the intestinal lumen (90, 91). These observations led to the hypothesis that 
viscous soluble fibers may increase excretion of bile acids. Alternatively, it has been 
suggested that viscous soluble fibers may form a thick unstirred water layer in the intestinal 
lumen. This layer may act as a physical barrier, thereby decreasing the (re)absorption of 
fats, including cholesterol and bile acids. This would lead to an increased fecal output of 
these two components. As a result, hepatic conversion of cholesterol into bile acids 
increases, hepatic pools of free cholesterol decrease and - to reach a new steady-state - 
endogenous cholesterol synthesis increases. This leads to increased activities of 7α-
hydroxylase and HMG-CoA reductase to compensate for the losses of bile acids and 
cholesterol from the liver stores. Furthermore, hepatic LDL cholesterol receptors become 
upregulated to restore hepatic cholesterol stores, which ultimately leads to decreased 
serum LDL cholesterol concentrations (Figure 2) (59). 
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Figure 2: Postulated hypocholesterolemic mechanism of viscous soluble fibers. 
The viscous water-soluble fibers form a thick unstirred water layer in the intestinal lumen, thereby decreasing the 
(re)absorption of cholesterol and bile acids (1). This leads to an increased fecal output of these two components (2). 
As a result hepatic conversion of cholesterol into bile acids increases (3), hepatic pools of free cholesterol decrease 
and endogenous cholesterol synthesis increases (4). In addition, hepatic LDL cholesterol receptors are upregulated to 
re-establish hepatic free cholesterol stores (5). These processes will ultimately lead to decreased serum LDL 
cholesterol levels (6). 
 
 
Several human studies have explored the effects of viscous soluble fibers on bile acid 
excretion. In hypercholesterolemic men, who were given 100 g of oat bran for 10 days, a 
reduction in serum cholesterol levels and an increase in fecal bile acid excretion were 
observed (47). In another study, ileostomy subjects were served for 2 consecutive days 4 
different breads in random order. The breads were mainly made from oat bran, oat bran 
treated with β-glucanase, barley, or wheat flour. The 24-hours excretion of bile acids was 
significantly higher in the oat bran-diet period than in the other 3 periods (92). The 
decreased molecular weight of the oat bran treated with β-glucanase and of the barley β-
glucan may explain the lack of effect of these latter 2 diets. Andersson et al. investigated 
whether the increased fecal bile acid excretion after consumption of β-glucan from oat 
bran indeed increased bile acid synthesis. For this, healthy subjects received either 75 g 
wheat bran or 75 g oat bran for breakfast in a randomized crossover study. It was found 
that oat bran almost doubled the serum concentrations of 7α-hydroxy-4-cholesten-3-one 
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(7α-OHC) shortly after intake (93). 7α-OHC is made from 7α-hydroxycholesterol, and 
serum 7α-OHC concentrations strongly correlate with the activity of the key enzyme 
cholesterol 7α-hydroxylase. In a study with hypercholesterolemic subjects, muesli enriched 
with 5 g β-glucan also increased 7α-OHC concentrations compared to the control muesli. 
Additionally, campesterol concentrations decreased and lathosterol concentrations 
increased, suggesting decreased cholesterol absorption and increased cholesterol synthesis, 
respectively (63). Also, Naumann et al. found decreased cholesterol absorption and 
increased cholesterol synthesis in hypercholesterolemic subjects, as measured by the same 
markers (64). In ileostomy subjects (94), 75 g oat bran with 11.6 g native β-glucan 
increased bile acid excretion within 24 hours of consumption compared to 4.5 g hydro-
lysed β-glucan, and this increase was paralleled by a rise in serum concentrations of 7α-
OHC. In addition, native β-glucan consumption decreased cholesterol absorption and 
increased lathosterol concentrations.  
Effects from short-chain fatty acids produced by fermentation in the colon 
Viscous soluble fibers escape absorption in the small bowel and are fermented in the large 
bowel by colonic bacteria. This fermentation results in the production of short-chain fatty 
acids (SCFA), such as acetate, propionate, and butyrate. Butyrate is primarily metabolized 
by colonic mucosal cells, while acetate and propionate are rapidly absorbed. It has been 
hypothesized that production of SCFA may influence cholesterol synthesis. However, this 
hypothesis mainly originates from animal studies, while properly controlled intervention 
studies in humans are scarce. Besides, data on the effects of SCFA production in the colon 
on serum lipids in humans are still conflicting.  
Bridges et al. compared the effects of oat bran and wheat bran on serum SCFA concentra-
tions in 20 hypercholesterolemic men. Oat bran decreased serum cholesterol concentra-
tions by 12.8%, whereas wheat bran had no effect. Serum acetate values were significantly 
higher in subjects fed the oat bran diet when compared with the wheat bran diet (95). 
These findings suggest that SCFA responses may contribute to the hypocholesterolemic 
effects of oat bran. In addition, serum acetate and propionate concentrations were 
negatively related to serum total and LDL concentrations in a cross-sectional study with 
healthy men and women. The relationships, however, disappeared in males and became 
less strong in females after adjusting for age and body mass index (96). On the contrary, 
rectal infusion studies showed that colonic acetate was incorporated into serum cholesterol 
and acutely raised the concentration of serum lipids, and that these effects were blocked by 
propionate (97, 98). Nevertheless, rectal infusion studies have been criticized as being non-
physiologic (96). 
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Reduced insulin stimulation of hepatic lipogenesis 
Viscous soluble fibers may lower the rate of glucose absorption, due to increased intestinal 
viscosity (99). The lowered postprandial glucose concentrations result in lowered post-
prandial insulin concentrations and decreased insulin-stimulated hepatic HMG-CoA 
activity and hence cholesterol synthesis. Changes in other hormones may also contribute to 
the decreased insulin concentrations after viscous soluble fiber consumption. Whether 
these hormonal changes result in lowered fasting serum LDL cholesterol concentrations 
has, however, never been demonstrated in humans. 
Conclusion 
Although the exact mechanism of viscous soluble fiber action is not known, the most likely 
mechanism is that viscous soluble fibers lower the (re)absorption of in particular bile acids. 
As a result hepatic conversion of cholesterol into bile acids increases, hepatic pools of free 
cholesterol decrease and - to reach a new steady-state - endogenous cholesterol synthesis 
increases. This leads to increased activities of 7α-hydroxylase and HMG-CoA reductase to 
compensate for the losses of bile acids and cholesterol from the liver stores. Furthermore, 
hepatic LDL cholesterol receptors become upregulated to re-establish hepatic cholesterol 
stores, which ultimately leads to decreased serum LDL cholesterol concentrations (net 
effect). 
 EPIDEMIOLOGY 
More than 30 years ago, Trowell formulated the fiber hypothesis related to coronary heart 
disease (CHD). He stated, “Data have been produced to support a hypothesis that high 
consumption of natural starchy carbohydrates, taken with their full complement of fiber, is 
protective against hyperlipidemia and ischemic heart disease (IHD)” (100). After these 
initial observations, a large number of epidemiological studies have strengthened this 
hypothesis. Results of prospective cohort studies published after 1995 are summarized in 
Table 1. Only those studies are presented that contrasted the intake of total dietary fiber 
with that of cereal fiber. From this table, it is evident that in most studies cereal fiber intake 
better predicts cardiovascular risk than total fiber intake. In the studies that also examined 
relationships between other sources of viscous soluble fiber (fruits, vegetables) with CVD 
risk, results were less consistent (101-105). This however may be because fruit and 
vegetable intake was too low to find any consistent findings. Taken together, however, 
these findings led to the approval by the FDA of the health claim: “Diets low in saturated 
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fat and cholesterol and rich in fruits, vegetables, and grain products that contain some 
types of dietary fiber, particularly viscous soluble fiber, may reduce the risk of heart 
disease” (10, 11, 82, 106). 
CONCLUSION 
Many well-controlled intervention studies have shown that four major viscous soluble fiber 
types - β-glucan, psyllium, pectin and guar gum - effectively lower serum LDL cholesterol 
concentrations, without affecting HDL cholesterol or TAG concentrations. Furthermore, 
epidemiological studies suggest that a diet high in viscous soluble fiber protects against 
CVD. These findings underlie current dietary recommendations to further increase viscous 
soluble fiber intake. 
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ABSTRACT 
Objective Intake of food products rich in the viscous soluble fiber β-glucan from oats and 
products enriched with plant stanols lower serum LDL cholesterol concentrations. 
Combining two functional food ingredients into one food product may achieve additional 
reductions in serum LDL cholesterol levels.  
 
Study design In a randomized, controlled, 3-period crossover study, 40 mildly hypercholes-
terolemic men and women received for 4 weeks in random order twice-daily muesli, 
which provided in total: 5 g control fiber from wheat (control muesli), 5 g β-glucan from 
oats (oat β-glucan enriched muesli), or 5 g oat β-glucan plus 1.5 g plant stanols (combina-
tion muesli). 
 
Results The oat β-glucan enriched muesli decreased serum LDL cholesterol concentrations 
by 5.0% compared to the control muesli (p=0.013). The combination muesli significantly 
reduced LDL cholesterol levels by 9.6% compared to the control muesli (p<0.001), and by 
4.4% compared to the oat β-glucan enriched muesli (p=0.036). Serum HDL cholesterol 
and triacylglycerol concentrations did not differ between the 3 treatments. Compared to the 
control muesli, the oat β-glucan enriched muesli increased bile acid synthesis (p=0.043) 
and decreased cholesterol absorption (p=0.011). Addition of plant stanols did not influence 
bile acid synthesis, but decreased cholesterol absorption and raised cholesterol synthesis, 
compared to the control muesli (p<0.001 and p=0.016, respectively) and the oat β-glucan 
muesli (p=0.004 and p=0.814, respectively). The combination muesli decreased serum 
concentrations of sitostanol compared to the control muesli (p=0.010). Plasma concentra-
tions of lipid-soluble antioxidants did not differ between the 3 treatments.  
 
Conclusions Oat β-glucan enriched muesli effectively lowered serum LDL cholesterol 
concentrations. Addition of plant stanols to the oat β-glucan enriched muesli further 
lowered serum LDL cholesterol levels, although effects were slightly less than predicted. 
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INTRODUCTION 
LDL cholesterol-lowering functional foods are gaining a prominent position in dietary 
guidelines. Such foods contain one or more components, and therefore provide positive 
health effects beyond their traditional nutritional value (9). Examples of such food compo-
nents with approved FDA-health claims are the viscous soluble fiber β-glucan from oats 
(10), and plant sterols and stanols (12). 
β-Glucans are viscous soluble fibers, which are found in a wide variety of products such as 
oats, barley, and yeast (107). Regardless of their source, all β-glucans are polysaccharides 
composed of glucose molecules. Although the exact mechanism explaining the choles-
terol-lowering effects of β-glucan is not known, the most likely explanation is that viscous 
soluble fibers lower the (re)absorption of bile acids (47, 68, 92, 108). As a result, hepatic 
conversion of cholesterol into bile acids increases, hepatic pools of free cholesterol 
decrease and - to reach a new steady-state - endogenous cholesterol synthesis increases 
(68). Furthermore, hepatic LDL cholesterol receptors become upregulated to re-establish 
hepatic cholesterol stores, which ultimately leads to decreased serum LDL cholesterol 
concentrations (109). The FDA has approved the claim that consumption of viscous soluble 
fiber (≥ 3g/d) from whole oats, as part of a diet low in saturated fat and cholesterol, may 
reduce the risk of heart disease (10). In the most recent meta-analysis, it was estimated that 
1 g of viscous soluble fiber from oats lowered serum LDL cholesterol concentrations by –
0.037 mmol/L (59). 
Plant sterols are found in a wide variety of plant lipids, such as oils from vegetables, nuts, 
grains, seeds, wood pulp, and leaves. Plant stanols, which are saturated plant sterols, occur 
in even smaller quantities in many of the same sources. Plant sterols and stanols, collec-
tively referred to as phytosterols, are essential components of plant cell membranes and 
structurally resemble cholesterol. Typical diets commonly provide sitosterol, campesterol, 
and stigmasterol, along with smaller amounts of plant stanols like sitostanol. Phytosterols 
decrease the absorption of dietary and endogenously derived cholesterol in the intestine 
(110). Accordingly, endogenous cholesterol synthesis increases (111) and receptor-
mediated cholesterol uptake becomes upregulated, which ultimately leads to decreased 
serum LDL cholesterol concentrations (19). The FDA has therefore authorized the claim 
that foods containing at least 0.65 g per serving of plant sterol and stanol esters (daily total 
intake ≥1.3 g), as part of a diet low in saturated fat and cholesterol, may reduce the risk of 
heart disease (12). As of January 2003, the FDA recognized that the scientific literature 
supports expanding the health claim to include free forms of plant sterols and stanols, and 
to include a wider range of products, including low-fat products. The FDA further stated 
that the lowest effective daily intake of free sterols is 0.8 g/d (13). A recent meta-analysis 
concluded that daily consumption of 2.0 to 2.4 g of plant sterols or stanols lowers on 
average serum LDL cholesterol concentrations by 8.9% (14). 
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The combination of oat β-glucan and plant stanols in a food product may result in even 
larger reductions in serum LDL cholesterol concentrations, also because the underlying 
mechanisms of these two ingredients are suggested to be different. In addition, a combined 
intake may lead to a larger product variety or food product formulations that are more 
easily accepted by consumers. However, a concurrent intake of these two food compo-
nents has not been examined before. We therefore decided to investigate the effects of the 
simultaneous intake of oat β-glucan and plant stanols on lipid metabolism in mildly 
hypercholesterolemic volunteers. 
MATERIALS AND METHODS 
Study population 
Healthy men and women, aged 18 to 65 y, with slightly elevated serum total cholesterol 
concentrations, were recruited from Maastricht and surroundings by advertisements in 
local newspapers. In addition, subjects who had participated in earlier studies at our 
Department were approached. People, who were willing to participate, were given a 
detailed description of the study. After signing the informed consent form, the volunteers 
were invited for two screening visits (with an interval of ≥2 days). A screening visit 
consisted of measurements of body weight, height, blood pressure, serum total and HDL 
cholesterol concentrations, serum triacylglycerol (TAG) concentrations, presence of 
glucosuria, and hematological parameters. In addition, all subjects completed a general 
and a medical questionnaire. Forty-three men and women were selected for the study 
according to the following inclusion criteria: stable body weight (weight gain or loss <3 kg 
in the past 3 months); Quetelet-index <32 kg/m2; systolic blood pressure <160 mmHg and 
diastolic blood pressure <95 mmHg; mean serum total cholesterol concentrations between 
5.0 mmol/L and 8.0 mmol/L; mean serum TAG concentrations <4.0 mmol/L; no presence 
of glucosuria, proteinuria or anemia; no use of medication or a prescribed diet known to 
affect lipid or glucose metabolism; no history of CHD, cancer, diabetes, kidney, liver, 
pancreatic disease or malignancies <5 y ago; no abuse of drugs and/or alcohol; no 
pregnant or breast-feeding women; willingness to stop the consumption of vitamin 
supplements, fish oil capsules or products rich in plant sterols or stanols 3 weeks before the 
start of the study. Blood donation or participation in another biomedical trial was not 
allowed 30 days before and during the study. The Medical Ethical Committee of the 
University of Maastricht had approved the study and all subjects gave written informed 
consent. 
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One subject withdrew in the second week of the first period of the study because he started 
blood pressure medication. All other 42 volunteers, 20 men and 22 women, completed the 
study. The mean (± SD) age of the men was 54 ± 10 y, and mean Quetelet-index 26 ± 2 
kg/m2. For the women, these values were 51 ± 12 y and 24 ± 3 kg/m2, respectively. Fasting 
concentrations of serum total, LDL, HDL cholesterol, and TAG in men were 6.66 ± 0.82 
mmol/L, 4.48 ± 0.77 mmol/L, 1.41 ± 0.35 mmol/L, and 1.69 ± 0.81 mmol/L, respectively. 
In women, these values were 6.59 ± 0.89 mmol/L, 4.10 ± 0.84 mmol/L, 1.83 ± 0.42 
mmol/L, and 1.45 ± 0.69 mmol/L, respectively. 
Study design 
The study had a randomized, double-blinded, controlled, multiple-crossover design. Before 
the study started, the subjects were randomly divided into 3 diet groups. During the first 4 
weeks, one group consumed muesli enriched with wheat fiber (control muesli), a second 
group consumed a muesli enriched with β-glucan from oats (oat β-glucan enriched muesli), 
and a third group a muesli enriched with both oat β-glucan and plant stanols (combination 
muesli). After a washout period of 2 weeks, during which time the participants consumed 
their habitual diets, subjects crossed over to another type of muesli for another period of 4 
weeks. After this period, a second washout period of 2 weeks was introduced. For the last 4 
weeks of the study, subjects received the type of muesli that they had not consumed during 
the first two periods. Subjects consumed the products twice daily (2 sachets of 50 g), with 
an interval of at least 5 h. 
To improve swelling of the fibers, the muesli had to be consumed with 200 mL liquid (e.g. 
milk, orange juice) or with yogurt. To avoid weight gain, subjects were urged to consume 
the muesli instead of another food item (e.g. bread, cereals). The energy content (1700 kJ/ 
100 g), total fiber content, fat/protein/carbohydrate content, and fatty acid composition of 
the three experimental products were the same. Each sachet of the oat β-glucan muesli 
provided 2.5 g β-glucan from oats. A sachet of the combination muesli also provided 2.5 g 
oat β-glucan with 0.75 g plant stanols, provided as fatty acid esters. Extra daily consump-
tion of oat β-glucan was therefore 0 or 5 g, and daily consumption of plant stanols 1.5 g 
(Table 1). 
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TABLE 1: Composition of the experimental products1. 
 Control Oat β-glucan Combination 
Energy (kJ) 1683 1671 1672 
Protein (g)  9.60 13.40 12.40 
Carbohydrates (g) 13.90 14.20 15.10 
Lipids (g) 15.20 15.30 14.60 
Total fiber (g) 11.40 11.70 11.50 
β-Glucan (g)  0.00  5.09   5.03 
Stanols (g)  0.00  0.00    1.481 
1Plus 0.10 g sterols 
 
 
Body weight without shoes or heavy clothes was recorded on day 0 and at the end of 
weeks 3 and 4. At the end of the treatment period, subjects recorded their food intake 
(previous 3 weeks) by completing food-frequency questionnaires (FFQ) to estimate their 
energy and nutrient intakes. FFQ were checked by a registered dietician in the presence of 
the subjects. The subjects recorded any illness, medication used, menstrual phase, alcohol 
consumption, any deviations to the study protocol, and any side-effects experienced 
(headache, stomach complaints, nausea, bloated feeling, flatulence, diarrhea, constipation, 
itching, eruptions/rashes, fatigue, and dizziness). 
Other possible side-effects were monitored on day 0 and at the end of week 4 by assessing 
hematological parameters and parameters to measure kidney and liver function. 
Blood sampling 
Volunteers fasted overnight, did not use alcohol the previous day and did not smoke on the 
morning of blood sampling. Venous blood samples were taken between 07:45 and 11:00 
on day 0 and on weeks 3 and 4 of each study period. All venipunctures were generally 
done by the same person, in the same room, and at the same time of the day. Blood was 
sampled from a forearm vein using vacutainers under minimal stasis with the subject in 
supine position.  
Ten mL of blood was collected in a serum tube (Becton Dickinson Vacutainer Systems, 
Franklin Lakes, NJ) for analysis of serum lipids (total serum cholesterol, HDL cholesterol, 
total TAG), lipoproteins (apoB and apoA-I), plant sterols and stanols (sitosterol, sitostanol, 
campesterol, and campestanol), a cholesterol precursor (lathosterol), and indices of kidney 
and liver function. Serum tubes were kept at room temperature after blood sampling. At 
least 1 h after venipuncture, serum was obtained by centrifuging at 2000 x g for 30 min at 
4°C. Serum was aliquoted and thereafter stored at –80°C. Furthermore, 10 mL of blood was 
collected in an EDTA tube (Becton Dickinson Vacutainer Systems) for analysis of hemato-
logical variables, lipid-soluble antioxidants, and 7α-hydroxy-4-cholesten-3-one (7α-OHC), 
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a marker of bile acid synthesis. Hematological parameters were determined directly after 
sampling. Plasma was obtained immediately by centrifugation at 2000 x g for 30 min at 
4°C. Plasma was then divided into aliquots, snap-frozen, and stored at –80°C. 
Analyses 
Concentrations of total cholesterol (ABX Diagnostics, Montpellier, France), HDL choles-
terol (precipitation method; Roche Diagnostics Corporation, Indianapolis, IN), and TAG 
corrected for free glycerol (Sigma-Aldrich Chemie, Steinheim, Germany) were analyzed 
enzymatically in serum. ApoA-I and apoB concentrations were analyzed in serum using an 
immunoturbidimetric method (ABX Diagnostics, Montpellier, France). Serum LDL choles-
terol concentrations were calculated by using the formula of Friedewald et al. (112). All 
samples from one subject were analyzed in the same analytical run.  
Serum plant sterols and stanols (sitosterol, sitostanol, campesterol, and campestanol) and 
the cholesterol precursor lathosterol were determined as described (111). Before analysis, 
serum samples of weeks 3 and 4 of each period were pooled.  
Serum samples were also analyzed to determine parameters of liver function (alanine 
transaminase, aspartate aminotransferase, γ-glutamyl transpeptidase (GGT), alkaline 
phosphatase, and total bilirubin), kidney function (creatinine), and inflammation (C-
reactive protein; CRP). These measurements were carried out on a Beckman Coulter 
Synchron LX20 PRO Clinical System (Beckman Coulter Inc., Fullerton, CA). 
Plasma samples were analyzed on a Coulter Ac•T diff (Coulter Corporation, Miami, FL) for 
the following hematological variables: number of white blood cells, % of lymphocytes, % 
of monocytes, % of granulocytes, number of red blood cells, hemoglobin, hematocrit, 
mean corpuscular volume, and number of platelets.  
Before analyzing lipid-soluble antioxidants, plasma samples taken at weeks 3 and 4 of each 
period were pooled. Concentrations of tocopherols (α-tocopherol, δ-tocopherol, and β- 
and γ-tocopherol), carotenoids (α-carotene, β-carotene, lycopene, lutein/zeaxanthin, β-
cryptoxanthin, and phytofluene), and retinol were determined simultaneously according to 
a modification of the assay of Hess et al (113), as described by Oostenbrug et al. (114). All 
samples from one subject were analyzed in the same analytical run. 
Before analyzing 7α-OHC, plasma samples of weeks 3 and 4 of each period were pooled. 
7α-OHC was determined by HPLC after modification of the method described by Gälman 
et al. (115). All analyses were done in duplicate. Briefly, plasma (0.5 mL) was diluted with 
2.5 mL of saline and 25 μL of the internal standard [7β-hydroxy-4-cholesten-3-one (5 
ng/μL) dissolved in H2O] was added. EC-C8 Isolute SPE columns (500 mg, 3 mL, Sopachem 
NV, Brussels, Belgium) were prewashed with 2 x 2 mL pure methanol and with 2 x 2 mL of 
water. Columns were then mounted on a Vac Elut SPS 24 (Analytichem International, 
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Harbor City, CA), to which a removable custom-made stainless steel water-jacketed block 
heater with 12 positions had been added. The column heater was connected to a water 
bath (model K6, MGW Lauda, Königshofen, Germany) set on 65.3°C in order to obtain a 
column temperature of 64°C. To facilitate passage through the columns, the samples were 
first heated to 64°C for 20 min. Subsequently, the supernatant, obtained after centrifugation 
at 2000 x g for 5 min at 2°C, was sonicated in water for 15 min and incubated at 37°C for 
15 min prior to loading onto the preheated columns. A stream of nitrogen was used 
occasionally to facilitate passage through columns. The eluted product was evaporated to 
dryness at 60°C under a stream of nitrogen and dissolved in 110 μL acetonitrile; 75 μL of 
this was injected into the HPLC system. All samples from one subject were analyzed within 
one run. 7α-OHC was quantified from the heights of the respective peaks using the known 
amount of internal standard and the response factor. 
Statistical analyses 
The statistical power needed to detect a true difference of 5% in serum LDL concentrations 
between the treatments with α=0.05 was 80%. Before the statistical analyses were carried 
out, serum lipid and lipoprotein concentrations from weeks 3 and 4 of each period were 
averaged for each subject. The data were analyzed by a three-way (subject number, period, 
and diet) ANOVA using the general linear model procedure. Differences in effects on the 
variables of interest were examined with diet and period as fixed factors, and subject 
number as a random factor. When a significant diet effect was found, the 3 treatments were 
compared pairwise using a Tukey post-hoc test for multiple comparisons. Values are 
presented as means ± SD. Differences were considered significant at p≤0.05. Statistical 
analyses were performed using SPSS 11.0 (version 11.0.3) for MacIntosh OS X (version 
10.3.9). 
RESULTS 
Side effects 
Side effects were monitored by assessing hematological parameters, and indices of kidney 
and liver function. Throughout the study, all variables remained within the normal range 
for all subjects and no treatment effects were present. Compared to other subjects, 
however, GGT values were consistently increased for two subjects during the study (100 
U/L and 180 U/L during the control period, 90 U/L and 132 U/L during the oat β-glucan 
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period, and 93 U/L and 105 U/L during the combination period). Results of these two 
subjects were therefore excluded from further statistical analyses. Except for the effects on 
the marker of bile acid synthesis 7α-OHC, this did not change the conclusions.  
Dietary intake and body weight 
As calculated from the returned sachets, daily consumption of oat β-glucan during the oat 
β-glucan period was 4.8 ± 0.3 (mean ± SD) g. During the combination period, daily intake 
of oat β-glucan and plant stanols was 4.8 ± 0.3 g and 1.4 ± 0.1 g, respectively. 
Daily energy intake and nutrient composition of the diets did not differ among the 3 
treatment groups, except for polyunsaturated fatty acids (p=0.045 for diet effect). However, 
between-diet comparisons were not significant (Table 2). 
 
 
TABLE 2: Nutrient composition of the 3 diets according to the food-frequency questionnaires1. 
 Control Oat β-glucan Combination p for diet effect2 
Energy   
  (MJ/d)   8.1 ± 2.4  8.3 ± 2.5  8.0 ± 2.4 0.256 
  (kcal/d) 1929 ± 582 1980 ± 603 1919 ± 581 0.255 
Protein (% of energy) 17.8 ± 3.0 18.0 ± 3.2 18.0 ± 3.4 0.815 
Fat (% of energy) 34.0 ± 5.7 34.0 ± 5.5 33.7 ± 5.7 0.737 
  Saturated fatty acids 12.5 ± 2.8 12.2 ± 2.4 12.4 ± 2.5 0.450 
  Monounsaturated fatty acids 11.1 ± 2.6 11.1 ± 2.7 11.0 ± 2.6 0.990 
  Polyunsaturated fatty acids   6.5 ± 6.6  6.8 ± 1.7  6.4 ± 1.6 0.045 
Carbohydrates (% of energy) 45.7 ± 5.8 45.1 ± 5.3 45.8 ± 6.1 0.425 
Alcohol (% of energy)   2.7 ± 2.6  3.0 ± 2.8  2.8 ± 2.9 0.506 
Cholesterol (mg/MJ) 23.3 ± 6.1 22.2 ± 5.3 22.1 ± 6.5 0.139 
Dietary fiber (g/MJ)   2.8 ± 0.8  2.7 ± 0.7  2.7 ± 0.8 0.457 
1 All values are means ± SD; n = 40 (19 men and 21 women). Pairwise comparisons by the least-squares means 
procedure with Tukey’s adjustment in a general linear model did not reveal any significant differences between any 
two diets. 
2 Calculated by using a general linear model with subject number as a random factor and diet and period as fixed 
factors. 
 
 
Body weights did not differ after the control (74 ± 11 kg), oat β-glucan (74 ± 11 kg), and 
combination (74 ± 11 kg) diet periods. Weight changes during each diet period were 
significant, but consistent [0.42 ± 0.80 kg during the control period (p=0.001), 0.37 ± 0.93 
kg during the oat β-glucan period (p=0.013), and 0.25 ± 0.68 kg during the combination 
period (p=0.027)]. 
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Serum lipids and lipoproteins 
The oat β-glucan enriched muesli decreased serum total cholesterol concentrations by 0.23 
mmol/L (3.4%) compared to the control muesli (p=0.015) (Table 3). The combination 
muesli reduced total cholesterol concentrations by 0.48 mmol/L (7.1%) compared to the 
control muesli (p<0.001), and by 0.25 mmol/L (3.6%) compared to the oat β-glucan 
enriched muesli (p=0.008). 
 
 
TABLE 3: Effects of 4-weeks daily intake of oat β-glucan and oat β-glucan plus plant stanols on fasting serum lipid 
and lipoprotein concentrations in healthy men and women1. 
 Control Oat β-glucan Combination p for diet effect2 
Total cholesterol (mmol/L) 6.49 ± 1.03  6.26 ± 0.96a    6.01 ± 0.92a,b <0.001 
LDL cholesterol (mmol/L) 4.31 ± 0.96  4.09 ± 0.91a    3.89 ± 0.90a,b <0.001 
HDL cholesterol (mmol/L) 1.46 ± 0.46 1.45 ± 0.49 1.45 ± 0.52   0.768 
TAG (mmol/L) 1.52 ± 0.84 1.66 ± 1.36 1.56 ± 0.94   0.277 
Total: HDL cholesterol 5.03 ± 1.12  4.81 ± 1.09a    4.56 ± 1.01a,b <0.001 
ApoB-100 (g/L) 1.24 ± 0.27 1.21 ± 0.27    1.15 ± 0.25a,b <0.001 
ApoA-I (g/L) 1.62 ± 0.31 1.60 ± 0.34 1.57 ± 0.32   0.065 
1 All values are means ± SD; n = 40 (19 men and 21 women). Superscript letters indicate significant differences 
(p≤0.05): avs. control; bvs. oat β-glucan (pairwise comparisons by least-squares means procedure with Tukey’s 
adjustment in a general linear model). 
2 Calculated by using a general linear model with subject number as a random factor and diet and period as fixed 
factors. 
 
 
After oat β-glucan consumption, serum LDL cholesterol concentrations were 0.21 mmol/L 
(5.0%) lower than after the control period (p=0.013). The combination muesli effectively 
lowered LDL cholesterol concentrations by 0.39 mmol/L (9.6%) compared to the control 
muesli (p<0.001), and by 0.18 mmol/L (4.4%) compared to oat β-glucan intake only 
(p=0.036).  
Consumption of oat β-glucan significantly decreased the ratio of total-to-HDL cholesterol 
by 0.09 (1.7%) compared to the control muesli (p=0.016). Consumption of oat β-glucan 
plus plant stanols reduced the ratio of total-to-HDL cholesterol by 0.27 (5.5%) compared to 
the control muesli (p<0.001), and by 0.18 (3.4%) compared to consumption of oat β-
glucan only (p=0.004). 
The combination muesli lowered serum apoB concentrations by 0.09 g/L (6.7%) compared 
to the control muesli (p<0.001), and by 0.06 g/L (4.1%) compared to the oat β-glucan 
enriched muesli (p=0.003). ApoB concentrations did not differ after the control and oat β-
glucan periods. Serum HDL cholesterol, apoA-I, and TAG concentrations did not differ 
after the 3 diet treatments. 
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Markers for cholesterol absorption, cholesterol synthesis, and bile acid synthesis 
Oat β-glucan consumption increased cholesterol-standardized serum lathosterol concentra-
tions by 0.20 μmol/mmol (17.6%) compared to the control muesli (p=0.050), indicating an 
elevated cholesterol synthesis (Table 4). The combination muesli increased cholesterol-
standardized serum lathosterol concentrations by 0.26 μmol/mmol (19.1%) compared to 
the control muesli (p=0.016). Relative to the oat β-glucan enriched muesli, the combina-
tion muesli did not alter cholesterol-standardized serum lathosterol concentrations 
(p=0.814).  
 
 
TABLE 4: Effects of 4-weeks daily intake of oat β-glucan and oat β-glucan plus plant stanols on markers for 
cholesterol synthesis, cholesterol absorption, and bile acid synthesis after correction for total cholesterol in healthy 
men and women1. 
 Control Oat β-glucan Combination p for diet effect2 
Lathosterol  195 ± 60 215 ± 60a 221 ± 57a   0.010 
Campesterol            318 ± 145           282 ± 129a    241 ± 114a,b <0.001 
Sitosterol  123 ± 60 113 ± 55 90.7 ± 44a,b <0.001 
Campestanol    8.26 ± 7.19  6.72 ± 4.77 6.69 ± 6.36   0.164 
Sitostanol    2.26 ± 1.19  2.10 ± 1.21  1.62 ± 0.94a   0.008 
7α-OHC   3.57 ± 2.22   4.28 ± 3.00a 4.18 ± 3.03   0.031 
1All values are means ± SD; n = 40 (19 men and 21 women), except for analyses of sterols and stanols (n=39; 19 men 
and 20 women; 1 missing value). All values are expressed in 102x μmol/mmol total cholesterol, except for 7α-OHC 
(expressed in mg/mmol total cholesterol). Superscript letters indicate significant differences (p≤0.05): avs. control; bvs. 
oat β-glucan (pairwise comparisons by least-squares means procedure with Tukey’s adjustment in a general linear 
model) 
2 Calculated by using a general linear model with subject number as a random factor and diet and period as fixed 
factors. 
 
 
Compared to the control period, cholesterol-standardized serum campesterol concentra-
tions significantly decreased by 0.36 μmol/mmol (7.1%) after oat β-glucan consumption 
(p=0.011), indicating decreased intestinal cholesterol absorption. The muesli enriched with 
oat β-glucan plus plant stanols significantly decreased cholesterol-standardized campes-
terol concentrations by 0.76 μmol/mmol (20.7%) compared to the control muesli 
(p<0.001), and by 0.40 μmol/mmol (11.1%) compared to oat β-glucan intake only 
(p=0.004). Changes in sitosterol concentrations paralleled those of campesterol, except that 
the effects of the oat β-glucan enriched muesli did not differ from those of the control 
muesli. 
The combination muesli significantly decreased cholesterol-standardized serum sitostanol 
concentrations by 0.007 μmol/mmol (21.3%) compared to the control muesli (p=0.010). 
Compared to oat β-glucan intake only, the effects of the combined intake on cholesterol-
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standardized serum sitostanol concentrations almost reached significance (p=0.066). The 
control and oat β-glucan periods did not differ in cholesterol-standardized serum sitostanol 
concentrations (p=0.753). Campestanol concentrations did not differ significantly between 
the 3 treatment groups.  
Compared to the control muesli, the muesli enriched with oat β-glucan effectively 
increased cholesterol-standardized plasma 7α-OHC concentrations by 0.70 mg/mmol 
(24.4%) (p=0.043). The control and combination, and the oat β-glucan and combination 
periods did not differ in cholesterol-standardized plasma 7α-OHC concentrations (p=0.106 
and p=1.000, respectively). 
Lipid-soluble antioxidants 
After correction for serum LDL cholesterol concentrations, plasma total tocopherol, 
oxygenated carotenoid, and hydrocarbon carotenoid concentrations did not differ signifi-
cantly between the 3 treatment periods. Also, plasma retinol concentrations were not 
affected (data not shown). 
DISCUSSION 
In this study, consumption of muesli enriched with oat β-glucan significantly decreased 
serum LDL cholesterol concentrations. Subjects consumed twice daily 2.4 g of oat β-
glucan, while the observed decrease in serum LDL cholesterol was 0.21 mmol/L. This is in 
agreement with the predicted reduction in LDL cholesterol of 0.18 mmol/L, based on the 
meta-analysis by Brown et al. (59). The reported study results on the hypocholesterolemic 
effects of oat β-glucan are however variable. Inconsistencies in the reported effects of oat 
products may be due to several factors, such as mode of administration, or differences in 
solubility or molecular weight.  
The combined effects of oat β-glucan and plant stanols on LDL cholesterol concentrations 
have not been systematically examined. We found that addition of plant stanols to the oat 
β-glucan enriched muesli significantly lowered LDL cholesterol concentrations by 4.4%. 
This effect is smaller than the estimated mean change of -8.5% for daily intakes of 1.5 to 
1.9 g sterols or stanols (14). Thus, our findings suggest that the viscous soluble fiber β-
glucan from oats may reduce the efficacy of plant stanols. However, several studies have 
concluded that the effects of plant sterols and stanols do not change when part of a 
recommended diet (14, 116), which is usually accompanied by a decrease in fat and 
cholesterol intake. When fats are replaced by complex carbohydrates, an increase in fiber 
intake can be expected as well. The majority of these studies (117-122) did unfortunately 
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not document (changes in) the intake of viscous soluble fibers. Recently, Yoshida et al. 
(123) examined the effects of 1.8 g/d free plant sterols with or without 10 g/d glucoman-
nan, a viscous soluble fiber derived from konjac root, in individuals with and without type 
II diabetes. In the non-diabetic group, serum LDL cholesterol concentrations decreased 
after the plant sterol, glucomannan, and combined intakes by 5.4%, 13.8%, and 21.7%, 
respectively. The results were less pronounced in the diabetic patients. Although the effects 
of the plant sterols were less than predicted, these findings did not suggest that glucoman-
nan attenuated the LDL-cholesterol lowering effects of the free plant sterols. In another 
recent study, a combination therapy including 2.6 g/d plant sterols and 10 g/d psyllium 
also decreased LDL cholesterol beyond expectations (14, 59). According to the literature, 
daily consumption of >2.5 g sterols or stanols lowers LDL cholesterol concentrations on 
average by 11.3%, which is already higher than the 10% decrease in serum LDL choles-
terol levels found after the combination therapy. However, separate contribution of the 
individual components was not evaluated (124). Also other recent studies with similar 
intakes of plant sterols and stanols have reported effects less than the estimated mean 
change of –8.5% (125-128). Moreover, Clifton et al. (129) reported that plant sterols (1.6 
g/d) incorporated in milk, yoghurt, bread, and cereals decreased serum LDL cholesterol 
concentrations by 15.9%, 8.6%, 6.5%, and 5.4%, respectively. Their results suggest that 
the food matrix may influence the cholesterol-lowering effectiveness of plant sterols. 
Altogether, the estimated mean percentage reduction of 8.5% in LDL cholesterol at daily 
intakes of 1.5 to 2.1 g of plant sterols or stanols may be overrated (14). Nevertheless, the 
4.4% change in LDL cholesterol is somewhat less than in other studies at comparable 
intakes and an effect of oat β-glucan or the food matrix on the efficacy of plant stanols can 
therefore not be excluded. In support, oat β-glucan consumption decreased serum 
cholesterol-standardized stanol concentrations, although the effect on campestanol was not 
statistically significant (p=0.164). Also adding plant stanols to the oat β-glucan enriched 
muesli did not change serum cholesterol-standardized stanol concentrations. Consumption 
of plant stanols normally leads to an increase in their serum concentrations (64). Thus, 
these findings suggest that oat β-glucan may interfere with the absorption of plant stanols. 
Plant stanols reduce intestinal cholesterol absorption through competition for micellar 
incorporation (110). However, recent findings indicate that stanols may also enter the 
intestinal cells and promote cholesterol efflux back into the intestinal lumen (18, 110). We 
speculate that a higher intestinal viscosity may lower the transport of plant stanols into the 
enterocytes. As a result, not only their serum concentrations, but also their cholesterol-
lowering efficacy may decrease. Alternatively, an increase in intestinal viscosity may affect 
lipid emulsification by increasing the droplet size of emulsions thereby decreasing the 
emulsion interface area. This may reduce the rate of lipolysis (130) and possibly also the 
hydrolysis of plant stanols. It can further be speculated that the active free plant stanols are 
released later in the intestinal tract, which may affect their efficacy and absorption. 
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Oat β-glucan consumption significantly increased total cholesterol-standardized 7α-OHC 
concentrations, indicating an increased bile acid synthesis. Additionally, cholesterol-
standardized campesterol and sitosterol concentrations decreased, suggesting reduced 
cholesterol absorption, although only the effect on campesterol was statistically significant. 
Cholesterol-standardized lathosterol concentrations, which are positively related with 
endogenous cholesterol synthesis, increased. Overall, these findings are in line with the 
proposed mechanism by which viscous soluble fibers decrease serum cholesterol concen-
trations (64, 68, 92, 108). Addition of plant stanols to the muesli enriched with oat β-
glucan did not further increase bile acid synthesis. In addition, plant stanols significantly 
lowered cholesterol absorption and tended to increase endogenous cholesterol synthesis, 
in line with their suggested working mechanism. 
Since viscous soluble fibers can change the physical characteristics of the contents of the 
small intestine, they may interfere with the absorption of lipid-soluble antioxidants. Oat β-
glucan consumption did, however, not change LDL cholesterol-standardized lipid-soluble 
antioxidant concentrations, which agrees with the results of previous studies (64, 131). In 
addition, we found no effects of a daily intake of 1.4 g plant stanols on LDL cholesterol-
standardized lipid-soluble antioxidant concentrations. Indeed, a meta-analysis showed that 
lipid-soluble antioxidants were not affected by stanols after correction for the decrease in 
cholesterol, with the exception of β-carotene (14). However, effects on β-carotene 
concentrations were mainly seen at daily intakes of >2 g plant stanols (14, 18).  
In summary, our results showed that muesli enriched with oat β-glucan effectively lowered 
serum LDL cholesterol concentrations. Addition of plant stanols to the oat β-glucan 
enriched muesli further lowered serum LDL cholesterol levels, although less than pre-
dicted. Whether this is due to an effect of the viscous soluble fiber oat β-glucan or the food 
matrix needs further investigation. 
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ABSTRACT 
Objective We have earlier demonstrated that muesli enriched with oat β-glucan effectively 
lowered serum LDL cholesterol concentrations. Addition of plant stanols further lowered 
serum LDL cholesterol levels. Besides these hypocholesterolemic effects, oat β-glucan and 
plant stanols may also affect inflammatory processes.  
 
Study design Forty-two mildly hypercholesterolemic subjects randomly received for 4 
weeks in a crossover design: control muesli (5 g/d of control fiber), oat β-glucan enriched 
muesli (5 g/d of oat β-glucan), or combination muesli (5 g/d of oat β-glucan plus 1.5 g/d of 
plant stanols). Changes in cytokine production (IL-6, IL-8, and TNF-α) of LPS-stimulated 
peripheral blood mononuclear cells (PBMC) and whole blood were evaluated, as well as 
changes in plasma high-sensitivity (hs)-CRP. Additionally, changes in expression profiles of 
84 genes involved in atherosclerosis metabolism were assessed in isolated PBMC.  
 
Results IL-6, IL-8, and TNF-α production by PBMC and whole blood after LPS stimulation 
did not differ between the treatments. Also hs-CRP levels were similar. Oat β-glucan 
consumption did not change gene expression, while only 3 genes (ADFP, CDH5, CSF2) out 
of the 84 genes from the atherosclerotic risk panel were differentially expressed (p<0.05) 
after consumption of plant stanols.  
 
Conclusion Consumption of oat β-glucan with or without plant stanols did not influence 
inflammatory parameters in mildly hypercholesterolemic subjects. 
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INTRODUCTION 
It is becoming more and more established that inflammation plays an important role in the 
development of atherosclerosis and cardiovascular disease (CVD). Many studies have 
therefore been initiated to examine the effects of diets and dietary components on inflam-
matory markers. In this respect, much attention is paid to functional foods. Such foods 
contain (or lack) one or more components and therefore provide positive health effects 
beyond their traditional nutritional value. Examples of such food components with 
approved FDA-health claims are the viscous soluble fiber β-glucan from oats (10), and 
plant sterols and stanols (12). These components were approved because of their consistent 
LDL cholesterol-lowering effects. We have recently demonstrated that muesli enriched with 
β-glucan derived from oats effectively lowered serum LDL cholesterol concentrations in 
slightly hypercholesterolemic subjects. Addition of plant stanols to the oat β-glucan 
enriched muesli even further lowered serum LDL cholesterol levels (63). 
Besides these hypocholesterolemic effects, in vitro and animal studies have suggested that 
oat β-glucan and phytosterols may also affect immune and inflammatory processes (29-37). 
Data from human studies are however limited and inconsistent. So far, only one study has 
examined the effects of oat β-glucan on inflammatory parameters. In this study, Queenan et 
al. could not demonstrate that dietary supplementation with oat β-glucan changed plasma 
concentrations of C-reactive protein (CRP) in hypercholesterolemic subjects (61). Like for 
oat β-glucan, effects of plant sterol and stanols on inflammatory markers have been hardly 
studied. Several studies showed no significant effects on markers of inflammation, such as 
CRP, soluble adhesion molecules, and monocyte chemotactic protein-1 (MCP1) (132-134). 
Nevertheless, Cater et al. (135) showed that combined administration of plant stanols with 
a statin compared to statin-treatment alone significantly reduced CRP concentrations in 
patients with a positive history for CVD. On the other hand, they found no significant 
change in CRP levels of hypercholesterolemic subjects with plant stanols alone. Devaraj et 
al. (136) found a significant reduction in CRP levels after consumption of a sterol-enriched 
orange juice in healthy subjects. Altogether, more research is needed to clarify the role of 
these cholesterol-lowering dietary components on the inflammatory processes related to 
atherosclerosis and CVD. 
To explore whether the effects of oat β-glucan enriched muesli with or without plant 
stanols not only changed LDL cholesterol, but also inflammatory processes, we first 
examined their effects on plasma high-sensitivity CRP (hs-CRP) concentrations. Hs-CRP is 
considered a marker for low-grade systemic inflammation and is positively associated with 
an increased risk for future cardiovascular events (38). Since leukocyte reactivity is easily 
triggered by modified LDL cholesterol, potential changes may be more evident in hyper-
cholesterolemic subjects. We therefore determined the effects of oat β-glucan with or 
without plant stanols on leukocyte function. This was studied ex vivo by measurement of 
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inflammatory cytokines (IL-6, IL-8, and TNF-α) production after LPS stimulation of isolated 
peripheral blood mononuclear cells (PBMC) and of whole blood. IL-6, IL-8, and TNF-α are 
pro-inflammatory markers involved in the development of atherosclerotic lesions (137, 
138). Finally, we studied in PBMC the effects of these functional ingredients on the 
expression of 84 genes involved in atherosclerosis. 
MATERIALS AND METHODS 
Study population 
This trial was part of a study on the simultaneous effects of oat β-glucan and plant stanols 
on the lipoprotein profile in healthy men and women with slightly elevated serum 
cholesterol concentrations. Details of the study have already been published (63). All 
participants were given a detailed description of the experimental protocol and purpose of 
the study before they gave their written informed consent. They were invited for 2 screen-
ing visits, which consisted of measurements of body weight, height, blood pressure, serum 
total and HDL cholesterol concentrations, serum triacylglycerol (TAG) concentrations, 
presence of glucosuria, and hematological parameters. In addition, all subjects had to fill in 
a general and medical questionnaire. 
Participants were selected for the study according to the following inclusion criteria: stable 
body weight (weight gain or loss <3 kg in the past 3 months); Quetelet-index <32 kg/m2; 
systolic blood pressure <160 mmHg; diastolic blood pressure <95 mmHg; mean serum 
total cholesterol concentrations between 5.0 mmol/L and 8.0 mmol/L; mean serum TAG 
concentrations <4.0 mmol/L; no presence of glucosuria, proteinuria or anemia; no use of 
medication or a prescribed diet known to affect lipid or glucose metabolism; no history of 
coronary heart disease, cancer, diabetes, kidney, liver, pancreatic disease or malignancies 
<5 y ago; no abuse of drugs and/or alcohol; no pregnant or breast-feeding women; 
willingness to stop the consumption of vitamin supplements, fish oil capsules or products 
rich in plant stanols or sterols 3 weeks before the start of the study. Blood donation or 
participation in another biomedical trial was not allowed 30 days before and during the 
study. The Medical Ethical Committee of the University of Maastricht had approved the 
study and all subjects gave written informed consent. 
Forty-three volunteers were selected for the study. One man withdrew in the 2nd week of 
the 1st period of the study because he started blood pressure medication. All other 42 
volunteers, 20 men and 22 women, completed this study. Baseline characteristics are 
shown in Table 1. 
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TABLE 1: Baseline characteristics of the participants1. 
 Control Oat β-glucan Combination p value2 
Number (M/F) 13 (8/5) 14 (6/8) 15 (6/9)  
Age (y)   54 ± 10   51 ± 13   51 ± 10 0.769 
BMI (kg/m2) 25 ± 3 25 ± 2 25 ± 3 0.997 
Systolic blood pressure (mmHg) 139 ± 17 140 ± 13 135 ± 15 0.690 
Diastolic blood pressure (mmHg) 85 ± 9 88 ± 8   86 ± 11 0.723 
Total cholesterol (mmol/L)   6.53 ± 0.96   6.53 ± 1.10   6.14 ± 1.13 0.537 
LDL cholesterol (mmol/L)   4.02 ± 1.06   4.43 ± 1.00   3.88 ± 0.85 0.307 
HDL cholesterol (mmol/L)   1.57 ± 0.59   1.57 ± 0.42   1.44 ± 0.49 0.744 
TAG (mmol/L)   1.90 ± 1.42   1.15 ± 0.57   1.63 ± 0.78 0.140 
1All values are presented as means ± SD; n = 42. 
2Data were analyzed by ANOVA using the general linear model procedure. Differences were considered significant 
at p<0.05. 
Study design 
The study had a randomized, double-blinded, controlled, multiple crossover design (63). 
Briefly, subjects consumed for 4 weeks in random order: control muesli (4.8 g/d of control 
fiber), oat β-glucan enriched muesli (4.8 g/d of oat β-glucan), or combination muesli [4.8 
g/d of oat β-glucan plus 1.4 g/d of plant stanols (as esters)]. There was a 2-week washout 
period between the treatment periods. 
Body weights did not differ after the control (73.8 ± 11.1 kg), oat β-glucan (73.9 ± 11.0 kg), 
and combination (73.8 ± 11.1 kg) diet periods (p=0.997). 
Blood sampling 
The volunteers fasted overnight and were not allowed to use alcohol the day preceding or 
to smoke on the morning of blood sampling (63). Blood was collected in three 10 mL 
EDTA tubes (Becton Dickinson Vacutainer Systems, Breda, The Netherlands) for analysis of 
plasma hs-CRP concentrations and total RNA isolation. In addition, 16 mL of blood was 
sampled in 2 endotoxin-free heparinized tubes (Becton Dickinson Vacutainer Systems, 
Breda, The Netherlands) for PBMC and whole blood stimulation. After sampling, all 5 tubes 
were immediately placed on ice. EDTA Plasma was obtained directly by centrifugation of 1 
EDTA tube at 2000 x g for 30 min at 4°C. Plasma was then divided into aliquots, snap-
frozen, and subsequently stored at -80°C until analysis. 
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CRP analysis 
Hs-CRP concentrations were measured in EDTA plasma with a highly sensitive immuno-
turbidimetric assay (Kamiya Biomedical Company, Seattle, WA, USA) (139).  
PBMC and whole blood stimulation 
Heparinized blood of 30 randomly selected subjects was used to study the effects of oat β-
glucan and plant stanols on leukocyte reactivity. The baseline characteristics and responses 
of this subgroup were comparable to that of the whole group. Leukocyte reactivity was 
evaluated by stimulating both PBMC as well as whole blood with LPS as described (139). 
Briefly, to examine ex vivo cytokine production in whole blood, 4 sterile 2 mL microcentri-
fuge tubes were each filled with 2 mL blood. Immediately, 20 μL LPS (Escherichia coli 
lipopolysaccharide serotype 055:B5, Sigma Chemical Co., St. Louis, MO, USA; final 
concentration 10 ng/mL in endotoxin-free buffered saline) was added to 2 tubes and 20 μL 
polymyxin B (antibiotic, Bedford Laboratories, Bedford, OH, USA; final concentration 1 
mg/mL) to the remaining 2 tubes. Blood samples were incubated at 37°C for 3 h (determi-
nation of plasma TNF-α levels) or 21 h (determination of plasma IL-6 and IL-8 levels). After 
incubation, samples were centrifuged at 1000 x g for 30 min and platelet-poor plasma was 
stored at -80°C until analysis. To examine ex vivo cytokine production by PBMC, cells 
were isolated from whole blood using Lymphoprep (Nycomed Pharma AS, Oslo, Norway) 
under sterile conditions. After isolation, PBMC of one subject were immediately plated in 4 
wells of a 24-well flat-bottom culture plate (2.5 x 106 cells/mL per well; 150-500 μL per 
well). For each subject, PBMC of 2 wells were mixed with 10 μL LPS (final concentration 
10 ng/mL) and the remaining 2 wells with 10 μL polymixin B (final concentration 1 
mg/mL). RPMI-1640 was used as the culture medium, containing 1% penicil-
lin/streptomycin, 1% sodium pyruvate, and 1% of a heat-inactivated human serum pool. 
The cells were incubated for 3 h (determination of plasma TNF-α levels) or 21 h (determi-
nation of plasma IL-6 and IL-8 levels) at 37°C. After incubation, the culture media were 
aspirated. The aspirated media were centrifuged at 1000 x g for 30 min to obtain cell-free 
media, which were stored at -80°C until analysis. 
Cytokine analyses 
TNF-α, IL-6, and IL-8 concentrations in platelet-poor plasma of stimulated whole blood 
and cell-free media of stimulated PBMC were assessed by sandwich ELISA as previously 
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described (139). Briefly, plates (Greiner Bio-One, Frickenhausen, Germany) were coated 
with monoclonal murine antihuman TNF-α, IL-6, and IL-8 antibodies. Recombinant human 
TNF-α, IL-6, and IL-8 were used for their respective standard titration curves. Immobilized 
TNF-α was detected using a specific rabbit-anti-human TNF-α antibody, followed by the 
addition of goat-anti-rabbit peroxidase (Jackson ImmunoResearch, West Grove, PA, USA) 
and tetramethylbenzidine (TMB) substrate (Kirkegaard & Perry Laboratories, Gaithersburg, 
MD, USA). Immobilized IL-6 or IL-8 was detected using a specific biotinylated rabbit-anti-
human IL-6 or IL-8 polyclonal antibody, followed by the addition of peroxidase-conjugated 
streptavidin (Zymed Laboratories, San Francisco, CA, USA) and TMB substrate. 
Total RNA isolation 
Blood of 8 subjects, randomly selected from the subgroup of 30 subjects, was used to 
examine the changes in expression of 84 genes related to atherosclerosis in PBMC. This 
subgroup of 8 subjects was a representative sample of the original group. Blood was 
processed immediately after collection as gene expression might change very rapidly. 
PBMC were first isolated from 20 mL EDTA blood using Lymphoprep density-gradient 
centrifugation (Nycomed Pharma AS, Oslo, Norway) according to instructions of the 
manufacturer. After isolation, RNA was purified form the cells using 1.5 mL Trizol 
(Invitrogen Corporation, Carlsbad, CA, USA). Subsequently, samples were stored at -80°C 
until RNA isolation.  
After Trizol extraction, total RNA was further purified using RNAeasy columns (with on-
column-DNAse treatment) according to the manufacturer’s protocol (QIAGEN Benelux BV, 
Venlo, Netherlands). Total RNA yield and integrity was assessed using the Agilent 2100 
bioanalyzer. Only samples with an RNA integrity number (RIN) >7.0 were used. Samples 
were stored at -80°C until further analysis. 
Gene expression analyses 
The expression of 84 genes related to atherosclerosis was profiled using the RT² Profiler™ 
PCR Array (Superarray, Bioscience Corporation, Frederick, USA) according to the manufac-
turer’s protocol. Genes involved in the processes of blood coagulation and circulation were 
included as well as genes involved in cell-adhesion, and lipid transport and metabolism. 
Genes involved in the stress response, cell growth and proliferation, and apoptosis were 
represented as well. The expression of the 84 genes of interest plus 5 housekeeping genes 
(human 18S ribosomal RNA, hypoxanthine phosphoribosyltransferase 1, ribosomal protein 
L13a, glyceraldehydes-3-phosphate dehydrogenase, β-actin) was monitored. The 96 (SYBR 
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Green) reactions were all carried out under the same cycling conditions in the same run. 
Data analysis was based on the ΔΔCt method. Briefly, the ΔCt for each pathway-focused 
gene in each treatment group was calculated first. The β-actin gene was used to calculate 
the ΔCt values. Next, the ΔΔCt was calculated for each gene across two groups, and used 
for statistical analyses. All 3 samples of one subject were analyzed in 3 runs on the same 
day. The correlation coefficient and efficiency of amplification were similar for all 24 
standard curves of β-actin. The mean correlation coefficient for all standard curves was 
0.995 ± 0.009. The mean slope value was −3.543 ± 0.263 and the mean efficiency of 
detection was 90%. 
Statistical analyses 
Normality was tested by the Shapiro-Wilk test. Hs-CRP concentrations were log-
transformed to achieve normality. Log-transformed hs-CRP and cytokine concentrations 
were analyzed by ANOVA using the general linear model procedure. Differences in effects 
on the parameters of interest were examined with diet and period as fixed factors and 
subject number as a random factor. When a significant diet effect was found, the 3 
treatments were compared pairwise using a Tukey post-hoc test for multiple comparisons 
of observed means. Values are presented as means ± SD. Gene expression levels were 
analyzed with the non-parametric Friedman test. When a significant diet effect was found, 
the 3 treatments were compared pairwise using the Wilcoxon test. ΔΔCt are presented as 
medians with ranges. Differences were considered significant at p<0.05. Statistical analyses 
were performed using SPSS 11.0 (version 11.0.3) for MacIntosh OS X (version 10.3.9). 
RESULTS 
Hs-CRP 
Mean hs-CRP concentration at the end of the control diet was 2.59 ± 3.57 (mean ± SD) 
mg/L, 2.24 ± 4.84 mg/L at the end of the oat β-glucan diet, and 2.07 ± 3.04 mg/L at the 
end of the combination diet. After log-transformation, these values were not significantly 
different from each other (p=0.622). After exclusion of 6 subjects with values >9 mg/L 
(152), the end hs-CRP value of the control diet was 1.56 ± 1.80 mg/L, 1.35 ± 1.31 mg/L of 
the oat β-glucan diet, and 1.59 ± 1.79 mg/L of the combination diet. Again, values did not 
differ significantly between the diets (p=0.933).  
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Proinflammatory cytokine production 
Effects of the interventions on IL-6, IL-8, and TNF-α production in whole blood and PBMC 
after LPS stimulation are shown in Tables 2 and 3. Because of a small volume of super-
natant, only TNF-α and IL-6 concentrations were determined in the cell-free media of 
PBMC. In whole blood, Il-6, IL-8, and TNF-α production did not differ significantly 
between the 3 dietary periods. Also in PBMC, IL-6 and TNF-α production did not differ 
significantly between the 3 intervention groups. 
 
 
TABLE 2: Effects of 4-weeks daily intake of oat β-glucan with or without plant stanols on cytokine concentrations in 
platelet-poor plasma of stimulated whole blood1. 
 Control Oat β-glucan Combination p for diet effect2 
TNF-α (ng/mL) 2.8 ± 1.8 2.9 ± 2.0 2.8 ± 1.5 0.905 
IL-6 (ng/mL) 28.5 ± 15.4 24.8 ± 16.9 27.5 ± 17.8 0.510 
IL-8 (ng/mL) 33.8 ± 16.3 34.1 ± 16.3 32.2 ± 15.9 0.533 
1All values are presented as means ± SD; n = 30. 
2Cytokine concentrations were analyzed by ANOVA using the general linear model procedure with subject number 
as a random factor and diet and period as fixed factors. Differences were considered significant at p<0.05. 
 
 
TABLE 3: Effects of 4-weeks daily intake of oat β-glucan with or without plant stanols on cytokine concentrations in 
cell-free media of stimulated PBMC1, 2. 
 Control Oat β-glucan Combination p for diet effect3 
TNF-α (ng/mL) 0.9 ± 0.8 1.1 ± 1.5 1.0 ± 1.1 0.300 
IL-6 (ng/mL) 50.9 ± 37.2 70.1 ± 43.6 71.8 ± 62.7 0.130 
1All values are presented as means ± SD; n = 30.  
2Because of a small volume of supernatant, only TNF-α and IL-6 were determined in cell-free media of PBMC. 
3Cytokine concentrations were analyzed by ANOVA using the general linear model procedure with subject number 
as a random factor and diet and period as fixed factors. Differences were considered significant at p<0.05. 
Gene expression 
Thirteen genes were not detectable (defined as requiring >35 cycles to obtain a measurable 
Ct) in PBMC: APOB (apolipoprotein B), COL3A1 (collagen type-3-α1), FABP3 (fatty acid 
binding protein-3), FGA (fibrinogen), FN1 (fibrinonectin-1), IL3 (CSF), KDR (kinase insert 
domain receptor), LAMA1 (laminin-α1), LPA (Lp(a)), MMP3 (matrix metalloproteinase-3), 
NPY (neuropeptide Y), PPARG (peroxisome proliferative activated receptor γ), and SPP1 
(secreted phosphoprotein-1). Among the remaining 71 detectable genes, only 3 genes were 
differentially expressed (p<0.05). These effects were only evident for the combination 
muesli, since supplementation with the oat β-glucan enriched muesli gave no differential 
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gene expression as compared to the control muesli. The combination muesli significantly 
increased expression of granulocyte-macrophage colony-stimulating factor (CSF2) gene as 
compared both to the control (p=0.043) and the oat β-glucan enriched (p=0.043) mueslis 
(Table 4). Compared to the control muesli, expression of adipose-differentiation-related 
protein (ADFP; p=0.017) gene was significantly decreased by consumption of the combina-
tion muesli. This combined intake also effectively lowered expression of ADFP (p=0.036) 
gene but only as compared to the oat β-glucan enriched muesli (Table 4). Gene expression 
of VE-cadherin (CHH5) gene differed among the 3 treatment groups (p=0.024). However, 
between-diet comparisons were not significant. 
 
 
TABLE 4: Effects of 4-weeks daily intake of β-glucan with or without plant stanols on PBMC gene expression1, 2. 
Gene 
ΔΔCt 
(β-Glucan - Control) 
ΔΔCt 
(Combination - Control) 
ΔΔCt 
(Combination - β-Glucan) 
p for diet 
effect3 
ADFP 
 
-0.28 (-0.70, 0.32) 
P = 0.123 
0.34 (-0.03, 0.65) 
P = 0.017* 
0.73 (-0.35, 1.10) 
P = 0.036* 0.021* 
CDH5 
 
0.21 (0.00, 0.86) 
P = 0.123 
0.10 (0.00, 0.86) 
P = 0.068 
0.00 (-0.30, 0.00) 
P = 0.180 0.024* 
CSF2 
 
0.00 (0.00, 0.71) 
P = 0.123 
-0.07 (-0.58, 0.00) 
P = 0.043* 
-0.42 (-0.79, 0.00) 
P = 0.043* 0.010* 
1The expression of 84 genes related to atherosclerosis was profiled using the RT² Profiler™ PCR Array; n = 8. 
2Values are ΔΔCt values and presented as medians with ranges. 
3Gene expression levels (ΔCt values) were analyzed with the non-parametric Friedman test. When a significant diet 
effect was found, the 3 treatments were compared pairwise using the non-parametric Wilcoxon test. Differences were 
considered significant at p<0.05*. 
DISCUSSION 
Statins, commonly prescribed lipid-lowering drugs, reduce CRP levels, independently of 
their effects on lipid metabolism. Whether direct targeting of inflammatory components by 
dietary changes also lowers the risk for CVD is difficult to say, since most dietary interven-
tions so far have aimed at lowering serum LDL cholesterol concentrations. Nevertheless, 
recent research has demonstrated an association between dietary fiber and levels of CRP. 
Viscous fiber, such as oat β-glucan, may improve CVD risk, at least partly, through 
improvements in serum LDL cholesterol (61). Oat β-glucan may also mediate immune and 
inflammatory processes (29-33, 37). However, data from human studies are scarce. Our 
results showed no effect of daily consumption of muesli enriched with 5 g oat β-glucan on 
plasma hs-CRP concentrations. Consumption of oat β-glucan had also no influence on ex 
vivo LPS-stimulated cytokine (IL-6, IL-8, TNF-α) production in whole blood and PBMC. 
Nevertheless, it is not likely that the lack of effect relates to the experimental approach 
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used. Previous studies have shown that effects of dietary components on cytokine produc-
tion by PBMC can be detected in relatively small groups of subjects. In a study by Han et 
al. (140), in which only 19 subjects participated, IL-6 and TNF-α production by PBMC was 
significantly increased after consumption of a soybean oil-based stick margarine compared 
with soybean oil. So far, only one human study has examined the effects of oat β-glucan on 
inflammatory parameters. Queenan et al. (61) found, except for a significant reduction in 
LDL cholesterol, no significant changes in plasma CRP levels. In this study, 75 hypercho-
lesterolemic subjects consumed either 6 g/d concentrated oat β-glucan or 6 g/d dextrose 
(control) for 6 weeks. We further found that the addition of 1.5 g plant stanol to the oat β-
glucan enriched muesli did not change the outcomes. Like for oat β-glucan, limited 
information exists on the effects of plant sterols and stanols on inflammatory markers in 
human volunteers. In line with our results, the majority of these studies showed no 
significant effects on markers of inflammation, such as CRP, soluble adhesion molecules, 
and MCP1 (131-134). Nevertheless, Cater et al. (135) found in 13 hypercholesterolemic 
patients with a positive history for CVD no significant effect of plant stanols on CRP levels, 
but the combined administration of plant stanols with a statin significantly reduced CRP 
concentrations as compared to statin-treatment alone (n = 10). In contrast, de Jong et al. 
(134) found no effects of plant stanols as add-on treatment in 45 statin-users on inflamma-
tion markers. Devaraj et al. (136), however, found in 72 healthy subjects, a significant 
reduction in CRP levels after consumption of an orange juice enriched with plant sterols (2 
g/d). Taken together, these studies suggest that the lack of effect on inflammation markers 
in the present study may not be related to the “health status” of the subjects, the dose 
administered, or the magnitude of the decrease in cholesterol. It should be noted that the 
magnitude of CRP reduction has been strongly associated with the magnitude of choles-
terol lowering by various lipid-altering interventions (statins, ezetimibe, and bile acid 
sequestrants). It should be noted that a combination of dietary factors, such as in the 
Mediterranean diet (141), the Portfolio diet (142), or a prudent diet (143) effectively 
reduced biomarkers of inflammation. These studies were however not designed to 
determine the impact of individual dietary factors and the possibility of synergy between 
dietary factors needs to be taken into consideration. However, it cannot be excluded that a 
type II error (insufficient power) contributed to the lack of significant differences in the 
measured inflammatory markers. It is possible that a larger sample size and/or greater 
reduction in LDL cholesterol would have resulted in a significant CRP response. 
Recent studies have shown that the RT² PCR array is a sensitive platform to detect differen-
tial expression of “thematic” genes in different human cell types, such as alterations in 
genes related to drug metabolism in primary hepatocytes (144) and genes related to Th2 
immune response in lymphocytes isolated from allergic subjects (145). More detailed 
characterization of diet-induced differential expression of genes involved in atherosclerosis 
may enhance the understanding of the effects of oat β-glucan and plant stanols on CVD 
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risk. PBMC may be surrogate target cells to monitor effects in target tissues (146). Daily 
consumption of muesli enriched with 5 g oat β-glucan did, however, not change gene 
expression of an atherosclerotic risk panel of 84 genes as measured in PBMC. Addition of 
1.5 g plant stanols increased expression of CSF2 gene (pro-inflammatory effect), and 
decreased expression of ADFP gene (anti-inflammatory effect) in PBMC as compared to 
both the control and the oat β-glucan enriched mueslis. The CSF2 gene encodes granulo-
cyte-macrophage colony-stimulating factor (GMCSF). CSF2 plays an important role in 
smooth muscle cell-dependent monocyte activation (147). The ADFP gene encodes 
adipose differentiation-related protein (ADRP). ADRP is a membrane-associated protein 
whose mRNA levels are induced rapidly and maximally after triggering adipocyte differen-
tiation. ADFP is highly expressed in advanced lipid-enriched human atherosclerotic 
plaques (148). However, giving functional significance to changes in gene expression level 
alone requires caution, as it provides no information on post-translational modifications or 
the rate of protein degradation. In addition, mRNA levels do not always correlate with 
protein synthesis. It should be noted, however, that the alterations found in gene expression 
after addition of plant stanols may have occurred by chance. If 84 genes are tested with a 
probability threshold of 0.05, 4 genes (84 x 0.05) are expected to be significant by chance 
alone. Nevertheless, it is known that gene expression in PBMC can change after consump-
tion of plant stanols (19). In that study, a daily consumption of 4 g plant stanols increased 
LDL receptor mRNA concentrations in mononuclear blood cells by 43% as measured by 
competitive RT-PCR. A reason for our lack of effect on the LDL receptor gene could be the 
difference in the dose administered and the concomitant reduction in serum LDL choles-
terol concentrations. 
In conclusion, the current level of supplementation of oat β-glucan and plant stanols as 
their fatty acid esters in the present study effectively lowered serum LDL cholesterol levels 
in slightly hypercholesterolemic subjects, but seemed to have no effects on inflammatory 
markers related to atherosclerosis and CVD. 
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ABSTRACT 
Objective Evidence is accumulating that high serum concentrations of triacylglycerols 
(TAG) are, like LDL cholesterol, causally related to CVD. A recent meta-analysis has 
indicated that plant stanols not only lower serum LDL cholesterol, but also serum TAG 
concentrations, especially in subjects with high baseline TAG concentrations. We therefore 
evaluated the effects of plant stanols on lipid and lipoprotein metabolism in a population 
with elevated fasting serum TAG concentrations. 
 
Study design In a randomized, placebo-controlled, parallel study, 28 subjects with elevated 
TAG concentrations (>1.7 mmol/L) were studied. After a 1-week run-in during which 
control margarine (60% absorbable fats) was used, subjects consumed for 3 weeks either 
control or plant stanol-enriched margarine [2.4 ± 0.2 g/d (mean ± SD) plant stanols].  
 
Results Plant stanol consumption significantly decreased serum total (6.7%, p=0.015) and 
LDL cholesterol (9.5%, p=0.041). A significant interaction between baseline serum TAG 
concentrations and plant stanol intake was found: intake of plant stanols lowered TAG 
concentrations, particularly in subjects with high baseline TAG concentrations (>2.3 
mmol/L; p=0.009 for the interaction between baseline TAG concentrations and plant stanol 
intake). Additionally, a significant interaction between baseline total number of LDL 
particles (LDL-P) and plant stanol intake was found (p=0.020). Plant stanol consumption 
lowered LDL-P, primarily in subjects with elevated baseline values, mainly due to a non-
significant decrease in the number of atherogenic small LDL subclass particles (small LDL-
P).  
 
Conclusion Plant stanol supplementation not only lowered serum LDL cholesterol, but also 
serum TAG concentrations, especially in subjects with overt hypertriglyceridemia. 
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INTRODUCTION 
The link between high serum low-density lipoprotein (LDL) cholesterol concentrations and 
cardiovascular disease (CVD) has been clearly established (39). However, evidence is 
accumulating that high serum concentrations of triacylglycerols (TAG) - also known as 
hypertriglyceridemia - and low serum concentrations of high-density lipoprotein (HDL) 
cholesterol are also causally related to CVD (39). High TAG and low HDL concentrations 
often occur together, frequently with normal concentrations of LDL cholesterol, increased 
concentrations of small dense LDL (smallèè LDL-P) and apolipoprotein B (apoB), and 
insulin resistance. This lipid abnormality is a fundamental characteristic of patients with the 
metabolic syndrome (MS) (39). 
Interestingly, a recent meta-analysis has indicated that consumption of plant stanols not 
only lowers serum LDL cholesterol, but also serum TAG concentrations, in particular in 
subjects with high baseline TAG concentrations (40). The reason that these effects have not 
been observed in individual studies may have been due to a lack of statistical power, as 
effects were only marginal in subjects with normal serum TAG concentrations. We 
therefore decided to design for the first time a study to specifically evaluate the effects of 
plant stanols on the plasma lipoprotein profile in a population with elevated fasting serum 
TAG concentrations. 
MATERIALS AND METHODS 
Study population 
Subjects, aged between 18 and 70 y, were recruited among an already existing cohort of 
patients diagnosed with familial combined hyperlipidemia (FCHL) at the Academic 
Hospital Maastricht (AZM). Patients were characterized by a specific phenotype, i.e. serum 
total cholesterol concentrations >6.5 mmol/L and/or elevated serum TAG concentrations 
(>2.3 mmol/L) at different visits before taking medication. Also subjects, who had serum 
TAG concentrations between 1.7 mmol/L and 4.0 mmol/L, as indicated in earlier studies at 
our Department, were approached. A fasting serum TAG concentration >1.7 mmol/L was 
chosen as lower boundary as higher concentrations are considered to be elevated (149). 
Subjects with concentrations >4.0 mmol/L need to be treated with medication and were 
therefore excluded (150). Further inclusion criteria were: no history of CVD like congestive 
heart failure or recent (<6 months) event (acute myocardial infarction, stroke), type I and II 
diabetes mellitus, epilepsy, asthma, COPD, inflammatory bowel diseases, cancer, or 
rheumatoid arthritis; no use of diuretics; no abuse of drugs and/or alcohol; willing to 
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abstain from alcohol 3 days before blood sampling; no pregnant or breast-feeding women; 
no use of an investigational product 30 days before the study; no participation in another 
biomedical study 30 days before the study. Blood donation or participation in another 
biomedical trial was not allowed 30 days before and during the study. The Medical Ethical 
Committee of the University of Maastricht had approved the study. Participants were given 
a detailed description of the experimental protocol and purpose of the study before they 
gave their written informed consent.  
Twenty-nine volunteers were selected for the study. One subject withdrew in the 3rd week 
of the study because of difficulty in performing venipuncture. All other 28 volunteers, 16 
men and 12 women, completed the study (Table 1). 
 
 
TABLE 1: Baseline characteristics1. 
 All Control diet Stanol diet 
Number (M/F) 28 (16/12) 14 (8/6) 14 (8/6) 
Age (y) 54 ± 8 55 ± 9 53 ± 8 
BMI (kg/m2) 28 ± 3 28 ± 3 29 ± 4 
Systolic blood pressure (mmHg) 131 ± 13 132 ± 12 131 ± 14 
Diastolic blood pressure (mmHg) 87 ± 8 89 ± 9 86 ± 6 
Total cholesterol (mmol/L)  7.17 ± 0.96  7.02 ± 1.14  7.32 ± 0.76 
LDL cholesterol (mmol/L)  4.75 ± 1.01  4.67 ± 1.00  5.03 ± 0.77 
HDL cholesterol (mmol/L)  1.27 ± 0.33  1.32 ± 0.43  1.21 ± 0.17 
TAG (mmol/L)  2.62 ± 0.68  2.61 ± 0.59  2.63 ± 0.77 
Smokers 4 0 4 
Lipid-lowering medication2 5 2 3 
1Values are means ± SD; n = 28. 
2Subjects had to stop the intake of their lipid-lowering medication 2 weeks before the actual start of the study and 
during the 4 weeks of the study. 
Study design 
The study had a randomized, double-blind, placebo-controlled, parallel design. Two weeks 
before the start of the actual study and during the 4 weeks of the study, subjects had to stop 
(in consultation with their general practitioner) the intake of their regular cholesterol-
lowering medication (when appropriate). During the first 2 weeks of the study (before the 
run-in period), subjects were given a control margarine containing 60% absorbable fats. 
After these 2 weeks, further participation (and thus continuation of the medication-free 
period) did only take place if serum total cholesterol concentrations were <8.0 mmol/L and 
TAG concentrations <4.0 mmol/L (150). These subjects continued to consume daily 20 g of 
the control margarine for one more week. At the end of this run-in period, subjects were 
randomly divided over 2 groups, stratified by gender. The following 3 weeks (experimental 
period), one group continued to consume the control margarine, while the other group 
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consumed daily 20 g of the experimental margarine, which had a similar fat content and 
fatty acid composition as the control margarine, but provided 2.5 g of plant stanols. Plant 
stanols were made by saturation of plant sterols from tall oil, giving sitostanol (77.7%), 
campestanol (16.7%), sitosterol (2.2%), campesterol (1.8%), brassicasterol (0.1%), 
stigmasterol (0.1%), and other phytosterols (1.4%) (Raisio, Finland). The free plant stanols 
were esterified with sunflower-oil fatty acids. The margarine was packed in tubs of 140 g, 
equivalent to margarine for 7 days. All products were color-coded to blind the subjects and 
the investigators. All margarine leftovers had to be returned and were weighed back to 
estimate average daily margarine intake. 
Participants recorded in diaries any signs of illness, medication used, menstrual phase, 
alcohol consumption, any deviations of the study protocol, and any experienced com-
plaints. Subjects also recorded their food intake for the previous 3 weeks at days 21 and 42 
by completing food-frequency questionnaires (FFQ) to estimate their energy and nutrient 
intakes (Table 2). Body weight without shoes and heavy clothes was recorded at each visit. 
Blood sampling 
During the study, five fasting blood samples (days 14, 21, 32, 37, and 42) from a forearm 
vein using vacutainers under minimal stasis with the subject in a supine position were 
drawn. On the morning of sampling, subjects were not allowed to smoke, to eat, or to 
drink (except water). Volunteers were fasting since 22:00 the day preceding blood 
sampling. In addition, subjects were not allowed to drink alcohol 3 days before sampling. 
Blood was collected in a 10 mL serum tube (Becton Dickinson Vacutainer Systems, Breda, 
The Netherlands) for analysis of lipids, apolipoproteins, phytosterols, insulin, high-
sensitivity C-reactive protein (hs-CRP), and indices of liver function. Serum tubes were kept 
at room temperature after blood sampling. At least 1 h after venipuncture, serum was 
obtained by centrifuging at 2000 x g for 30 min at 4°C. At the same time, 4 mL of blood 
was also collected in a NaFl tube (Becton Dickinson Vacutainer Systems, Breda, The 
Netherlands) for analysis of glucose. Plasma was obtained immediately by centrifugation at 
2000 x g for 30 min at 4°C. At days 21 and 42, blood was also collected in a 10 mL EDTA 
tube (Becton Dickinson Vacutainer Systems, Breda, The Netherlands) for analysis of the 
plasma lipoprofile (number of lipoprotein particles). EDTA plasma was obtained directly by 
centrifugation of the EDTA tube at 2000 x g for 30 min at 4°C. Serum and plasma were 
divided into aliquots, snap-frozen, and subsequently stored at -80°C until analysis. All 
samples from one subject were analyzed in the same analytical run.  
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Side effects 
Serum samples of days 21 and 42 were analyzed to determine hs-CRP (Kamiya Biomedical 
Company, Seattle, WA, USA) and parameters of liver function (alanine transaminase, 
aspartate aminotransferase, γ-glutamyl transpeptidase, alkaline phosphatase, and total 
bilirubin) by routine procedures. 
Lipid and lipoprotein metabolism 
Concentrations of total cholesterol (ABX Diagnostics, Montpellier, France), HDL choles-
terol (precipitation method; Roche Diagnostics Corporation, Indianapolis, IN, USA), and 
TAG corrected for free glycerol (Sigma-Aldrich Chemie, Steinheim, Germany) were 
analyzed in all serum samples. Apolipoprotein concentrations (apoA-I, apoB-100) were 
analyzed in serum samples from days 14, 21, 37, and 42 (ABX Diagnostics, Montpellier, 
France). Serum LDL cholesterol concentrations were calculated using the Friedewald-
equation (112). The plasma lipoprofile (number of lipoprotein particles) was analyzed by 
NMR (NMR LipoProfile test, Liposcience Inc., Raleigh, NC, USA). 
Glucose metabolism 
Plasma samples of days 14, 21, 37, and 42 were analyzed to determine glucose concentra-
tions (Roche Diagnostic Systems, Hoffmann-La Roche Ltd., Basel, Switzerland). Insulin was 
measured using an ELISA method (DRG Instruments GmbH, Germany). The HOMA index, 
a measure of insulin sensitivity, was calculated as described (151). 
Serum plant sterols and stanols  
Plant sterols and stanols (campestanol, sitostanol, campesterol, sitosterol, lathosterol) were 
determined in serum samples of days 21 and 42 as described (111). 
Statistical analyses 
Before the statistical analyses, concentrations of serum lipid and lipoproteins, glucose and 
insulin from days 14 and 21, and days 37 and 42 were averaged for each subject. Normal-
ity was tested by the Shapiro-Wilk test. Hs-CRP concentrations and indices of liver function 
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were not normally distributed and analyzed accordingly by the non-parametric Mann-
Whitney test. Differences in baseline characteristics between the control and intervention 
groups, and differences in changes in dietary intakes were analyzed by the independent 
Student’s T test. Metabolic parameters were analyzed by ANCOVA. To answer the question 
whether baseline subject characteristics influenced response-to-treatment, the baseline 
value of that variable was included as a covariate into the model together with an interac-
tion term (baseline value x treatment). The interaction term was only included in the final 
statistical model if statistically significant. Values are presented as means ± SD. Pearson 
correlation coefficients were determined for the relationship between the plant stanol-
induced changes in TAG and the changes in the different lipoprotein particles. Individuals 
were also stratified for low and high serum baseline TAG concentrations (149). Due to non-
normality of the data, these values are presented as medians with ranges. Differences were 
considered statistically significant at p<0.05. Statistical analyses were performed using SPSS 
11.0 (version 11.0.3) for MacIntosh OS X (version 10.3.9). 
Inspection of the diaries revealed that 5 subjects had consumed alcohol during the 3-day 
period before blood sampling. For this reason, their corresponding TAG values for that 
particular day were omitted from analyses. In addition, one subject had to be excluded 
from the statistical analyses, because of alcohol consumption at days 14, 37, and 42. 
Another subject was excluded, because he continued his use of lipid-lowering medication 
during part of the study. Therefore, data of 26 subjects were used in the statistical analyses. 
RESULTS  
Side effects 
Throughout the study, all variables related to liver function remained within the normal 
range for all subjects and no treatment effects were present (data not shown). Also 
concentrations of hs-CRP did not change during the study. Five subjects had, unrelated to 
the dietary treatments, on one (or more) occasion(s) hs-CRP concentrations >9 mg/L (152). 
When these subjects were excluded from the analyses, conclusions did not change (data 
not shown).  
Dietary intake and body weight 
Average daily consumption of margarine on the control and plant stanol diets was 19.3 ± 
1.9 g and 19.3 ± 1.8 g, respectively. Average daily plant stanol intake was therefore 2.41 ± 
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0.23 g. Changes in daily energy intake and nutrient composition of the diets did not differ 
among the treatment groups (Table 2). Also changes in body weight were similar for the 
control and plant stanol groups (p=0.579), and were -0.10 ± 0.92 kg and 0.11 ± 0.74 kg, 
respectively. 
 
 
TABLE 2: Nutrient composition of the two diets according to FFQ1. 
 Run-in period Test period p value2 
Energy (MJ) 
   Control diet 
   Stanol diet 
 
10.0 ± 2.0 
8.9 ± 2.3 
 
10.3 ± 2.9 
8.6 ± 2.1 
 
0.167 
Protein (en%) 
   Control diet 
   Stanol diet 
 
17.5 ± 2.5 
17.3 ± 2.3 
 
17.1 ± 2.3 
17.2 ± 2.2 
 
0.697 
Total fat (en%) 
   Control diet 
   Stanol diet 
 
35.7 ± 4.6 
35.5 ± 4.1 
 
35.8 ± 1.3 
36.0 ± 3.6 
 
0.583 
SFA (en%) 
   Control diet 
   Stanol diet 
 
12.5 ± 2.5 
11.9 ± 1.5 
 
12.5 ± 2.6 
12.2 ± 1.1 
 
0.656 
MUFA (en%) 
   Control diet 
   Stanol diet 
 
11.7 ± 1.6 
11.6 ± 2.0 
 
11.7 ± 1.6 
11.6 ± 2.0 
 
0.865 
PUFA (en%) 
   Control diet 
   Stanol diet 
 
8.0 ± 1.5 
9.1 ± 1.8 
 
8.0 ± 1.8 
9.3 ± 1.7 
 
0.560 
Carbohydrates (en%) 
   Control diet 
   Stanol diet 
 
44.7 ± 4.0 
45.0 ± 5.8 
 
44.5 ± 4.5 
44.9 ± 6.0 
 
0.975 
Fiber (g/MJ) 
   Control diet 
   Stanol diet 
 
3.0 ± 0.8 
3.0 ± 0.5 
 
2.9 ± 0.9 
2.9 ± 0.6 
 
0.603 
Alcohol (en%) 
   Control diet 
   Stanol diet 
 
1.7 ± 2.3 
1.9 ± 3.0 
 
2.2 ± 2.4 
1.8 ± 3.5 
 
0.373 
Cholesterol (mg/MJ) 
   Control diet 
   Stanol diet 
 
22.2 ± 5.2 
22.0 ± 4.3 
 
21.0 ± 5.4 
21.7 ± 5.4 
 
0.446 
1Values are means ± SD; n = 26. 
2 Changes were analyzed by the independent Student’s T test. Differences were considered statistically significant at 
p<0.05. 
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Lipid and lipoprotein metabolism 
Compared to the control diet, consumption of plant stanols significantly decreased serum 
total and LDL cholesterol concentrations by 6.7% (p=0.015) and 9.5% (p=0.041), respec-
tively (Table 3). In addition, serum apoB-100 concentrations were significantly lowered by 
7.1% (p=0.007). Changes in serum HDL cholesterol and apoA-1 concentrations did not 
differ among the diet groups. A significant interaction between baseline TAG value and 
plant stanol intake was found (p=0.009).  
 
 
TABLE 3: Effects of plant stanol consumption on serum lipids and lipoproteins1. 
1Values are means ± SD (n = 26) and are expressed in mmol/L, except for apoB-100 and apoA-1 which are expressed 
in mg/L. Days 14 and 21 were averaged for the end of the run-in period. Days 37 and 42 were averaged for the end 
of the experimental period. 
2Data were analyzed by ANCOVA. To answer the question whether baseline subject characteristics influenced 
response-to-treatment, the baseline value of the variable of interest was included (as a covariate) into the model 
together with an interaction term (baseline value x diet). The interaction term was only included in the statistical 
model if statistically significant. For the control group, diet was coded with a “0” and for the intervention group with 
a “1”. Differences were considered statistically significant at p<0.05. 
 
 
To further explore this significant interaction, we stratified the individuals for low and high 
baseline TAG concentrations (149). Plant stanol consumption lowered TAG concentrations 
(11%, p=0.051) in subjects with high baseline TAG concentrations (>2.3 mmol/L; Figure 
 Run-in period Test period p value2 
   Baseline Diet Baseline x diet 
Total cholesterol  
   Control diet 
   Stanol diet 
 
7.14 ± 0.89 
7.35 ± 0.67 
 
7.13 ± 1.03 
6.85 ± 0.73 
 
0.866 
 
0.015 
 
- 
LDL cholesterol 
   Control diet 
   Stanol diet 
 
4.63 ± 0.89 
4.96 ± 0.70 
 
4.62 ± 0.97 
4.48 ± 0.66 
 
0.265 
 
0.041 
 
- 
HDL cholesterol 
   Control diet 
   Stanol diet 
 
1.30 ± 0.41 
1.20 ± 0.18 
 
1.19 ± 0.40 
1.18 ± 0.17 
 
0.271 
 
0.586 
 
- 
Triacylglycerols  
   Control diet 
   Stanol diet 
 
2.63 ± 0.58 
2.52 ± 0.66 
 
2.71 ± 0.71 
2.50 ± 0.47 
 
- 
 
- 
 
0.009 
ApoB-100 
   Control diet 
   Stanol diet 
 
1.28 ± 0.23 
1.36 ± 0.16 
 
1.30 ± 0.22 
1.28 ± 0.16 
 
0.322 
 
0.007 
 
- 
ApoA-1 
   Control diet 
   Stanol diet 
 
1.46 ± 0.34 
1.42 ± 0.19 
 
1.46 ± 0.35 
1.41 ± 0.19 
 
0.746 
 
0.666 
 
- 
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1). For subjects with lower baseline serum TAG concentrations (<2.3 mmol/L), plant stanol 
consumption did not affect serum TAG concentrations (p=0.909). 
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FIGURE 1. Interaction between baseline serum TAG values and response-to-treatment. 
The median change (with ranges) in serum TAG levels (mmol/L) is plotted for 2 groups of subjects; subjects with 
baseline TAG values between 1.7 mmol/L and 2.3 mmol/L (n = 10) and subjects with baseline values >2.3 mmol/L (n 
= 16). Plant stanols lowered serum TAG levels, particularly in subjects with high baseline TAG levels (>2.3 mmol/L). 
 
 
Further, a significant interaction between baseline total number of LDL particles (LDL-P) 
and plant stanol intake was found (p=0.020; Table 4). Supplementation of plant stanols 
lowered LDL-P, primarily in subjects with elevated baseline values. This decrease was 
reflected by a reduction of similar magnitude in the number of small LDL-subclass particles 
(small LDL-P), but this decline did not reach statistical significance (p=0.150). 
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TABLE 4: Effects of plant stanol consumption on the plasma NMR lipoprofile1. 
 Run-in period Test period p value2 
   Baseline Diet Baseline x diet 
Total VLDL  
   Control diet 
   Stanol diet 
 
107 ± 29 
117 ± 29 
 
106 ± 28 
116 ± 29 
 
0.040 
 
0.643 
 
- 
Large VLDL 
   Control diet 
   Stanol diet 
 
13 ± 6 
11 ± 7 
 
12 ± 5 
13 ± 10 
 
0.028 
 
0.897 
 
- 
Medium VLDL 
   Control diet 
   Stanol diet 
 
46 ± 20 
54 ± 22 
 
53 ± 20 
51 ± 16 
 
0.007 
 
0.322 
 
- 
Small VLDL 
   Control diet 
   Stanol diet 
 
48 ± 18 
52 ± 19 
 
41 ± 17 
52 ± 26 
 
0.052 
 
0.148 
 
- 
Total LDL 
   Control diet 
   Stanol diet 
 
1784 ± 413 
1901 ± 337 
 
1791 ± 519 
1688 ± 306 
 
- 
 
- 
 
0.020 
IDL 
   Control diet 
   Stanol diet 
 
78 ± 57 
105 ± 44 
 
99 ± 55 
82 ± 58 
 
0.015 
 
0.368 
 
- 
Large LDL 
   Control diet 
   Stanol diet 
 
240 ± 197 
175 ± 158 
 
224 ± 189 
168 ± 137 
 
0.009 
 
0.600 
 
- 
Small LDL  
   Control diet 
   Stanol diet 
 
1466 ± 471 
1621 ± 364 
 
1468 ± 531 
1438 ± 320 
 
0.277 
 
0.150 
 
- 
Total HDL 
   Control diet 
   Stanol diet 
 
30 ± 7 
31 ± 4 
 
31 ± 8 
31 ± 3 
 
0.873 
 
0.268 
 
- 
Large HDL 
   Control diet 
   Stanol diet 
 
4.7 ± 3.6 
3.6 ± 2.1 
 
4.7 ± 3.7 
3.8 ± 2.0 
 
0.341 
 
0.728 
 
- 
 
Medium HDL 
   Control diet 
   Stanol diet 
 
5.6 ± 4.8 
4.2 ± 3.3 
 
5.3 ± 2.9 
5.0 ± 4.7 
 
0.004 
 
0.992 
 
- 
Small HDL 
   Control diet 
   Stanol diet 
 
20 ± 6 
24 ± 3 
 
21 ± 6 
23 ± 4 
 
0.052 
 
0.748 
 
- 
1Values are means ± SD (n = 26) and are expressed in nmol/L, except for HDL particles which are expressed in 
μmol/L. 
2Data were analyzed by ANCOVA. To answer the question whether baseline subject characteristics influenced 
response-to-treatment, the baseline value of the variable of interest was included (as a covariate) into the model 
together with an interaction term (baseline value x diet). The interaction term was only included in the statistical 
model if statistically significant. For the control group, diet was coded with a “0” and for the intervention group with 
a “1”. Differences were considered statistically significant at p<0.05. 
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Serum sterols and stanols 
Cholesterol-standardized serum sterol and stanol concentrations are depicted in Table 5. A 
significant interaction between baseline concentrations of cholesterol-standardized 
sitostanol and response-to-treatment was found (p=0.011). Consumption of plant stanols 
increased cholesterol-standardized sitostanol concentrations, in particular in subjects with 
elevated baseline values. Additionally, eating the plant stanol-enriched margarine signifi-
cantly increased cholesterol-standardized serum campestanol concentrations (p<0.001). 
Plant stanol concentrations increased in every subject receiving the plant stanol-enriched 
margarines, which demonstrates good compliance with the study protocol. 
 
 
TABLE 5: Serum sterols and stanols (corrected for serum cholesterol as measured by GC)1. 
 Run-in period Test period p value2 
   Baseline Diet Baseline x diet 
Sitostanol 
   Control diet 
   Stanol diet 
 
2.58 ± 0.70 
2.51 ± 0.69 
 
2.41 ± 0.62 
22.97 ± 7.60 
 
- 
 
- 
 
0.011 
Campestanol 
   Control diet 
   Stanol diet 
 
1.12 ± 0.49 
1.20 ± 0.56 
 
1.12 ± 0.42 
10.06 ± 3.58 
 
0.270 
 
< 0.001 
 
- 
Sitosterol 
   Control diet 
   Stanol diet 
 
129 ± 31 
141 ± 47 
 
123 ± 27 
114 ± 39 
 
0.007 
 
0.008 
 
- 
Campesterol 
   Control diet 
   Stanol diet 
 
159 ± 41 
183 ± 73 
 
154 ± 42 
152 ± 61 
 
0.021 
 
0.020 
 
- 
Lathosterol 
   Control diet 
   Stanol diet 
 
188 ± 64 
184 ± 54 
 
195 ± 46 
210 ± 65 
 
- 
 
- 
 
0.043 
1Values are means ± SD (n = 26) and are expressed in (μmol/mmol cholesterol) x100. 
2Data were analyzed by ANCOVA. To answer the question whether baseline subject characteristics influenced 
response-to-treatment, the baseline value of the variable of interest was included (as a covariate) into the model 
together with an interaction term (baseline value x diet). The interaction term was only included in the statistical 
model if statistically significant. For the control group, diet was coded with a “0” and for the intervention group with 
a “1”. Differences were considered statistically significant at p<0.05. 
 
 
Compared to the control diet, cholesterol-standardized serum sitosterol (p=0.008) and 
campesterol (p=0.020) concentrations significantly decreased after plant stanol consump-
tion, indicating decreased intestinal cholesterol absorption. A significant interaction 
between baseline cholesterol-standardized lathosterol concentrations and plant stanol 
intake was found (p=0.043). Daily intake of plant stanols increased this marker for 
endogenous cholesterol synthesis, especially in subjects with elevated baseline values. 
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Glucose metabolism 
Changes in plasma glucose and insulin concentrations, and HOMA index did not differ 
among the diet groups (data not shown). 
Correlations 
Significant correlations were found between plant stanol-induced changes in serum 
concentrations of TAG and the number of large VLDL-subclass particles (large VLDL-P; 
r=0.713, p<0.001), large LDL-P (r=-0.575, p=0.002), and small LDL-P (r=0.438, p=0.025). 
Further, plant stanol-induced changes in serum TAG levels significantly correlated with the 
number of medium HDL-subclass particles (medium HDL-P; r=0.394, p=0.047). Regarding 
the remaining lipoprotein particles, no significant correlations were found with the plant 
stanol-induced changes in serum TAG concentrations (data not shown). 
DISCUSSION 
This study was specifically designed to examine the effects of plant stanols on serum TAG 
concentrations in subjects with elevated serum concentrations of TAG. In line with our 
recent meta-analysis (40), a significant interaction between baseline TAG concentrations 
and plant stanol intake was found. Furthermore, we have recently shown that plant stanols 
lowered serum TAG concentrations in subjects with the MS (Plat et al, in press). Based on 
the meta-analysis (40), the expected decrease in serum TAG concentrations was on average 
-0.09 mmol/L for “borderline high” baseline TAG concentrations [1.7 - 2.2 mmol/L; (149)] 
and a daily plant stanol intake of 2.5 g. At a similar intake, the expected decline for 
subjects with “high” baseline TAG values [2.3 - 4.0 mmol/L; (149)], was on average -0.19 
mmol/L. Compared to these predicted effects, our results are slightly different since a 
reduction in serum TAG concentrations was hardly present at baseline TAG values <2.3 
mmol/L. In contrast, at “high” baseline TAG concentration, the average decrease was larger 
than anticipated, i.e. -0.35 mmol/L. It is possible that the estimates from the meta-analysis 
for subjects selected on disturbances in TAG metabolism are less precise, because most of 
the subjects in the meta-analysis had serum TAG concentrations <2.0 mmol/L. 
As TAG, in the fasted state are mainly transported by VLDL particles, it can be suggested 
that plant stanols change VLDL metabolism. However, plasma total number of VLDL 
particles (VLDL-P; including large VLDL-P, medium VLDL-P, small VLDL-P) were not 
significantly altered after the plant stanol diet. Possibly, the variation in response of the 
different VLDL particles was too large to reach statistically significant dietary effects. 
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Daily consumption of 2.4 g plant stanols also significantly decreased serum LDL choles-
terol concentrations by 9.5%. This is in line with the estimated mean change in LDL 
cholesterol concentrations of -8.9% for daily intakes of 2.0 to 2.4 g plant sterols or stanols 
(14). Serum apoB-100 concentrations were lowered by 7.1%, which is in the same range as 
the reductions in total and LDL cholesterol. As expected, no effects on serum HDL 
cholesterol and apoA-1 concentrations were found. The serum LDL cholesterol-lowering 
effect was mainly related to a decrease (-11.2%) in the atherogenic small LDL-P, but this 
effect was not statistically significant. A significant positive correlation, however, was found 
between the plant stanol-induced changes in serum TAG levels and small LDL-P. Small 
dense LDL-P are particularly considered to be atherogenic, since these particles are 
retained preferentially by the artery wall and are readily oxidized (39, 153). Generation of 
small, dense LDL occurs by intravascular lipoprotein remodelling as a result of metabolic 
disturbances, which are frequently present in patients with DM2 and the MS (153). The 
common underlying predisposing factor may be the development of a fatty liver resulting in 
hypertriglyceridemia, due to in particular large VLDL-P. Large VLDL-P are a precursor for 
the synthesis of small dense LDL by LPL mediated processes (154). 
Hypertriglyceridemia is also associated with an overproduction of other cardiovascular risk 
factors, such as glucose, hs-CRP, plasminogen activator inhibitor-1 (PAI-1), fibrinogen, and 
coagulation factors (39). We therefore looked into the effects of the plant stanol diet on 
glucose metabolism in our hypertriglyceridemic study population. However, no effects on 
glucose and insulin concentrations, and the HOMA index were found. These effects agree 
with earlier findings in healthy subjects, where glucose concentrations were not changed 
after supplementation of a reduced-calorie orange juice beverage enriched with plant 
sterols (2 g/d) (136). In addition, consumption of plant sterol (1.9 g/d) and plant stanol (2.0 
g/d)-enriched spreads for 10 weeks did not change plasma glucose and serum insulin 
concentrations in hypercholesterolemic subjects (155).  
As plant stanol consumption interferes with intestinal cholesterol absorption, effects on 
postprandial lipid metabolism may even be more pronounced. Studies on the postprandial 
effects of phytosterols are however scarce. In healthy subjects, 2-week plant stanol 
consumption (3 g/d plant stanols) only tended to diminish postprandial TAG concentrations 
(156). In another study, the use of plant stanol (3 g/d)-enriched margarine did not decrease 
postprandial hypertriglyceridemia in statin patients (157). 
To summarize, consumption of plant stanols significantly lowered serum LDL cholesterol 
concentrations in subjects with elevated TAG concentrations, primarily by a decrease in 
the atherogenic small LDL-P. The plant stanol-induced TAG-lowering in these subjects was 
related to their baseline TAG concentrations, and was particularly evident in subjects with 
high serum TAG concentrations. Taken together, these findings show that functional foods 
enriched with plant stanols are not only of benefit to lower increased serum LDL choles-
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terol concentrations, but also serum triacylglycerols in subjects with overt hypertriglyc-
eridemia. 
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ABSTRACT 
Objective Oxysterols may be atherogenic and accordingly play an active role in the 
pathogenesis of cardiovascular disease (CVD). Similar to cholesterol, phytosterols are 
susceptible to oxidation. However, it is unknown whether oxyphytosterols are atherogenic. 
 
Study design After a 2-week run-in period, 33 female heterozygous LDL receptor-deficient 
(LDLR+/-) mice were divided to receive for 35 weeks: a control diet (atherogenic diet), an 
oxysterol diet (control diet with 0.025% oxysterols), or an oxyphytosterol diet (control diet 
with 0.025% oxyphytosterols). 
 
Results At the end of the experiment, serum cholesterol concentrations did not differ 
between the treatments. Also cholesterol exposure and lipoprotein profiles were similar. 
During the experiment, changes in serum cholesterol concentrations did not differ between 
the treatments, except for weeks 7 and 17 (cholesterol-lowering effect of the oxyphytos-
terols). A shift toward more severe lesions was found after the oxysterol (p=0.004) and 
oxyphytosterol (p=0.011) diets compared to the control diet. Lesion severity did not differ 
between the oxysterol and oxyphytosterol groups. Also lesion size and collagen content 
were similar. 
 
Conclusion Not only oxysterols, but also oxyphytosterols may promote atherosclerosis in 
LDLR+/- mice, primarily by a shift toward more severe atherosclerotic lesions. 
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INTRODUCTION 
In vitro and animal studies have suggested that oxidized cholesterol (oxysterols) is athero-
genic and may accordingly play an active role in the pathogenesis of cardiovascular 
disease (CVD). In fact, various oxysterols have been detected in human tissues and fluids, 
including plasma, atherogenic lipoproteins, and atherosclerotic plaques (21). Oxysterols 
arise in tissues not only as a result of enzymatic (during cholesterol catabolism) or non-
enzymatic (in vivo oxidation) oxidation reactions, but also from dietary sources (dairy 
products, egg, meat, fish, bakery products) (21). In vitro, oxysterols have a negative impact 
on several aspects of cellular cholesterol homeostasis, such as upregulating cholesterol 
biosynthesis and enhancing cholesterol esterification. In addition, some oxysterols inhibit 
cholesterol export from foam cells, impair vascular reactivity, are cytotoxic, and induce 
apoptosis (21). Animal studies have also shown that oxidized cholesterol in the diet 
accelerates fatty streak lesion formation (22, 23). Although, there is no direct evidence that 
oxysterols contribute to atherogenesis in humans, these observations suggest that oxysterols 
can contribute to atherogenesis. 
Plant sterols (phytosterols) are found in various lipid sources, such as oils from vegetables, 
nuts, grains, seeds, wood pulp, and leaves. Functional foods enriched with these plant 
sterols are gaining a prominent position in dietary guidelines to lower the concentrations of 
the atherogenic LDL particles (14). Plant sterols are structurally related to cholesterol and 
the presence of one or more unsaturated bonds makes plant sterols susceptible to oxidation 
as well. Small amounts of oxidized phytosterols (oxyphytosterols) have been demonstrated 
in the diet (coffee, fried potatoes, wheat flour, vegetable oils) (158, 159) and in serum from 
sitosterolemic patients (25). Although at lower concentrations, oxyphytosterols have also 
been found in plasma from healthy volunteers (26). In rats, it has been demonstrated that 
oxyphytosterols were absorbed from the diet and transported into the lymphatics (27). In 
addition, in apolipoprotein E (apo E)-deficient mice, dietary oxyphytosterols were absorbed 
and accumulated in serum, liver, and aorta (27). Further, in vitro studies have shown that 
oxyphytosterols exhibit cytotoxic effects in cultured macrophages similar to those of 
oxysterols (28). So far, only one study has examined the effects of an oxyphytosterol diet on 
atherosclerosis in apo E-deficient mice (27). In that study, dietary oxyphytosterols did not 
promote the development of atherosclerosis compared to phytosterols. Thus, in vitro and 
animal studies are contrasting and it is still unclear whether oxyphytosterols are athero-
genic, as has been suggested for oxysterols. We therefore decided to investigate the effects 
of oxysterols and oxyphytosterols on lipid metabolism and atherosclerotic lesion develop-
ment using heterozygous LDL receptor-deficient (LDLR+/-) mice. 
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METHODS 
Animal model 
LDLR+/- mice were bred in our laboratory by mating LDLR-/- males with C57BL6/J 
(Charles River Laboratories, Wilmington, MA, USA) females. Thirty-six female LDLR+/- 
littermates were used for the experiment. Heterozygous LDLR-deficient mice were chosen 
to simulate a human model for mild hypercholesterolemia. Female mice were used 
because they are more responsive to the development of diet-induced atherosclerosis 
(160). At the age of 5 weeks, these mice were divided over 12 cages, with 3 animals per 
cage. Mice were housed under standard conditions (temperature 20-23°C, normal 
day/night rhythm) in wire-topped Macrolon type-I cages with a layer of maize fibers as 
bedding. All diets and water were given ad libitum. Before the start of the study, mice were 
fed a regular mouse diet (Hope Farms, Woerden, The Netherlands). The research was 
conducted in conformity with the Public Health Service Policy on Human Care and Use of 
Laboratory Animals. The study was approved by The Animal Ethics Committee of Maas-
tricht University. 
Test diets and experimental protocol 
At the age of 8 weeks, a run-in period of 2 weeks started, during which all animals 
received an atherogenic control diet (Table 1). This control diet contained 17.2 percent of 
energy (en%) fat with a western-like fatty acid profile (4.5 en% palm oil, 1.7 en% coconut 
oil, 4.0 en% soy oil, 2.2 en% olive oil, and 4.8 en% cacao oil), 47.1 en% carbohydrate 
(37.1 en% sucrose and 10.0 en% corn starch), 20.0 en% protein (casein), 0.25 en% 
cholesterol, 0.25 en% cholic acid, 0.20 en% methionine, 4.85 en% mineral mixture, and 
0.25 en% vitamin mixture. Thereafter, the 12 cages were randomly allocated to one of the 
3 semi-synthetic test diets. For the next 35 weeks, one group (n=12) was fed the athero-
genic control diet. Three animals from this group died in weeks 2, 16, and 17, respectively. 
The 1st animal died from hydrocefalie, the 2nd from overgrown teeth, and the 3rd for 
unknown reasons. Results of the control group therefore refer to 9 animals. A second group 
(n=12) received the same atherogenic control diet except that 10% of the added choles-
terol was replaced by oxysterols (0.025%). A third group (n=12) was given the same 
atherogenic diet, but now with 0.025% oxyphytosterols replacing cholesterol. As a result, 
daily intake of oxy(phyto)sterols mimicked daily intake of these oxidation products from the 
human Western diet.  
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TABLE 1: Design of the study1. 
Western diet 
+ 0.25% cholesterol + 0.25% cholate 
n = 9* (4 cages with 3 animals) 
Western diet
+ 0.225% cholesterol + 0.25% cholate 
+ 0.025% oxysterols 
n = 12 (4 cages with 3 animals) 
Western diet 
+ 0.25% cholesterol + 0.25% cholate 
n = 36 (12 cages with 3 animals) 
Western diet 
+ 0.225% cholesterol + 0.25% cholate 
+ 0.025% oxyphytosterols 
n = 12 (4 cages with 3 animals) 
Weeks 0                                 2       7                       17                        27                     37 
1The study had a randomized, controlled, parallel design. After a 2-week run-in period, 33 female LDLR+/- mice 
were divided to receive for 35 weeks: a control diet (atherogenic diet), an oxysterol diet (control diet + 0.025% 
oxysterols), or an oxyphytosterol diet (control diet + 0.025% oxyphytosterols). *Three animals receiving the control 
diet died in weeks 2, 16, and 17, respectively. 
 
 
Oxysterols and oxyphytosterols were prepared by heating cholesterol/sterols at 180ºC for 3 
h (Raisio, Finland). A minor fraction of the identified sterols was still present in non-
oxidized form; 4.1% and 6.4% for cholesterol and phytosterols, respectively. Given the 
low amounts of the oxysterol and oxyphytosterol mixtures supplied in the diets, these 
amounts are negligible and may not interfere with cholesterol metabolism. The composi-
tion of the oxysterols and oxyphytosterols is shown in Table 2. Diets were stored at -20ºC. 
 
 
TABLE 2: Composition of the oxysterol and oxyphytosterol mixtures1. 
 Oxysterol mixture Oxyphytosterol mixture 
7-Keto (% of total) 40.3 28.2 
Epoxides (% of total) 35.7 20.0 
   5α, 6α-epoxy- 30.3   7.2 
   5β, 6β-epoxy-   5.4 12.7 
Hydroxides (% of total) 24.0 51.8 
   7α-hydroxy-   4.0 19.8 
   7β-hydroxy- 13.8 32.0 
   others   6.1   0.0 
1Oxysterols and oxyphytosterols were prepared by heating cholesterol/sterols at 180ºC for 3 hours. 
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Blood sampling and body weight 
Fasting blood samples were collected 5 times (weeks 2, 7, 17, 27, and 37) by orbital 
puncture. Blood was collected into plastic tubes (Eppendorf AG, Hamburg, Germany) 
which were filled with glass beads to prepare serum. Animals were weighed before blood 
sampling. At the end of the study, all animals were sacrificed after blood sampling. The 
entire hearts (with aorta) of each mouse were dissected, sectioned perpendicularly to the 
heart axis just below the atrial tips, and directly placed in aluminum cryotubes (Omnilabo 
International, Breda, The Netherlands) sited in dry-ice cooled isopentane. The cryotubes 
were stored at -80°C until use.  
Serum cholesterol and lipoprotein profiles 
All blood samples were analyzed directly after sampling for serum total cholesterol using a 
commercially available enzymatic kit (CHOD/PAP method, Roche Diagnostics, Basel, 
Switzerland). The area under the curve (AUC) of total cholesterol was calculated for each 
animal as an indicator of overall cholesterol exposure of the aorta during the 37 week 
experiment (22). Lipoprotein profiles were made at the end of the intervention period 
(week 37) by means of fast protein liquid chromatography (FPLC) as described (25). Serum 
of mice housed in the same cage was pooled. All FPLC fractions of the pooled serum were 
analyzed for total cholesterol concentrations. Subsequently, these fractions were averaged 
for each of the 3 diet groups and compared.  
Atherosclerotic lesion size and severity  
After storage and before sectioning, the hearts were first placed on an object holder in the 
microtome/cryostat with the sectioned plane facing up, and were subsequently embedded 
in Tissue Tek (Sakura Finetek Europe BV, Zoeterwoude, The Netherlands). In this way, the 
frozen hearts were sectioned toward the aortic axis. Upon reaching the aortic root, serial 7 
μm sections were taken until the aortic valves disappeared. These sections were mounted 
onto microscope slides, and then air-dried for 24 hours on silica. The slides were kept 
frozen at -80°C until staining. 
Atherosclerotic lesion size was analyzed using four serial sections with a 42 μm interval 
per animal. The collected sections were stained with toluidine blue, and digitally photo-
graphed (Nikon DXM1200) and quantified using digital image software (Adobe Photoshop 
CS3). Also lesion severity was quantified, and three types of lesions were discerned: (1) 
mild lesions: fatty streaks containing only foam cells, (2) moderate lesions: characterized by 
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the additional presence of a collagenous cap, and (3) severe lesions: involvement of the 
media and increased fibrosis, cholesterol clefts, and/or necrosis of the plaque. After scoring 
each mouse individually, the percentages of lesions classified as mild, moderate, and 
severe were calculated for each diet group. All analyses were performed by our experimen-
tal pathologist, who was blinded with respect to the design of the study. 
Atherosclerotic lesion collagen content 
Sirius red staining was performed to visualize collagen content. One section was used per 
animal. The stained sections were all photographed under the same conditions with a 
digital microscope camera (Nikon DXM1200). To quantify the percentage of collagen 
within the lesions, the lesion area was selected manually and a color range selection was 
applied to measure collagen content (Adobe Photoshop CS3). The same color settings were 
used for all sections. All analyses were performed by the same technician, who was 
blinded with respect to the design of the study. 
Statistical analyses 
For each animal, responses to the diet were calculated for body weight and serum total 
cholesterol as the changes between values at the end of the run-in period and the end of 
the intervention period. Differences between diet groups in body weight, serum total 
cholesterol concentrations, cholesterol exposure, lipoprotein profiles, atherosclerotic lesion 
size, and in collagen content were tested for statistical significance by the non-parametric 
Kruskal-Wallis test. When a significant diet effect was found, the 3 treatments were 
compared pairwise using a Mann-Whitney test. Values are presented as medians with 
ranges. Differences in atherosclerotic lesion severity were tested with the Chi-square test. 
Values are presented as means ± standard deviation (SD). Differences were considered 
statistically significant at p<0.017. Statistical analyses were performed using SPSS 11.0 
(version 11.0.3) for MacIntosh OS X (version 10.3.9). 
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RESULTS 
Body weight, serum cholesterol, and lipoprotein profiles 
At the end of the experiment, changes in body weight (p=0.867; Table 3) and in serum 
total cholesterol concentrations (p=0.843; Table 3) were similar for all 3 treatments. There 
were no differences in AUC of total cholesterol between the 3 animal groups (p=0.163; 
Table 3), implying that overall cholesterol exposure of the aorta was similar for all 3 
groups. Also lipoprotein profiles did not differ between the 3 diets (data not shown).  
 
 
TABLE 3: Effects of oxysterols and oxyphytosterols on body weight, serum total cholesterol concentrations, 
cholesterol exposure, and collagen content1. 
 Control Oxysterols Oxyphytosterols 
Body weight (g)2 23.9 
(22.5 – 24.2) 
23.4 
(21.4 – 27.9) 
23.9 
(22.8 – 27.4) 
Total cholesterol (mmol/L)2 11.8 
(9.6 – 16.1) 
11.0 
(9.8 – 16.7) 
12.1 
(9.5 – 13.6) 
Cholesterol exposure (mmol/L x wk) 450 
(341 – 465) 
405 
(323 – 494) 
384 
(329 – 448) 
Collagen content (103 x mm2)2 117 
(22 – 194) 
149 
(39 – 307) 
189 
(7 – 268) 
Collagen content (% of lesion size)2 52 
(32 – 71) 
55 
(17 – 74) 
67 
(11 – 75) 
1All values are medians (with ranges); n = 33. 
2Body weight, serum total cholesterol concentrations, and collagen content are from week 37 of the experiment. 
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During the experiment, changes in serum total cholesterol concentrations did not differ 
between the 3 diet groups, except for weeks 7 and 17. Compared to the control diet, the 
oxyphytosterol diet significantly lowered serum total cholesterol levels at week 7 by 13% 
(p=0.006; Figure 1) and at week 17 by 12% (p=0.001; Figure 1). Serum total cholesterol 
concentrations in the oxysterol group followed the same pattern as observed for the 
oxyphytosterols, but the concentrations at weeks 7 and 17 did not differ significantly from 
those in the control group. 
 
FIGURE 1: Time course of serum cholesterol. 
Data are presented as the median of the % changes relative to the control group; n = 33. Changes in serum 
cholesterol were tested for statistical significance by the Kruskal-Wallis test. Pair-wise comparisons were performed 
by the Mann-Whitney test. *p<0.05 vs. control. 
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Atherosclerotic lesion size and severity 
Lesion size did not differ between the 3 animal groups after 35 weeks of feeding the 
control, oxysterol, or oxyphytosterol diets (p=0.420; Table 3). Nevertheless, the atheroscle-
rotic lesion severity pattern differed significantly between the oxysterol and control groups 
(p=0.004), and the oxyphytosterol and control groups (p=0.011). Compared to the control 
diet, a shift towards more severe lesions was observed after dietary intake of oxysterols and 
oxyphytosterols (Figures 2 and 3). No difference was found between the oxysterol and 
oxyphytosterol groups (p=0.125). 
 
FIGURE 2: Lesion size and severity. 
(A) Lesion area (103 x mm2) in LDLR+/- mice. Values are presented as medians with ranges; n = 33. (B) Lesion 
severity (mean % of total lesions). Lesions were categorized as mild, moderate, and severe. Differences in 
atherosclerotic lesion severity were tested with the Chi-square test. Values are presented as means ± SD; n = 33. 
*p<0.05 vs. control. 
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FIGURE 3: Atherosclerotic lesion severity. 
(A) Representative sections of the aortic valve area (toluidine blue staining) are presented per diet group (40x). (B) 
One valve from each section is enlarged (100x). (1A) Section of the aortic valve area of a control animal. (1B) Mild 
lesion: characterized by only foam cells. (2A) Section of the aortic valve area of an animal from the oxysterol group. 
(2B) Severe lesion: characterized by foam cells, fibrosis, and necrosis of the plaque. (3A) Section of the aortic valve 
area of an animal from the oxyphytosterol group. (3B) Severe lesion: characterized by foam cells, fibrosis, and 
necrosis of the plaque. 
Atherosclerotic lesion collagen content 
Collagen content did not differ between the treatments (p=0.377). Also relative collagen 
content (% of lesion size) was the same (p=0.675), indicating that lesion stability was 
comparable for all 3 diet groups. 
DISCUSSION 
In the present study, we found that consumption of oxysterols as well as of oxyphytosterols 
shifted the atherosclerotic lesion severity pattern toward more severe lesions in female 
LDLR+/- mice. However, no statistically significant differences in atherosclerotic lesion size 
were found between any of the diet groups. It is possible that this was due to the duration 
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of our study, which might have been too long to observe differences between the diets in 
lesion size, but not in lesion severity. Also collagen content was the same for the diet 
groups, implying that lesion stability, contrary to lesion severity, was not differently affected 
by consumption of the oxysterols and oxyphytosterols.  
Only a few studies have examined the atherosclerotic potential of oxysterols or oxyphytos-
terols. Staprans et al. (23) found significant increases in lesion size after 4 months when 
comparing a cholesterol with an oxysterol diet in apoE-deficient mice (n = 12). These 
effects as such were not strain-dependent, as after 7 months of feeding, an oxysterol diet 
also significantly increased lesion size in homozygous LDLR-deficient mice (n = 12). On 
the other hand, Ando et al. (161) observed no significant differences in lesion size after 8 
weeks of feeding a control, cholesterol, or oxysterol diet to apoE-deficient mice (n = 15). 
Nevertheless, the lack of effect may have been related to the relatively short duration of the 
study. So far, only one study has examined the atherogenicity of oxyphytosterols. In that 
study, no significant differences were found in lesion size after 9 weeks of feeding a 
phytosterol or oxyphytosterol diet to apoE-deficient mice (n = 14)  (27). It should be noted, 
however, that the effects of oxyphytosterols were compared to those of phytosterols and 
not to those of an atherogenic control diet, making it difficult to compare these results to 
our findings. In addition, the duration of that study was substantially shorter than that of our 
study. 
There are several potential mechanisms by which oxy(phyto)sterols may promote the 
development of atherosclerosis. Oxysterols are cytotoxic for many different cell types, such 
as endothelial cells (162), macrophages (163), smooth muscle cells (SMC) (164), and 
lymphocytes (165). Also oxyphytosterols are cytotoxic for cultured macrophages (28). In 
addition, animal studies have reported that oxysterols induce endothelial injury in vivo 
(166, 167). Finally, oxyphytosterols increased monocyte chemotactic protein-1 (MCP1, 
biomarker for endothelial dysfunction) production by endothelial cells (HCAEC; human 
coronary artery endothelial cells) in vitro (Plat et al., unpublished results). Thus, negative 
effects of oxy(phyto)sterols on endothelial function may be one of the mechanisms by 
which dietary oxy(phyto)sterols could promote atherosclerosis. Oxy(phyto)sterols may also 
accelerate atherosclerosis by inducing foam cell formation (168), affecting proteins 
involved in lipoprotein metabolism (169, 170), or stimulating the expression of cytokines 
involved in atherogenesis (171, 172). Clearly, more research is needed to elucidate the 
potential atherogenic mechanism of oxy(phyto)sterols. 
The observed shift toward more severe lesions was not paralleled by differences in serum 
total cholesterol levels (at the end of the experiment), cholesterol exposure, or lipoprotein 
profiles. Consumption of oxyphytosterols, however, resulted in a significant reduction in 
serum total cholesterol at weeks 7 and 17. Oxysterol consumption resulted in the same 
pattern, but differences never reached statistical significance. Staprans et al. (23) observed 
no significant differences in serum total cholesterol between the control (18.6 ± 0.9 
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mmol/L; mean ± SEM) and oxysterol (18.8 ± 1.2 mmol/L) diets in the apoE-deficient mice 
after 4 months. However, serum total cholesterol was significantly reduced by the oxysterol 
diet (14.4 ± 1.4 mmol/L) compared to the control diet (19.4 ± 2.1 mmol/L) in the homozy-
gous LDLR-deficient mice after 7 months of feeding (23). Also in the study by Ando et al. 
(161), no significant differences were observed in serum total cholesterol after 8 weeks of 
feeding the control (15.3 ± 1.4 mmol/L; mean ± SEM), cholesterol (16.9 ± 1.6 mmol/L), or 
oxysterol (17.5 ± 0.3 mmol/L) diets to the apoE-deficient mice. Further, no significant 
differences were found in serum cholesterol of the apoE-deficient mice after 9 weeks of 
feeding the phytosterol (13.7 ± 1.1 mmol/L; mean ± SEM) or oxyphytosterol (16.0 ± 1.9 
mmol/L) diets (27). However, a notable difference between these findings is the applied 
dose of oxy(phyto)sterols. It could be that the administered dose in our study was too low 
to achieve any significant reductions, as serum cholesterol concentrations were (consis-
tently) lower, but not significantly, after consumption of oxy(phyto)sterols. There is no 
obvious explanation for the differences in the extent of cholesterol lowering at the different 
points in time. 
In this study, daily intake of oxy(phyto)sterols mimicked daily intake of these oxidation 
products from the human Western diet (≈1% of dietary cholesterol is oxidized). Results 
from animal studies suggest that an increased dietary intake of oxyphytosterols, similarly to 
phytosterols, can elevate their serum concentrations (27). Data regarding the relative 
absorption of oxyphytosterols are, however, limited. Tomoyori et al. (27) observed a greater 
total lymph recovery of both oxidized campesterol (15.9%) and  -sitosterol (9.1%) com-
pared to campesterol (5.5%) and  -sitosterol (2.2%) in lymph duct-cannulated rats fed 
cholesterol, phytosterols, or their oxidized derivatives. There is, however, no direct 
evidence that an increased consumption of oxyphytosterols increases their circulating and 
tissue concentrations in humans. Various food products, such as dairy products, eggs, 
meat, and fish are an exogenous source of oxysterols (21). In general, food processing, 
especially heat treatment, drying, and storage can also induce oxidation. Oxyphytosterols 
have been identified in coffee beans (173), French fries (174), heated vegetable oils (174), 
infant milk formulas (175), parenteral nutrition (25), and potato chips (176). Also phytos-
terol-enriched foods may be a minor dietary source of oxyphytosterols (159). The dietary 
intake of oxyphytosterols from phytosterol-enriched foods or supplements is estimated to 
be relatively low (≤1.7 mg/d). Except from dietary sources, like oxysterols, oxyphytosterols 
present in tissues can also be derived from endogenous formation (177). An important 
question is whether in vivo formed oxysterols and oxyphytosterols could have the same 
atherogenic potential as their diet-derived counterparts. The extent to what oxyphytosterols 
are formed and metabolized in the human body is however not clear yet. 
In summary, the present results indicate that not only dietary oxysterols but also dietary 
oxyphytosterols can promote the development of atherosclerosis in LDLR+/- mice, 
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primarily by a shift toward more severe atherosclerotic lesions. To what extent these results 
can be extrapolated to the human situation, warrants further investigation. 
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Introduction 
Cardiovascular disease (CVD) is the number one cause of death globally and is expected to 
remain in this position for the coming years. This high risk in CVD reflects unhealthy 
dietary habits, physical inactivity, and tobacco consumption as a result of industrialization, 
urbanization, economic developments, and food market globalization. For the past 20 
years, the focus of public health strategies for reducing the risk of CVD has been lowering 
serum LDL cholesterol levels. However, recent findings have highlighted not only elevated 
LDL cholesterol, but also elevated triacylglycerol (TAG) levels as an important risk factor 
for CVD (39). Also low-grade systemic inflammation is emerging as a novel risk factor, as 
atherosclerosis is in part due to the accumulation of lipids and inflammatory factors within 
the vessel wall (178). 
Dietary changes are a basic step in managing CVD risk. Functional foods especially 
developed to lower the cholesterol concentration in the atherogenic LDL particles, and 
therefore the risk for CVD, are gaining a prominent position in dietary guidelines (9). Such 
foods contain one or more functional dietary components and therefore provide positive 
health effects beyond their traditional nutritional value. A dietary strategy with multiple 
dietary components to target a single CVD risk factor may achieve cumulative effects on 
that risk factor. Next to this, a dietary strategy that targets multiple CVD risk factors may 
have a greater impact than a single risk factor-intervention strategy. For example, omega-3 
fish-oil fatty acids may exert antithrombotic (179) and hypotriglyceridemic (180) effects. 
Within this context, we investigated the role of (combining) different dietary components, 
such as oat β-glucan, plant stanols, and oxy(phyto)sterols in managing CVD risk. 
Role of oat β-glucan in managing CVD risk 
Management of hypercholesterolemia 
Oat grains are an important source of dietary fiber, especially the viscous soluble fiber β-
glucan, minerals, and other nutrients, and are becoming increasingly known for their 
health benefits (181). Daily ingestion of modest quantities of oat β-glucan can help 
lowering serum LDL cholesterol levels, thereby reducing the risk of CVD. In our study with 
slightly hypercholesterolemic volunteers (Chapter 3), daily consumption of muesli enriched 
with 5 g oat β-glucan significantly decreased serum LDL cholesterol concentrations with 
0.21 mmol/L, in agreement with the predicted reduction of 0.18 mmol/L (59). 
Based on numerous clinical studies, the US Food and Drug Administration (FDA) permitted 
the use of a claim that viscous soluble fiber from oats has the ability to reduce the risk of 
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CVD. The required dose of oat β-glucan for a single food serving was set at 0.75 g (daily 
total intake ≥3 g) (10). This recommendation is supported by the results of studies that 
demonstrated significant, although variable, reductions in serum LDL cholesterol concen-
trations after consumption of different oat β-glucan-containing products (45, 48, 60, 61, 
182-184). Inconsistencies in the reported effects of oat products may be due to several 
factors, such as total fiber intake, baseline serum total cholesterol concentrations, mode of 
administration, and solubility or molecular weight (MW) of the fiber. Also the viscosity of 
the β-glucan in the intestinal tract, which is positively related to its solubility in water and 
MW, may be an important determinant of its cholesterol-lowering effects. 
Regardless of its source, β-glucan is a polysaccharide composed of glucose molecules 
(185). In yeast and mushrooms, however, the glucose molecules are joined by β-(1→3)- 
and β-(1→6)-glycosidic bonds, while oats and barley are comprised of β-(1→4)- and β-
(1→3)-glycosidic bonds. Oats contain around 4% β-glucan; 5 to 10% β-glucan is present 
in barley (72). The FDA recently concluded that whole-grain barley and dry milled barley 
products are also appropriate sources of β-glucan to claim that they reduce the risk of CVD 
(11). In contrast to oats and barley, yeast contains up to 85% of β-glucan after processing. 
However, the β-(1→3, 1→6) structure decreases solubility, thereby compromising the 
ability to build viscosity in the gastrointestinal tract (185). To our knowledge, only one 
study has examined the cholesterol-lowering properties of yeast, but unfortunately this 
study lacked a proper control group (77). Information on the hypocholesterolemic effects of 
β-glucan from mushrooms is, however, lacking. It would be therefore interesting to 
investigate into more detail the importance of the molecular structure of β-glucan by 
comparing the hypocholesterolemic effects of the different β-glucan sources. 
Management of inflammation  
Inflammation is emerging as a novel risk factor for CVD, as atherosclerosis is in part due to 
the accumulation of inflammatory factors within the vessel wall (178). Whether direct 
targeting of these inflammatory components within the vessel wall by dietary changes also 
lowers the risk for CVD is difficult to say, since most dietary interventions so far have 
aimed at lowering serum LDL cholesterol levels. Nevertheless, indirect evidence has been 
provided by animal studies. For example, mice lacking inflammatory markers, such as the 
chemokine receptor subtype-2 (CCR2) (186) and the intercellular adhesion molecule-1 
(ICAM1) (187) are at decreased risk for atherosclerosis. In humans, infusion of C-reactive 
protein (CRP) aggravated endothelial dysfunction independent of changes in cholesterol 
(188). In addition, statins, commonly prescribed lipid-lowering drugs, reduce CRP levels, 
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independently of their effects on lipid metabolism (189). Altogether, this suggests that 
selective targeting of these players in atherogenesis may be useful. 
Limited studies, however, have shown that dietary components reduce pro-inflammatory 
markers. Most studies with fish oil supplementation have shown no effects; conflicting 
results have been reported with saturated and trans fatty acids, and soy intake. Neverthe-
less, recent research has demonstrated an association between dietary fiber intake and 
plasma levels of CRP. A cross-sectional study based on the NHANES cohort, relating total 
dietary fiber consumption to CRP levels, was one of the first to demonstrate this association 
(190). In agreement, a 2-year high-fiber Mediterranean-style diet (32 g/d of fiber) signifi-
cantly lowered CRP levels compared to a prudent diet (17 g/d of fiber) (141). Recently, it 
has also been shown that 3-week fiber intake from a diet naturally rich in fiber (30 g/d) or a 
supplement (30 g/d of fiber) lowered CRP levels by 14% and 18%, respectively, with no 
difference between these treatment groups (191). Overall, these studies suggest that diets 
rich in fiber may affect inflammatory parameters However, these studies were not designed 
to determine the impact of (viscous soluble) fiber alone. 
So far, only two studies have examined the effects of viscous soluble fiber on pro-
inflammatory parameters. In a randomized, controlled trial, 6-week supplementation with 
oat β-glucan (6 g/d) did not change plasma CRP concentrations in hypercholesterolemic 
subjects (61). However, daily (viscous soluble) fiber intake was not documented. In line 
with these results, we did not find a beneficial effect of 4-week consumption of oat β-
glucan (5 g/d) enriched-muesli on inflammatory parameters related to atherosclerosis and 
CVD (Chapter 4). In our study, the mean daily total dietary fiber intake was 22 g, including 
the supplemented oat β-glucan (Chapter 3). Recently, 3-month psyllium supplementation 
(7 or 14 g/d) did not reduce CRP levels compared to no supplements in overweight and 
obese individuals (192). The initial daily dietary fiber consumption of these participants 
was 14 g. Again, information regarding total fiber intake during the intervention period is 
lacking. These findings, however, suggest that taking a single-fiber supplement in contrast 
to a high-fiber diet may not be an effective way to reduce CRP levels. Nevertheless, it is 
possible that total daily (viscous soluble) fiber intake was too low and/or the intervention 
period too short to achieve substantial changes in CRP levels. It would therefore be 
interesting to evaluate the long-term effects of a high dose of viscous soluble fiber.  
The mechanism by which a high-fiber diet reduces the inflammatory state associated with 
CVD is unclear. Increased consumption of high-density and low-quality foods, such as 
those rich in refined starches, sugar, and unhealthy lipids (saturated and trans fatty acids), 
and poor in antioxidants and fiber, may cause an activation of the innate immune system, 
most likely by an excessive production of pro-inflammatory cytokines associated with a 
reduced production of anti-inflammatory cytokines (193). This imbalance may favor the 
generation of a pro-inflammatory milieu, which in turn may produce insulin resistance and 
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endothelial dysfunction, an early step in atherogenesis, which will lead to an increased risk 
for the metabolic syndrome (MS), type II diabetes (DM2), and CVD. 
Taken together, future research should provide more insight into the nutritional modulation 
of inflammation by a single-fiber supplement compared to a whole (high-fiber) diet 
approach. Elucidating the mechanism by which dietary fiber influences inflammation holds 
the premise to fully understand the association with cardiovascular health. 
Role of plant sterols and stanols in managing CVD risk 
Management of hypercholesterolemia 
Food products enriched with plant sterols or stanols (also called phytosterols) can also 
lower the atherogenic LDL particles (14). Plant sterols and stanols are already part of our 
everyday diets, but the amounts are often not high enough to have significant cholesterol-
lowering effects. The challenge of incorporating larger amounts of phytosterols into the diet 
has been overcome by fortifying foods with plant sterols and stanols. The FDA has also 
authorized the use of health claims on food labels indicating that regular consumption of 
food products enriched with plant sterol or stanol esters may reduce the risk of CVD (12). 
In early 2003, FDA expanded the enforcement discretion regarding the use of the interim 
health claim rule with respect to free plant sterols and stanols, and CVD (13). The required 
dose for a single food serving phytosterol esters and free phytosterols is 0.65 g and 0.40 g, 
respectively.  
In our study (Chapter 3), addition of plant stanols [1.5 g plant stanols (as esters)] to the oat 
β-glucan enriched muesli significantly lowered LDL cholesterol levels by 4.4% (compared 
to muesli enriched with only oat β-glucan) (63). The reported effects of the plant stanols in 
our study were calculated as the difference in effects after oat  -glucan and oat  -glucan 
plus plant stanol consumption. The fact that we did not include a separate stanol group is 
an inherent limitation in our study design. Nevertheless, the calculated plant stanol-
induced effect is smaller than the estimated mean change of -8.5% for daily intakes of 1.5 
to 1.9 g phytosterols (14). Thus, simultaneous consumption of oat β-glucan may have 
interfered with the efficacy of the plant stanols. Several studies have, however, concluded 
that the effects of plant sterols and stanols do not change when subjects consume a 
recommended diet, usually characterized by a decrease in fat and cholesterol intake (117-
121). When complex carbohydrates replace fats, an increase in dietary fiber intake can be 
expected as well. The majority of these studies did unfortunately not document (changes 
in) the intake of (viscous soluble) fiber. Also a possible effect of the food matrix on the 
cholesterol-lowering effectiveness of the phytosterols cannot be ruled out. In a randomized, 
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incomplete 3-week crossover study (129), consumption of different plant sterol (1.6 g/d)-
enriched low-fat foods (e.g. milk, yoghurt, bread, and cereals) decreased serum LDL 
cholesterol concentrations by 5.4 to 15.9%. It should be noted, however, that also other 
more recent studies with similar intakes of plant sterols and stanols have reported effects 
less than the estimated mean change of -8.5%, based on studies published before 2003 
(14, 125-127). Based on a recent meta-analysis (40), the expected decrease in serum LDL 
concentrations is on average 5.1% for elevated baseline LDL values (>2.5 mmol/L) and a 
daily plant stanol intake of 1.5 g. Altogether, the estimated mean reduction of 8.5% in 
serum LDL cholesterol concentrations at daily intakes of 1.5 to 1.9 g of phytosterols may 
have been overrated. Nevertheless, the 4.4% change in LDL cholesterol is somewhat less 
than in other studies at comparable intakes and therefore interactions of the viscous soluble 
fiber oat β-glucan or the food matrix on the efficacy of the plant stanols cannot be 
excluded.  
Phytosterols lower LDL cholesterol by preventing cholesterol absorption (18). Plant sterols 
and stanols are structurally related to cholesterol and are incorporated into mixed micelles 
in the intestinal tract. If enough phytosterols are consumed, they may displace cholesterol 
from the mixed micelles. This ultimately results in a reduction of intestinal cholesterol 
absorption and a higher fecal excretion of cholesterol and its metabolites. However, plant 
sterols and stanols do not need to be present in the intestinal lumen simultaneously with 
cholesterol to inhibit its absorption, suggesting that reduced incorporation of cholesterol 
into mixed micelles is not the only mechanism. Other processes within the enterocytes, 
like ABC transporter activity may also play a role in lowering cholesterol by transporting 
absorbed sterols out of the enterocytes back into the lumen. This hypothesis, however, 
demands further study. A lower absorption of cholesterol triggers peripheral cells to restore 
cellular cholesterol homeostasis by a compensatory increase in endogenous cholesterol 
synthesis (19). Additionally, receptor-mediated cholesterol uptake becomes upregulated 
(19). The overall effect is a reduction in serum LDL cholesterol concentrations. Addition of 
plant stanols to the oat β-glucan-enriched muesli further decreased cholesterol absorption 
and further raised endogenous cholesterol synthesis in mildly hypercholesterolemic 
subjects, fitting this suggested mechanism (Chapter 3). In agreement, daily consumption of 
plant stanol-enriched margarine [2.5 g plant stanols (as esters)] significantly influenced 
cholesterol absorption and synthesis in subjects with elevated serum TAG concentrations 
(Chapter 5). 
In these hypertriglyceridemic subjects, the LDL cholesterol-lowering effect was mainly 
related to a decrease in the number of the atherogenic small-dense LDL particles, but this 
effect was however not statistically significant. Nevertheless, a significant correlation was 
found between the plant-stanol induced changes in serum TAG and small LDL particle 
levels (r=0.758, p=0.003). Large VLDL particles are a precursor for the synthesis of small-
dense LDL by LPL-mediated processes (154). Indeed, when the number of large VLDL 
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particles decreased, parallel reductions were found in the number of small LDL particles 
(r=0.687, p=0.010; Chapter 5). However, effects on VLDL particles did not reach statistical 
significance (see next paragraph). Whether these results suggest that consumption of plant 
stanols may beneficially affect the number of small-dense LDL particles in hypertriglyc-
eridemic subjects by influencing the hepatic production of VLDL particles requires further 
study.  
Management of hypertriglyceridemia 
Recent evidence suggests that elevated serum TAG concentrations [>2.3 mmol/L; (149, 
194)], are also associated with an increased risk for CVD (39). A meta-analysis has also 
indicated that consumption of plant stanols not only lowers serum LDL cholesterol, but 
also serum TAG concentrations, in particular in subjects with high baseline TAG concen-
trations (40). The reason that these effects have not been observed in previous studies may 
have been due to a lack of statistical power, as effects were only marginal in subjects with 
normal serum TAG concentrations. In line with this meta-analysis, we found a significant 
interaction between baseline TAG levels and response-to-treatment (Chapter 5). Based on 
the meta-analysis, the expected decrease in serum TAG concentrations was on average -
0.09 mmol/L for “borderline high” baseline TAG concentrations [1.7 - 2.2 mmol/L (149)] 
and a daily plant stanol intake of 2.5 g. At a similar intake, the expected decline in serum 
TAG concentrations was on average -0.19 mmol/L for “high” baseline TAG values [2.3 - 
4.0 mmol/L (149)]. Compared to these predicted effects, our results were slightly different; 
the expected reduction in serum TAG concentrations was hardly present at baseline TAG 
values <2.3 mmol/L. In contrast, at “high” baseline TAG concentration, the average 
decrease was larger than anticipated, i.e. -0.39 mmol/L. It is possible that the estimates 
from the meta-analysis for subjects selected on disturbances in TAG metabolism are less 
precise, because most of the subjects in the meta-analysis had serum TAG concentrations 
<2.0 mmol/L. 
As TAG are mainly transported by VLDL particles, it can be suggested that VLDL metabo-
lism is changed after consumption of plant stanols. However, plasma concentrations of 
VLDL particles (large, medium, and small) were not significantly altered after consumption 
of plant stanols (Chapter 5). Possibly, the variation in response was too large to reach 
statistical significance. Nevertheless, a significant correlation was found between the plant 
stanol-induced changes in TAG and the number of large VLDL particles. It could be 
possible that the mean TAG baseline value (2.6 mmol/L) was still too low to discern any 
valid changes in VLDL particle levels. 
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Management of inflammation  
In our study, addition of 1.5 g plant stanols to the oat β-glucan-enriched muesli did not 
change inflammatory parameters related to atherosclerosis and CVD (Chapter 4). Like for 
oat β-glucan, limited information exists on the effects of plant sterols and stanols on 
inflammatory markers in human volunteers. In line with our results, the majority of these 
studies showed no significant effects on markers of inflammation, such as CRP, soluble 
adhesion molecules, and monocyte chemotactic protein-1 (MCP1) (131-134). Neverthe-
less, the combined administration of plant stanols (3 g/d) with a statin significantly reduced 
CRP concentrations as compared to statin-treatment alone (study 1), but no significant 
effect was found when supplementing hypercholesterolemic patients (with a positive 
history for CVD) with the same amount of plant stanols (study 2) (135). In another study 
(134), however, consumption of plant stanols (2.5 g/d) as add-on treatment in statin-users 
did not change inflammation markers. In contrast, a significant reduction in CRP levels was 
described after consumption of an orange juice enriched with plant sterols (2 g/d) in 
healthy subjects (136). Overall, no clear explanation can be given to explain these 
inconsistent effects of phytosterols on parameters of inflammation. As mentioned before, 
however, a single-dietary supplement may not be an effective way to reduce inflammation. 
Combining 2 functional food ingredients 
Management of hypercholesterolemia 
Combining two (or more) functional ingredients into one food product or combining the 
consumption of several dietary ingredients as part of one dietary portfolio, may achieve 
cumulative changes in serum LDL cholesterol levels. Indeed, 4-week consumption of a 
dietary portfolio (1.8 g/d plant sterols, 17.9 g/d viscous fiber, 39.1 g/d soy protein, and 25.6 
g/d almonds) lowered cholesterol levels by 20.6% compared to a control diet (195). 
However, the study was not designed to determine the impact of the individual dietary 
factors. In this respect, the combination of viscous soluble fiber and phytosterols in one 
product may theoretically be interesting, because the underlying mechanisms of these two 
ingredients are suggested to be different.  
In our study (Chapter 3), daily consumption of the combination muesli enriched with oat 
β-glucan (5 g) and plant stanols (1.5 g) lowered serum LDL cholesterol concentrations by 
9.6%. However, this reduction was not as much as expected and an interaction with 
viscous soluble fiber may have played a role. Indeed, oat β-glucan consumption decreased 
serum stanol concentrations, and adding plant stanols did not change the serum stanol 
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concentrations (Chapter 3). In contrast, 3-week supplementation with either a plant sterol 
(1.8 g/d)-enriched bar, a glucomannan-enriched bar (10 g/d of viscous soluble fiber derived 
from konjac root), or a combination bar lowered serum LDL cholesterol concentrations by 
5.4%, 13.8%, and 21.7%, respectively (123). These findings did not suggest that gluco-
mannan may attenuate the hypocholesterolemic effects of the plant sterols, although the 
effect of the plant sterols was less than predicted. Nevertheless, 4 week-combined 
consumption of plant sterols (2.6 g/d) and psyllium (7.7 g/d), provided by cookies, also 
decreased serum LDL cholesterol levels below expectations (124). According to literature 
(14), daily consumption of >2.5 g phytosterols lowers serum LDL cholesterol concentra-
tions on average by -11.3%, which is already higher than the -9.8% decrease in LDL 
cholesterol found after the combination of psyllium and plant sterols. Unfortunately, the 
separate contribution of the individual dietary components was not evaluated. 
A higher intestinal viscosity may have lowered the phytosterol transport into the entero-
cytes and accordingly their cholesterol-lowering efficacy. Alternatively, an increase in the 
intestinal viscosity may have affected lipid emulsification by increasing the droplet size of 
emulsions thereby decreasing the emulsion interface area. This may reduce the rate of 
lipolysis and possibly also the hydrolysis of phytosterols. It can than be speculated that 
active free plant sterols and stanols are released later in the intestinal tract, which may 
affect their efficacy and absorption. However, more studies are needed to confirm this 
hypothesis. It should be noted, however, that also the LDL cholesterol-reducing effect of a 
combination therapy of ezetimibe and plant sterols was not significantly greater than that of 
ezetimibe monotherapy (196). Ezetimibe may also counteract the plant sterol effect by 
decreasing the phytosterol amount within the enterocytes. In this study as well, combining 
two cholesterol-absorption inhibitors had hardly any therapeutic benefit compared with a 
monotherapy in subjects with mild hypercholesterolemia. 
Effects on inflammation 
Similar to supplementing with oat β-glucan or plant stanols alone, the combination of these 
dietary factors did not influence inflammatory parameters related to atherosclerosis and 
CVD (Chapter 4). As mentioned before, however, combining several dietary factors, such 
as in the Mediterranean-style diet (141), a portfolio diet (37), or a prudent diet (143) may be 
more effective in reducing parameters of inflammation Indeed, consumption of a prudent 
diet (higher intakes of fruit, vegetables, legumes, fish, poultry, and whole grains) was 
inversely associated with plasma concentrations of CRP (143). In agreement, 4-week 
consumption of the dietary portfolio (1.8 g/d plant sterols, 17.9 g/d viscous fiber, 39.1 g/d 
soy protein, and 25.6 g/d almonds) lowered CRP levels by 18.2% compared to a control 
diet (37). As mentioned already, the 2-year consumption of the Mediterranean-style diet 
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(whole grains, fruits, vegetables, nuts, and olive oil) significantly lowered CRP levels 
compared to the control diet (141). These studies were however not designed to determine 
the impact of the individual dietary factors. Nevertheless, a change in dietary pattern, 
compared to changing the intake of one (or two) dietary component(s), may be needed to 
achieve significant effects on markers of inflammation. 
“Reverse of the medal”  
Atherogenicity of phytosterols  
Phytosterolemia is an autosomal recessive disorder with an incidence of 1 in 5 million 
people (15). Phytosterolemia is characterized by markedly increased serum and tissue plant 
sterol concentrations, which may lead to premature atherosclerosis. Mutations in the 
ABCG5 and/or ABCG8 genes disturb the reverse transport of phytosterols from enterocytes 
into the intestinal lumen and the secretion of phytosterols out of hepatocytes into bile. 
Altogether, this results in increased intestinal phytosterol absorption and a lower biliary 
excretion, ultimately leading to phytosterolemia. Studies of patients with phytosterolemia 
have demonstrated increased phytosterol absorption of 16 to 63%. This augmented 
phytosterol absorption does not appear to interfere with cholesterol absorption. However, 
phytosterolemia is associated with a marked reduction in cholesterol synthesis. LDL-
receptor activity is normal or enhanced, possibly to compensate for the reduced cholesterol 
production. Bile acid synthesis is reduced as well, which may increase serum cholesterol 
levels in some patients. The presence of premature atherosclerosis in individuals with 
phytosterolemia raises the possibility that even mild increases in serum phytosterol 
concentrations may be atherogenic. This has important implications because phytosterols 
are increasingly used as cholesterol-lowering agents. It should be noted, however, that 
consumption of plant sterols and stanols produces only minor increases in their serum 
concentrations (0.01 to 0.05 mmol/L). 
The possibility that phytosterols promote atherosclerosis has been examined using animal 
models and several cross-sectional human studies. The majority of animal studies suggest 
that plant sterols and stanols are not atherogenic (160, 197-200). Recently, however, 
supplementation with plant sterols impaired endothelial function, aggravated ischemic 
brain injury, and promoted atherogenesis in mice (201). Also results of human studies 
examining the atherogenic potential of phytosterols were not consistent (202-207). It is 
possible that individuals with polymorphisms in the ABCG5 and ABCG8 genes that affect 
phytosterol absorption are at higher risk because of their ability to over-absorb phytosterols. 
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Clearly, more studies are warranted to examine whether increased serum levels of 
phytosterols increase the risk for atherosclerosis.  
Oxyphytosterols: novel risk factor for CVD 
Several novel risk factors for CVD have emerged, such as small-dense LDL particles, hs-
CRP, homocysteine, and oxysterols (oxidized cholesterol). Oxysterols possess many potent 
and diverse biological activities in vitro, several of which may implicate a role in the 
process of atherosclerosis (21). Various food products, such as dairy products, eggs, meat, 
and fish are an exogenous source of oxysterols. In general, food processing, especially heat 
treatment, drying, and storage can also induce oxidation. Due to the presence of a double 
bound in the steroid nucleus, plant sterols may undergo oxidative processes similar to 
cholesterol, but detailed knowledge is however lacking. Oxyphytosterols (oxidized plant 
sterols) have been identified in coffee beans, French fries, heated vegetable oils, infant milk 
formulas, parenteral nutrition, and potato chips (24). Also phytosterol-enriched foods may 
be a minor dietary source of oxyphytosterols. However, <0.1% of oxyphytosterols was 
found in commercially available plant sterol-enriched spreads (12 to 68 μg/g of spread). 
This corresponds to a possible daily ingestion of <1.7 mg of oxyphytosterols for a recom-
mended daily intake of 20 to 25 g of spread. In addition to food sources, oxyphytosterols 
were also detected in human plasma. The plasma concentrations of oxyphytosterols found 
in the circulation (5 to 57 ng/mL) were lower or comparable to those of oxysterols (3 to 154 
ng/mL). However, there is no direct evidence yet that an increased consumption of 
oxyphytosterols increases their circulating and tissue concentrations in humans.  
Phytosterols (<5%) are absorbed in smaller proportion than cholesterol (55 to 60%). The 
ABCG5 and ABCG8 transporters preferentially secrete phytosterols back into the intestinal 
lumen. It is possible that the secretion of oxyphytosterols is mediated by the same regula-
tory complex (ABCG5-ABCG8). In that case, a lower absorption of oxyphytosterols 
compared to oxysterols can be expected as well. However, no direct comparison of 
oxyphytosterol versus oxysterol absorption has yet been made. Absorption data regarding 
the comparison of oxyphytosterols versus phytosterols are still conflicting. It would 
therefore be interesting to compare the relative absorption of cholesterol, phytosterols, 
oxysterols, and oxyphytosterols. 
It is unknown whether oxyphytosterols are atherogenic, as suggested for oxysterols. 
Different animal models have shown that dietary oxysterols increase atherosclerotic lesion 
size. In our animal study (Chapter 6), consumption of oxysterols and oxyphytosterols 
shifted the atherosclerotic lesion severity pattern toward more severe lesions. So far, 
however, only one study examined the atherogenicity of oxyphytosterols. In that study (27), 
no significant differences were found in lesion size of apoE-deficient mice after 9 weeks of 
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feeding either a phytosterol or an oxyphytosterol diet. It should be noted however that 
effects of oxyphytosterols were compared to those of phytosterols and not to those of an 
atherogenic control diet, making it difficult to compare these results to our findings. In 
addition, the duration of that study was substantially shorter than our study. Except from 
dietary sources, like oxysterols, oxyphytosterols can also be derived from endogenous 
formation. An important question is whether in vivo formed oxysterols and oxyphytosterols 
could have the same atherogenic potential as their diet-derived counterparts. The extent to 
what oxyphytosterols are formed and metabolized in the human body is however not clear 
yet. 
There are several potential mechanisms by which oxy(phyto)sterols could promote the 
development of atherosclerosis. Oxysterols are cytotoxic for many different cell types, such 
as endothelial cells (162), macrophages (163), smooth muscle cells (SMC) (164), and 
lymphocytes (165). Also oxyphytosterols are cytotoxic for cultured macrophages (28). In 
addition, animal studies have reported that oxysterols induce endothelial injury in vivo 
(164, 167). Finally, oxyphytosterols increased MCP1, a biomarker for endothelial dysfunc-
tion, production by endothelial cells (HCAEC; human coronary artery endothelial cells; Plat 
et al., unpublished results). Thus, a negative effect of the oxy(phyto)sterols on endothelial 
function may be a possible mechanism by which dietary oxy(phyto)sterols promote 
atherosclerosis. Oxy(phyto)sterols may also accelerate atherosclerosis by inducing foam 
cell formation (168), affecting proteins involved in lipoprotein metabolism (169, 170), or 
stimulating the expression of cytokines involved in atherosclerosis (171, 172). 
Taken together, to what extent these results can be extrapolated to the human situation, 
warrants further investigation. At the present time, however, there is not sufficient evidence 
to advice against phytosterol supplementation to reduce LDL cholesterol.  
CONCLUSION 
Functional foods enriched with the viscous soluble fiber oat β-glucan and plant stanols are 
efficient in lowering the number of atherogenic LDL particles, and therefore the risk for 
CVD. However, the combined intake of oat β-glucan and plant stanols lowered LDL 
cholesterol levels below expectations, possibly because of interference of the viscous 
soluble fiber with the phytosterol efficacy. Recent findings have highlighted not only 
elevated LDL cholesterol, but also elevated TAG levels as an important risk factor for CVD. 
Supplementation with plant stanols not only lowered LDL cholesterol, but also serum TAG 
levels, particularly in subjects with high baseline TAG levels. Modulation of inflammatory 
markers may also be a valuable step in managing CVD risk, but consumption of oat β-
glucan and plant stanols did not influence markers related to inflammation. Probably, a 
change in dietary pattern, compared to changing the intake of one (or two) dietary 
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component(s), may be needed to achieve significant effects on markers of inflammation. 
Oxysterols (oxidized cholesterol) also emerged as a novel risk factor for CVD. Phytosterols 
may undergo similar oxidative processes, and therefore oxyphytosterols (oxidized phytos-
terols) may have the same atherogenic potential. In our animal study, consumption of 
oxysterols and oxyphytosterols promoted atherosclerotic lesion development by a shift 
toward more severe lesions. How these results compare to the human situation, warrants 
further study. 
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Cardiovascular disease (CVD) is the leading cause of death in many parts of the world. The 
conventional risk factors for CVD include smoking, unhealthy dietary habits, physical 
inactivity, being overweight, hypertension, and abnormal blood lipid levels. As these 
factors are strongly influenced by behavioral factors, there is now broad consensus that 
encouraging people to adopt a healthy lifestyle (i.e. not smoking, being physically active, 
and eating a healthy diet) is fundamental to reduce CVD risk. The inability of the estab-
lished risk factors to account for all the variations in CVD between and within populations 
has further led to the emergence of a number of novel CVD risk markers. These factors 
include oxidative stress, infectious agents, and increased levels of small-dense low-density 
lipoproteins (sdLDL), C-reactive protein (CRP), and oxysterols. 
Dietary therapy is effective to reduce CVD risk and mortality, associated with high serum 
LDL cholesterol levels. Functional foods made to lower the atherogenic LDL particles, and 
thereby the risk for CVD, are therefore gaining a prominent position in dietary guidelines. 
Such foods contain (or lack) one or more functional components and therefore provide 
positive health effects beyond their traditional nutritional value. Examples of such food 
components with FDA-approved health claims are the water-soluble fiber β-glucan from 
oats and barley, and plant sterols and stanols. These functional foods are in particular 
helpful for those individuals with elevated serum LDL cholesterol levels, if the product is 
substituted for a standard product and eaten as part of a cholesterol-lowering diet and in 
conjunction with a healthy lifestyle. 
 
The aim of the studies described in this thesis was to investigate the role of (combining) 
different dietary components, such as oat β-glucan, plant stanols, and oxy(phyto)sterols in 
managing CVD risk. Within this objective, we have formulated several specific research 
questions, as described below. 
 
The combined intake of oat β-glucan and plant stanols may be more effective than either 
component alone. In our first study (Chapter 3), we therefore investigated the effects of a 
simultaneous intake of oat β-glucan and plant stanols on lipid metabolism in mildly 
hypercholesterolemic volunteers. In a randomized, controlled, 3-period crossover study, 40 
mildly hypercholesterolemic men and women received for 4 weeks either control muesli (5 
g of wheat fiber), β-glucan enriched muesli (5 g of oat β-glucan), or combination muesli [5 
g of oat β-glucan plus 1.5 g of plant stanols (as their fatty acids)]. The β-glucan enriched 
muesli effectively lowered serum LDL cholesterol concentrations by 5%. Addition of plant 
stanols to this muesli further lowered serum LDL cholesterol levels by 4%. The muesli rich 
in β-glucan increased bile acid synthesis and decreased cholesterol absorption, in line with 
the proposed cholesterol-lowering mechanism of viscous soluble fibers. The addition of 
plant stanols did not influence bile acid synthesis, but decreased cholesterol absorption 
and raised cholesterol synthesis, also in correspondence to their suggested working 
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mechanism. We concluded that muesli rich in oat β-glucan effectively lowered serum LDL 
cholesterol concentrations. Addition of plant stanols to the β-glucan-enriched muesli 
further lowered LDL cholesterol levels, although less than predicted. We therefore 
speculated that the presence of the viscous soluble fiber oat β-glucan or the food matrix 
may modulate the cholesterol-lowering efficacy of the plant stanols. 
 
Besides their hypocholesterolemic effects, in vitro and animal studies have suggested that 
oat β-glucan and phytosterols may also affect inflammatory processes. To explore whether 
the effects of oat β-glucan and plant stanols on CVD risk may be mediated in part by 
affecting inflammation, we examined in Chapter 4 the effects of these functional food 
ingredients on inflammatory markers. Pro-inflammatory cytokine (IL-6, IL-8, and TNFα) 
production by PBMC and whole blood after LPS stimulation did not differ between the 
treatments. Also plasma levels of hs-CRP, a marker for low-grade systemic inflammation, 
were the same. No effects of oat β-glucan consumption on gene expression (human 
atherosclerosis PCR array) of PBMC were observed, while only 3 out of 84 genes from the 
atherosclerotic risk panel were differentially expressed after addition of the plant stanols. 
We concluded that consumption of oat β-glucan with or without plant stanols effectively 
lowered LDL cholesterol levels, but did not influence inflammatory parameters in slightly 
hypercholesterolemic subjects. 
 
The link between high serum LDL cholesterol levels and CVD has been clearly established. 
However, evidence is accumulating that high levels of triacylglycerols (TAG), also known 
as hypertriglyceridemia, and low levels of HDL cholesterol are also causally related to 
CVD. In a second study (Chapter 5), we therefore investigated the effects of plant stanols 
on the serum lipoprotein profile in 26 men and women, especially selected for elevated 
fasting serum TAG concentrations. After a 1-week run-in period, during which control 
margarine (containing 60% absorbable fats) was used, subjects were randomized to receive 
daily either control margarine or plant stanol-enriched margarine [2.5 g/d of plant stanols 
(as esters)] for 3 weeks. Consumption of plant stanols significantly decreased serum total 
and LDL cholesterol levels. A significant interaction between baseline TAG values and 
response-to-treatment was found. Supplementation of plant stanols lowered serum TAG 
concentrations, particularly in subjects with high baseline TAG concentrations (>2.3 
mmol/L). Additionally, a significant interaction between baseline number of total LDL 
particles and plant stanol intake was found. Consumption of plant stanols lowered the total 
number of LDL particles, primarily in subjects with elevated baseline values, and this was 
mainly due to a decrease in the sdLDL particles. We therefore concluded that consumption 
of plant stanols not only lowered serum LDL cholesterol, but also serum TAG concentra-
tions, especially in subjects with elevated serum TAG concentrations. 
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Oxysterols are suggested to be atherogenic and accordingly may also play an active role in 
the pathogenesis of CVD. Plant sterols structurally resemble cholesterol and the presence of 
one or more unsaturated bonds makes plant sterols susceptible to oxidation as well. 
However, it is unknown whether oxyphytosterols are atherogenic, as has been suggested 
for oxysterols. In a third study (Chapter 6), we therefore examined the effects of oxysterols 
and oxyphytosterols on serum lipoproteins and atherosclerotic lesion development in 
female transgenic mice. After a 2-week run-in period, 33 female heterozygous LDL 
receptor-deficient (LDLR+/-) mice were randomized to receive either control diet (athero-
genic diet), oxysterol diet (control diet with 0.025% oxysterols), or oxyphytosterol diet 
(control diet with 0.025% oxyphytosterols) for 35 weeks. At the end of the experiment, 
serum cholesterol concentrations did not differ between the treatments. Also cholesterol 
exposure and lipoprotein profiles were similar. Nevertheless, a shift toward more severe 
lesions was found after the oxysterol and oxyphytosterols diets compared to the control diet 
(no difference between oxysterols and oxyphytosterols). Lesion size and collagen content 
did however not differ between the different treatments. We concluded that not only 
dietary oxysterols, but also dietary oxyphytosterols may promote the development of 
atherosclerosis in LDLR+/- mice, primarily by a shift toward more severe atherosclerotic 
lesions. 
 
Taken together, functional foods enriched with the viscous soluble fiber oat β-glucan and 
plant stanols effectively lower the atherogenic LDL particles, and thereby the risk profile for 
CVD. However, the combined intake of oat β-glucan and plant stanols lowered LDL 
cholesterol less than expected, possibly because of interference of the viscous soluble fiber 
with the plant stanol efficacy. Modulation of inflammatory markers may also be a valuable 
step in managing CVD risk, but consumption of oat β-glucan and plant stanols did not 
influence markers related to inflammation within a period of 4 weeks. Possibly, a more 
rigorous or longer-lasting change in dietary patterns is needed to achieve significant effects 
on markers of inflammation. Recent findings have highlighted not only elevated LDL 
cholesterol, but also elevated TAG levels as an important risk factor for CVD. We now 
found that plant stanols not only lowered LDL cholesterol, but also serum TAG levels, 
particularly in subjects with high baseline TAG levels. Oxysterols have also emerged as a 
risk factor for CVD. Phytosterols may undergo similar oxidative processes, and therefore 
oxyphytosterols may have the same atherogenic potential. In our animal study, consump-
tion of oxysterols and oxyphytosterols promoted atherosclerotic lesion development by a 
shift toward more severe lesions. How these results compare to the human situation, 
warrants further study. 
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Hart- en vaatziekten (HVZ) vormen de belangrijkste doodsoorzaak in de Westerse wereld. 
De traditionele risicofactoren voor het verkrijgen van HVZ zijn: roken, ongezonde voeding, 
lichamelijke inactiviteit, overgewicht, hypertensie en een ongunstig lipoproteïnenprofiel. 
Om het hart en de bloedvaten gezond te houden, is het dus noodzakelijk om het risico op 
HVZ te verlagen (niet roken, voldoende beweging, gezonde voeding). De afgelopen jaren 
zijn er echter een aantal nieuwe factoren gevonden die ook geassocieerd zijn met een 
verhoogd risico op HVZ, zoals oxidatieve stress, infecties, en verhoogde serum concentra-
ties van de schadelijke kleine LDL-deeltjes (sdLDL), CRP, en oxysterolen. 
De huidige voedingsrichtlijnen om het risico voor HVZ te verlagen zijn met name gericht 
op het verlagen van het LDL-cholesterolgehalte of van de verhouding totaal choleste-
rol/HDL-cholesterol. Echter, ondanks strikte dieettrouw, zal het lipoproteïnenprofiel voor 
een groot deel van de bevolking ongunstig blijven. Voor deze mensen bieden de zoge-
naamde functionele voedingsmiddelen nieuwe mogelijkheden. Functionele voedingsmid-
delen zijn voedingsmiddelen waarin de hoeveelheid of de beschikbaarheid van een 
bepaald bestanddeel is veranderd, of waaraan een component is toegevoegd, dan wel 
waaruit een component is verwijderd. De consumptie van een dergelijk voedingsmiddel 
kan dan leiden tot een verbeterde gezondheid en/of een verminderd risico op ziekte. 
Voorbeelden van functionele voedingsmiddelen om het LDL-cholesterol te verlagen zijn 
producten die verrijkt zijn met plantenstanolen of met de visceuze voedingsvezel  -glucan 
uit haver of gerst. 
 
Het onderzoek dat in dit proefschrift wordt beschreven is gericht op de rol (van het 
combineren) van verschillende voedingscomponenten, zoals β-glucan uit haver, planten-
stanolen en oxy(fyto)sterolen in het cardiovasculair risicomanagement. Om deze vraagstel-
ling te beantwoorden werden onderstaande studies uitgevoerd. 
 
Het tegelijktijdig consumeren van β-glucan uit haver en plantenstanolen kan effectiever 
zijn dan het consumeren van de afzonderlijke componenten. In een eerste studie (Hoofd-
stuk 3) onderzochten we daarom de effecten van een gelijktijdige consumptie van β-glucan 
uit haver en plantenstanolen op de vetstofwisseling van hypercholesterolemische vrijwilli-
gers. In een gerandomiseerde, placebo-gecontroleerde studie consumeerden 40 hypercho-
lesterolemische mannen en vrouwen gedurende 4 weken dagelijks ofwel controle-muesli 
(5 g tarwevezel), β-glucan-verrijkte muesli (5 g β-glucan uit haver) of een combinatie-
muesli [5 g β-glucan uit haver plus 1.5 g plantenstanolen (in de vorm van esters)]. De β-
glucan-verrijkte muesli verlaagde het serum LDL-cholesterolgehalte met 5%. Het toevoe-
gen van plantenstanolen aan deze muesli zorgde voor een extra daling in het serum LDL-
cholesterolgehalte van 4%. Voor wat betreft het werkingsmechanisme werd gevonden dat 
β-glucan uit haver de galzoutsynthese verhoogde en de cholesterolabsorptie verlaagde. Het 
toevoegen van plantenstanolen had geen invloed op de galzoutsynthese, maar verlaagde 
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wel de cholesterolabsorptie en verhoogde de cholesterolsynthese. We concludeerden dat 
muesli verrijkt met β-glucan uit haver het serum LDL-cholesterolgehalte verlaagde. Hoewel 
het toevoegen van plantenstanolen aan deze muesli een verdere daling bewerkstelligde, 
was de daling minder sterk dan verwacht. Het is mogelijk dat de visceuze voedingsvezel β-
glucan of de voedingsmatrix een negatief effect had op het cholesterolverlagende effect van 
de plantenstanolen. 
 
In vitro en dierstudies suggereren dat β-glucan uit haver en plantenstanolen naast het LDL-
cholesterolgehalte ook ontstekingsparameters kunnen beïnvloeden. Om te onderzoeken of 
de invloed van deze functionele voedingsmiddelen op het risico op HVZ (gedeeltelijk) 
verloopt via het ontstekingsproces, onderzochten we in Hoofdstuk 4 de effecten van β-
glucan uit haver en plantenstanolen op ontstekingsparameters. De pro-inflammatoire 
cytokineproductie (IL-6, IL-8, TNF-α) door perifere mononucleaire bloedcellen (PBMC) en 
volbloed na LPS-stimulatie verschilden niet tussen de interventiegroepen. Ook het serum 
hs-CRP-gehalte, een marker voor chronische ontsteking, was gelijk voor alle groepen. Het 
consumeren van de β-glucan-verrijkte muesli had tevens geen effecten op de genexpressie 
van PBMC (humane atherosclerose-PCR array), terwijl slechts 3 van de 84 genen verschil-
lend tot expressie kwamen na het toevoegen van plantenstanolen aan deze muesli. We 
concludeerden dan ook dat consumptie van β-glucan uit haver met of zonder plantensta-
nolen effectief het LDL-cholesterolgehalte verlaagde, maar dat het geen invloed had op 
ontstekingsparameters in hypercholesterolemische vrijwilligers. 
 
Het verband tussen een verhoogd LDL-cholesterolgehalte en een verhoogd risico op HVZ 
is algemeen aanvaard. De laatste jaren wordt echter ook in toenemende mate melding 
gemaakt van een verband tussen een verlaagd HDL-cholesterolgehalte en een verhoogd 
triglyceridengehalte, ook wel hypertriglyceridemie genoemd, en een verhoogd risico op 
HVZ. We onderzochten daarom in een tweede studie (Hoofdstuk 5) de effecten van 
plantenstanolen op het serum lipidenprofiel in 26 mannen en vrouwen, geselecteerd op 
basis van een verhoogd triglyceridengehalte. Na een 1 week run-in periode (gebruik van 
een controle-margarine), werden de deelnemers willekeurig verdeeld over 2 groepen: 
controlegroep (controle-margarine) of stanol-groep [margarine verrijkt met 2.5 g/d 
plantenstanolen (in de vorm van esters)]. De dagelijkse consumptie van plantenstanolen 
zorgde voor een significante verlaging van het serum LDL-cholesterolgehalte na 3 weken. 
Ook werd er een significante interactie teruggevonden tussen de startwaarde van het 
triglyceridengehalte en de inname van plantenstanolen: het consumeren van plantenstano-
len verlaagde met name het serum triglyceridengehalte in personen met verhoogde 
startwaarden (>2.3 mmol/L). Tevens werd een significante interactie gevonden tussen het 
totale aantal LDL-cholesterol-deeltjes en de inname van plantenstanolen. De consumptie 
van plantenstanolen verlaagde het totale aantal LDL-deeltjes, met name in personen met 
SAMENVATTING 
  124
verhoogde startwaarden, en dit grotendeels via een verlaging in de sdLDL-deeltjes. We 
concludeerden dat de consumptie van plantenstanolen niet alleen het serum LDL-
cholesterolgehalte, maar ook het triglyceridengehalte verminderde, en dit voornamelijk in 
personen met verhoogde startwaarden. 
 
Oxysterolen zijn mogelijk ook atherogeen en kunnen daarom een actieve rol spelen bij het 
ontstaan van HVZ. Plantensterolen hebben een vergelijkbare structuur als cholesterol en de 
aanwezigheid van een of meerdere onverzadigde bindingen maakt deze stoffen ook 
vatbaar voor oxidatie. Echter, het is nog niet bekend of oxyfytosterolen ook atherogeen 
zijn, zoals gesuggereerd wordt voor oxysterolen. We onderzochten daarom in een derde 
studie (Hoofdstuk 6) de effecten van oxysterolen en oxyfytosterolen op het serum lipiden-
profiel en de atherosclerotische plaque-vorming in transgene muizen. Na 2 weken run-in 
werden 33 vrouwelijke heterozygote LDL-receptor deficiënte (LDLR+/-) muizen willekeurig 
verdeeld over 3 groepen: controlegroep (atherogeen controledieet), oxysterol-groep 
(controledieet met 0.025% oxysterolen), of de oxyfytosterol-groep (controledieet met 
0.025% oxyfytosterolen). Na 35 weken verschilde het serum cholesterolgehalte niet tussen 
de verschillende dieetgroepen. Ook het lipoproteïnenprofiel was gelijk voor alle groepen. 
Echter werd er wel een verschuiving gevonden richting meer gevorderde laesies na 
consumptie van oxysterolen en oxyfytosterolen in vergelijking tot het controledieet (geen 
verschil tussen de oxysterolen en oxyfytosterolen). Laesiegrootte en de hoeveelheid 
collageen in de laesies verschilden niet tussen de 3 dieetgroepen. We concludeerden dat 
niet alleen oxysterolen uit de voeding, maar ook oxyfytosterolen de ontwikkeling van 
atherosclerose kunnen beïnvloeden in vrouwelijke LDLR+/- muizen, en dit met name via 
een verschuiving naar meer ernstige atherosclerotische laesies. 
 
Als onderdeel van een verantwoord voedingspatroon, kunnen voedingsmiddelen verrijkt 
met plantenstanolen of met wateroplosbare voedingsvezels een bijdrage leveren tot het 
verbeteren van een ongunstig lipoproteïnenprofiel. Echter, gelijktijdige consumptie van 
deze twee functionele voedingscomponenten verlaagde het LDL-cholesterolgehalte minder 
sterk dan verwacht, waarschijnlijk door de interferentie van visceuze voedingsvezel met 
het cholesterolverlagende effect van de plantenstanolen. Het gunstig beïnvloeden van 
ontsteking kan ook een belangrijke bijdrage leveren aan het cardiovasculair risicomanage-
ment, maar de consumptie van β-glucan uit haver en plantenstanolen had hier geen effect 
op. Mogelijk is een verandering van een volledig voedingspatroon in vergelijking tot 
slechts 2 voedingscomponenten nodig om effecten te bekomen op ontsteking. Recent 
onderzoek toonde aan dat naast een verhoogd cholesterolgehalte ook een verhoogd 
triglyceridengehalte een belangrijke risicofactor is voor HVZ. Consumptie van plantensta-
nolen gaf naast een verlaging in het LDL-cholesterolgehalte ook een reductie in de serum 
triglyceridenconcentraties, en dit met name in personen met verhoogde startwaarden. Ook 
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oxysterolen worden gezien als een mogelijke risicofactor voor HVZ. Evenals cholesterol, 
kunnen ook plantensterolen worden geoxideerd. De consumptie van oxysterolen en 
oxyfytosterolen stimuleerden de atherosclerotische plaque-ontwikkeling door een ver-
schuiving naar meer ernstige laesies. Hoe deze resultaten zich vertalen naar de menselijke 
situatie vraagt echter meer onderzoek. 
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ABBREVIATIONS 
7α-OHC  7α-hydroxy-4-cholesten-3-one 
GGT    γ-glutamyl transferase 
ABC   ATP-binding cassette transporter 
Acetyl-CoA acetyl-coenzyme A 
ADFP  adipose differentiation-related protein 
ADRP  adipose differentiation-related protein 
APO   apolipoprotein 
AUC   area under the curve 
AZM   Academic Hospital Maastricht 
CETP   cholesteryl ester-transfer protein 
CHD5  VE-cadherin 
COL3A1  collagen type-3-α1 
COPD  chronic obstructive pulmonary disease 
CSF2   granulocyte-macrophage colony-stimulating factor 
CVD   cardiovascular disease 
DM2   type 2 diabetes 
FABP3  fatty acid-binding protein-3 
FCHL  familial combined hyperlipidemia 
FDA   Food and Drug Administration 
FGA   fibrinogen 
FN1   fibrinonectin-1 
FPLC   fast protein liquid chromatography 
GMCSF  granulocyte-macrophage colony-stimulating factor 
GRAS  Generally Recognized as Safe 
HCAEC  human coronary artery endothelial cells 
HDL   high-density lipoprotein 
HMG-CoA 3-hydroxy-3-methyl-glutaryl CoA reductase 
Hs-CRP  high-sensitivity C-reactive protein 
IDL   intermediate-density lipoprotein 
IHD   ischaemic heart disease 
IL   interleukin 
KDR   kinase insert domain receptor 
LAMA1  laminin-α1 
LCAT  lecithin-cholesterol acyltransferase 
LDL   low-density lipoprotein 
LDLR+/-  heterozygous LDL receptor-deficient 
LPA   Lp(a) 
LPL   lipoprotein lipase 
LPS   lipopolysaccharide 
MCP1  monocyte chemotactic protein-1 
MMP3  matrix metalloproteinase-3 
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MS   metabolic syndrome 
NMR   nuclear mass spectrometry 
NPC1L1  Niemann-Pick C-1 like-1 transporter 
NPY   neuropeptide Y 
PBMC  peripheral blood mononuclear cells 
PPARG  peroxisome proliferative activated receptor-γ 
IN   RNA integrity number 
SCFA   short-chain fatty acids 
CHD   coronary heart disease 
SMC   smooth muscle cells 
SPP1   secreted phosphoprotein-1 
TAG   triacylglycerols 
TMB   tetramethylbenzidine 
VLDL  very low-density lipoprotein 
 
